1,2,4-TRIAZIN-3(2H)-ONE COMPOUNDS FOR TREATING HYPERPROLIFERATIVE DISORDERS - Patent application

Triazin-3(2H)-one compounds selectively inhibit tumor cell proliferation by modulating PDE3A-SLFN12 and PDE3B-SLFN12 complexes, addressing the need for effective cancer treatments by enhancing drug sensitivity and safety.

JP7582953B2Active Publication Date: 2024-11-13BAYER AG +1
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
JP2021544608
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-02-01
Filing Date
2020-01-30
Publication Date
2024-11-13
Estimated Expiration
2040-01-30

AI Technical Summary

Technical Problem

Many cancer patients lack effective treatment options due to the lack of selective anticancer drugs that target specific cancer cell lines, and existing triazinone derivatives primarily focus on cardiovascular diseases rather than cancer treatment.

Method used

Development of triazin-3(2H)-one compounds that modulate the formation of PDE3A-SLFN12 and PDE3B-SLFN12 complexes, offering selective inhibition of tumor cell proliferation without inhibiting the enzymes PDE3A and/or PDE3B, thereby providing a therapeutic approach for hyperproliferative diseases like cancer.

Benefits of technology

The compounds demonstrate potent anticancer activity with IC50 values below 100 nM in HeLa cells, indicating strong tumor cell proliferation inhibition and improved pharmacokinetic and safety properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007582953000001
    Figure 0007582953000001
  • Figure 0007582953000002
    Figure 0007582953000002
  • Figure 0007582953000003
    Figure 0007582953000003
Patent Text Reader

Abstract

The present invention relates to compounds of the general formula (I): TIFF2022519080000159.tif52152 (in the formula, R 1 , R 2 , R 3 and R 4 as defined herein), methods for their preparation, pharmaceutical compositions and combinations comprising said compounds, and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention includes triazin-3(2H)-one compounds of general formula (I) as described and defined herein, processes and intermediates for their preparation, pharmaceutical compositions, combinations comprising said compounds, and uses thereof. [Background technology]

[0002] Cancer causes more than 550,000 deaths in the United States and more than 8 million deaths worldwide each year. New agents, including small molecules, molecules that affect tissue-specific growth requirements, and immunomodulatory agents, have been shown to benefit subsets of patients whose cancers harbor unique genomic alterations or other characteristics. Unfortunately, many cancer patients are left without effective treatment options.

[0003] One approach to identifying new anticancer drugs is phenotypic screening to discover novel small molecules that exhibit strong selectivity among cancer cell lines, followed by predictive chemogenomics to identify cellular features associated with drug response. In the 1990s, Weinstein and colleagues demonstrated that the cytotoxicity profile of a compound can be used to identify cellular characteristics, such as gene expression profiles and DNA copy number, that correlate with drug sensitivity. In recent years, automated high-throughput chemosensitivity testing of large panels of cell lines combined with comprehensive genomic and phenotypic characterization of cell lines has greatly increased the ability to identify features of cancer cell lines that mediate response to small molecules. Phenotypic observations of small molecule sensitivity can be correlated with expression patterns or somatic alterations, as in the case of trastuzumab-sensitive HER2-amplified breast cancer or erlotinib-sensitive EGFR-mutated lung cancer.

[0004] Phenotypic screening has identified some compounds known in the literature to be PDE3 inhibitors that are useful in the treatment of certain cancers. Co-expression of PDE3A and / or PDE3B and Schlafen 12 (SLFN12) polynucleotides or polypeptides is typically required for cells to become sensitive. PDE3A and / or B inhibitors that cause drug sensitivity have been found to stabilize the formation of complexes between PDE3A and / or PDE3B and SLFN12. PDE3A and / or B inhibitors that do not cause inhibition of tumor cell growth typically do not stabilize the PDE3A- and / or PDE3B-SLFN 12 complex.

[0005] Several triazinone derivatives are known, especially in the context of the treatment of cardiovascular diseases: JP 07-1107 (1995), US 4616015 (EP 0122627), EP 0052442, EP 0080296, EP 0123254, EP 0122627, EP 0122494. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Japanese Patent Application Publication No. 7-1107 (1995) [Patent Document 2] U.S. Pat. No. 4,616,015 [Patent Document 3] European Patent No. 0122627 [Patent Document 4] European Patent No. 0052442 [Patent Document 5] European Patent No. 0080296 [Patent Document 6] European Patent No. 0123254 [Patent Document 7] European Patent No. 0122627 [Patent Document 8] European Patent No. 0122494 Summary of the Invention [Problem to be solved by the invention]

[0007] It has now been found that the compounds of the invention have surprising and advantageous properties, which form at least in part one basis of the present invention.

[0008] In particular, the compounds of the present invention surprisingly exhibit IC 50 It has been shown that compounds inhibit tumor cell proliferation at IC values ​​below 100 nM. In addition, the compounds do not inhibit the enzymes PDE3A and / or PDE3B at concentrations that inhibit tumor cell proliferation, but do not inhibit the enzymes PDE3A and / or PDE3B at IC values ​​below 100 nM. 50 IC value for tumor cell proliferation 50 At concentrations that can be more than 10 times higher than the value.Without wishing to be bound by theory, this feature of inhibitory properties may be related to the induction of PDE3A and / or PDE3B-SLFN12 complex and / or the improvement of pharmacokinetic parameters in vivo or in vitro and / or the improvement of physicochemical properties and / or the improvement of safety pharmacological properties.Therefore, due to these advantageous properties, the compounds described herein can be used for the treatment or prevention of hyperproliferative diseases, such as cancer diseases.

[0009] The present invention provides compounds of general formula (I) that regulate the formation of PDE3A-SLFN12 complex and / or PDE3B-SLFN12 complex, their preparation methods, pharmaceutical compositions, and their uses, as well as methods for treating or preventing diseases, particularly hyperproliferative diseases, more particularly cancer diseases.These and other features of the present teachings are presented herein. [Means for solving the problem]

[0010] According to a first aspect, the present invention relates to compounds of general formula (I): [ka] (In the formula, R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group, or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom, However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 teeth, C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups and NR 5 R 6 C1-C3-alkyl groups substituted one or more times with groups independently selected from the groups; C2-C6-alkenyl groups optionally substituted by C1-C3-alkoxy groups, C5-C6-cycloalkenyl group, a phenyl group substituted one or more times by a group independently selected from halogen atoms, C1-C3-alkyl groups and C1-C3-haloalkyl groups, a 4- to 6-membered heterocycloalkyl group substituted one or more times with a group independently selected from a fluorine atom, a hydroxy group, and a C1-C3 alkyl group; [ka] base, [ka] base, [ka] base, a 5- to 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a halogen atom, and a C1-C3-haloalkyl group; C1-C6-alkoxy groups optionally substituted with groups independently selected from C1-C3-haloalkyl groups, hydroxy groups, C1-C3-alkoxy groups, C4-C6-cycloalkyl groups, 4- to 6-membered heterocycloalkyl groups, and 5- to 6-membered heteroaryl groups, excluding unsubstituted methoxy groups; NR 5 R 6 Groups, and [ka] basis and R 4 is a hydrogen atom or a C1-C3 alkyl group, R 5 is a hydrogen atom, R 6 teeth, C1-C3-alkyl groups which are substituted one or more times by groups independently selected from 5-6 membered heteroaryl groups, C1-C3-alkoxy groups, hydroxy groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group (selected from or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

[0011] Another aspect of the present invention is a method for treating hyperproliferative diseases, particularly cancer, more particularly brain cancer, cervical cancer, skin cancer and ovarian cancer, comprising administering to the patient a therapeutically effective amount of R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group, or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; R 3 but, C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups and NR 5 R6 C1-C3-alkyl groups substituted one or more times with groups independently selected from the groups; C2-C6-alkenyl groups optionally substituted by C1-C3-alkoxy groups, C5-C6-cycloalkenyl group, a phenyl group substituted one or more times by a group independently selected from halogen atoms, C1-C3-alkyl groups and C1-C3-haloalkyl groups, a 4- to 6-membered heterocycloalkyl group substituted one or more times with a group independently selected from a fluorine atom, a hydroxy group, and a C1-C3 alkyl group; [ka] base, [ka] base, [ka] base, a 5- to 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a halogen atom, and a C1-C3-haloalkyl group; C1-C6-alkoxy groups optionally substituted by groups independently selected from C1-C3-haloalkyl groups, hydroxy groups, C1-C3-alkoxy groups, C4-C6-cycloalkyl groups, 4- to 6-membered heterocycloalkyl groups, and 5- to 6-membered heteroaryl groups; NR 5 R 6 Groups, and [ka] basis and R 4 is a hydrogen atom or a C1-C3 alkyl group, R 5 is a hydrogen atom, R 6 but, C1-C3-alkyl groups which are substituted one or more times by groups independently selected from 5-6 membered heteroaryl groups, C1-C3-alkoxy groups, hydroxy groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group Selected from: The use of a compound of formula (I) or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or a mixture thereof. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] definition Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present invention belongs.The following references provide those skilled in the art with many of the general definitions of the terms used in the present invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd Edition 1994); The Cambridge Dictionary of Science and Technology (Walker, ed., 1988); The Glossary of Genetics, 5th Edition, R. Rieger et al. (ed.), Springer Verlag (1991); and Hale&Marham, The Harper Collins Dictionary of Biology (1991).As used herein, the following terms have the meanings ascribed to them below, unless otherwise specified.

[0013] The structure depicted includes all allowed rotations about the bonds.

[0014] The term "substituted" means that one or more hydrogen atoms on the specified atom or group are replaced with one selected from the indicated group, provided that the normal valence of the specified atom, under the circumstances present, is not exceeded. Combinations of substituents and / or variables are permissible.

[0015] The term "optionally substituted" means that the number of substituents can be equal to or different from 0. Unless otherwise indicated, an optionally substituted group can be substituted with as many optional substituents as can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon or nitrogen atom. In general, when present, the number of optional substituents can be 1, 2 or 3, particularly 1 or 2.

[0016] As used herein, the term "one or more" in, for example, the definition of a substituent of a compound of general formula (I) of the present invention means "1, 2, 3, 4 or 5, in particular 1, 2, 3 or 4, more in particular 1, 2 or 3, even more in particular 1 or 2".

[0017] When radicals in the compounds according to the invention are substituted, unless otherwise specified, said radicals can be mono- or polysubstituted with one or more substituents.Within the scope of the present invention, the meanings of all recurring radicals are independent of each other.Radicals in the compounds according to the invention can be substituted with 1, 2 or 3 identical or different substituents, in particular with 1 substituent.

[0018] As used herein, an oxo substituent represents an oxygen atom that is attached via a double bond to a carbon or sulfur atom.

[0019] The term "oxo", "oxo group" or "oxo substituent" refers to a double-bonded oxygen atom =O. Oxo can be attached to an atom of appropriate valence, such as a saturated carbon atom or a sulfur atom. For example, but not limited to, one oxo group can be attached to a carbon atom to form a carbonyl group, C(=O), or two oxo groups can be attached to one sulfur atom to form a sulfonyl group, -S(=O)2.

[0020] The term "ring substituent" means a substituent attached to an aromatic or non-aromatic ring that replaces an available hydrogen atom on the ring.

[0021] When a composite substituent is composed of two or more moieties, e.g. (C1-C4-alkoxy)-(C1-C4-alkyl)-, the position of a given moiety can be in any suitable position of said composite substituent, i.e. the C1-C4-alkoxy moiety can be attached to any carbon atom of the C1-C4-alkyl moiety of said (C1-C4-alkoxy)-(C1-C4-alkyl)- group. The first or last hyphen of such a composite substituent indicates the point of attachment of said composite substituent to the rest of the molecule. When a ring containing carbon atoms and optionally one or more heteroatoms, e.g. nitrogen, oxygen or sulfur atoms, is substituted with a substituent, said substituent can be attached at any suitable position of said ring, being attached to the suitable carbon atoms and / or suitable heteroatoms.

[0022] As used herein, the term "comprising" includes "consisting of," but not necessarily to the extent indicated by "consisting of."

[0023] In the text, when any item is referred to as "mentioned in the present specification", it means that it may be mentioned anywhere in the text.

[0024] When an item is referred to in the text as "above" in the specification, it refers to either the preceding page or to the respective disclosure made in the specification on that same page.

[0025] Whenever an item is referred to in the text as "below" in the specification, it refers to either one of the following pages or to the respective disclosure made in the specification below that page.

[0026] The term "halogen atom" means a fluorine, chlorine, bromine or iodine atom, especially a fluorine or chlorine atom, except where halogen is intended to be a leaving group.

[0027] The term "C1-C6-alkyl-" means a linear or branched saturated hydrocarbon group having 1, 2, 3, 4, 5 or 6 carbon atoms, such as methyl-, ethyl-, propyl-, iso-propyl-, n-butyl-, iso-butyl-, sec-butyl-, tert-butyl-, n-pentyl-, iso-pentyl-, 2-methylbutyl-, 1-methylbutyl-, 1-ethylpropyl-, 1,2-dimethylpropyl-, neopentyl-, 1,1-dimethylpropyl-, n-hexyl-, 4-methylpentyl-, 3-methylpentyl-, 2-methylpentyl-, 1-methylpentyl-, 2-ethylbutyl-, 1-ethylbutyl-, 3,3-dimethylbutyl-, 2,2-dimethylbutyl-, 1,1-dimethylbutyl-, 2,3-dimethylbutyl-, 1,3-dimethylbutyl-, 1,2-dimethylbutyl- groups, or isomers thereof. In particular, said radicals have 1, 2, 3 or 4 carbon atoms ("C1-C4-alkyl-"), such as a methyl-, ethyl-, n-propyl-, iso-propyl-, n-butyl-, iso-butyl-, sec-butyl- or tert-butyl-group, have 1, 2 or 3 carbon atoms ("C1-C3-alkyl-"), such as a methyl-, ethyl-, n-propyl- or iso-propyl-group, or have 1 or 2 carbon atoms ("C1-C2-alkyl-"), such as a methyl group or an ethyl group.

[0028] The same definition may be applied when the alkyl group is arranged in a chain as a divalent "C1-C6-alkylene" moiety. In that case, all the above names have an "ene" added to the end, so that, for example, "pentyl" becomes a divalent "pentylene" group. Furthermore, the term "C1-C6-heteroalkyl" refers to a C1-C6-alkyl group in which one or more of the carbon atoms are replaced with an atom selected from N, O, S, or P, and is substituted as referred to herein to satisfy the valence requirements.

[0029] The term "C1-C3-hydroxyalkyl" is as defined above for the term "C1-C6-alkyl" and means a linear or branched saturated monovalent hydrocarbon radical in which one, two or three hydrogen atoms are replaced by hydroxy groups, such as, for example, hydroxymethyl-, 1-hydroxyethyl-, 2-hydroxyethyl-, 1,2-dihydroxyethyl-, 3-hydroxypropyl-, 2-hydroxypropyl-, 1-hydroxypropyl-, 1-hydroxypropan-2-yl-, 2-hydroxypropan-2-yl-, 2,3-dihydroxypropyl-, 1,3-dihydroxypropan-2-yl- radicals.

[0030] The term "C1-C6-haloalkyl" means a linear or branched saturated monovalent hydrocarbon radical, in which the term "C1-C6-alkyl" is as defined above and in which one or more of the hydrogen atoms are replaced, identically or differently, by halogen atoms. In particular, the halogen atom is a fluorine atom. The C1-C6-haloalkyl radical is, for example, a fluoromethyl-, difluoromethyl-, trifluoromethyl-, 2-fluoroethyl-, 2,2-difluoroethyl-, 2,2,2-trifluoroethyl-, pentafluoroethyl-, 3,3,3-trifluoropropyl- or 1,3-difluoropropan-2-yl radical. In particular, the haloalkyl is trifluoromethyl or difluoromethyl.

[0031] The term "C1-C6-alkoxy" means a linear or branched saturated monovalent radical of the formula (C1-C6-alkyl)-O-, where the term "C1-C6-alkyl" is defined above, such as a methoxy-, ethoxy-, n-propoxy-, isopropoxy-, n-butoxy-, sec-butoxy-, iso-butoxy-, tert-butoxy-, pentyloxy-, isopentyloxy or n-hexyloxy radical, or an isomer thereof.

[0032] The term "C1-C6-haloalkoxy" means a linear or branched saturated monovalent C1-C6-alkoxy group as defined above, in which one or more hydrogen atoms are replaced, identically or differently, by halogen atoms. In particular, the halogen atom is a fluorine atom. Said C1-C6-haloalkoxy group is, for example, a fluoromethoxy-, difluoromethoxy-, trifluoromethoxy-, 2,2,2-trifluoroethoxy- or pentafluoroethoxy group.

[0033] The term "C2-C6-alkenyl" means a linear or branched monovalent hydrocarbon radical containing one or two double bonds and having 2, 3, 4, 5 or 6 carbon atoms, in particular 2 or 3 carbon atoms ("C2-C3-alkenyl"), where if the alkenyl radical contains more than one double bond, the double bonds can be isolated from one another or conjugated to one another. The alkenyl group is, for example, ethenyl, prop-2-enyl, (E)-prop-1-enyl, (Z)-prop-1-enyl, iso-propenyl, but-3-enyl, (E)-but-2-enyl, (Z)-but-2-enyl, (E)-but-1-enyl, (Z)-but-1-enyl, 2-methylprop-2-enyl, 1-methylprop-2-enyl, 2-methylprop-1-enyl, (E)-1-methylprop-1-enyl, ( Z)-1-Methylprop-1-enyl-, buta-1,3-dienyl-, pent-4-enyl-, (E)-pent-3-enyl-, (Z)-pent-3-enyl-, (E)-pent-2-enyl-, (Z)-pent-2-enyl-, (E)-pent-1-enyl-, (Z)-pent-1-enyl-, 3-methylbut-3-enyl-, 2-methylbut-3-enyl-, 1-methylbut-3-enyl-, 3-methylbut-2-enyl-, (E)-2-methylbut-2 -enyl-, (Z)-2-methylbut-2-enyl-, (E)-1-methylbut-2-enyl-, (Z)-1-methylbut-2-enyl-, (E)-3-methylbut-1-enyl-, (Z)-3-methylbut-1-enyl-, (E)-2-methylbut-1-enyl-, (Z)-2-methylbut-1-enyl-, (E)-1-methylbut-1-enyl-, (Z)-1-methylbut-1-enyl-, 1,1-dimethylprop-2-enyl-, 1-ethylprop-1 -enyl-, 1-propylvinyl-, 1-isopropylvinyl-, (E)-3,3-dimethylprop-1-enyl-, (Z)-3,3-dimethylprop-1-enyl-, penta-1,4-dienyl-, hex-5-enyl-, (E)-hex-4-enyl-, (Z)-hex-4-enyl-, (E)-hex-3-enyl-, (Z)-hex-3-enyl-, (E)-hex-2-enyl-, (Z)-hex-2-enyl-, (E)-hex-1-enyl-,(Z)-Hex-1-enyl-, 4-methylpent-4-enyl-, 3-methylpent-4-enyl-, 2-methylpent-4-enyl-, 1-methylpent-4-enyl-, 4-methylpent-3-enyl-, (E)-3-methylpent-3-enyl-, (Z)-3-methylpent-3-enyl-, (E)-2-methylpent-3-enyl-, (Z)-2-methylpent-3-enyl-, (E)-1-methylpent-3-enyl-, (Z)-1-methylpent-3-enyl-, (E)-4-methylpent-2-enyl-, (Z)-4-methylpent pent-2-enyl-, (E)-3-methylpent-2-enyl-, (Z)-3-methylpent-2-enyl-, (E)-2-methylpent-2-enyl-, (Z)-2-methylpent-2-enyl-, (E)-1-methylpent-2-enyl-, (Z)-1-methylpent-2-enyl-, (E)-4-methylpent-1-enyl-, (Z)-4-methylpent-1-enyl-, (E)-3-methylpent-1-enyl-, (Z)-3-methylpent-1-enyl-, (E)-2-methylpent-1-enyl-, (Z)-2-methylpent-1-enyl -, (E)-1-methylpent-1-enyl-, (Z)-1-methylpent-1-enyl-, 3-ethylbut-3-enyl-, 2-ethylbut-3-enyl-, 1-ethylbut-3-enyl-, (E)-3-ethylbut-2-enyl-, (Z)-3-ethylbut-2-enyl-, (E)-2-ethylbut-2-enyl-, (Z)-2-ethylbut-2-enyl-, (E)-1-ethylbut-2-enyl-, (Z)-1-ethylbut-2-enyl-, (E)-3-ethylbut-1-enyl-, (Z)-3-ethylbut-1-enyl-, 2-ethylbut- 1-enyl-, (E)-1-ethylbut-1-enyl-, (Z)-1-ethylbut-1-enyl-, 2-propylprop-2-enyl-, 1-propylprop-2-enyl-, 2-isopropylprop-2-enyl-, 1-isopropylprop-2-enyl-, (E)-2-propylprop-1-enyl-, (Z)-2-propylprop-1-enyl-, (E)-1-propylprop-1-enyl-, (Z)-1-propylprop-1-enyl-, (E)-2-isopropylprop-1-enyl-, (Z)-2-isopropylprop-1-enyl-,(E)-1-isopropylprop-1-enyl, (Z)-1-isopropylprop-1-enyl, hexa-1,5-dienyl or 1-(1,1-dimethylethyl)ethenyl.

[0034] The same definition may be applied when the alkenyl group is arranged in a chain as a divalent "C1-C6-alkenylene" moiety, in which case all of the above names would have an "ene" added to the end, thus, for example, "pentenyl" would become a divalent "pentenylene" group.

[0035] The term "C3-C6-cycloalkyl-" means a saturated monocyclic or bicyclic hydrocarbon ring ("C3-C6-cycloalkyl-") containing 3, 4, 5 or 6 carbon atoms. The C3-C6-cycloalkyl- group may be, for example, a monocyclic hydrocarbon ring, such as a cyclopropyl-, cyclobutyl-, cyclopentyl- or cyclohexyl-ring. In particular, the hydrocarbon ring is monocyclic and contains 3, 4, 5 or 6 carbon atoms ("C3-C6-cycloalkyl-"), such as a cyclopropyl-, cyclobutyl-, cyclopentyl- or cyclohexyl ring. Cycloalkyl groups may be optionally substituted as defined in the respective moieties where the term is used.

[0036] The term "C5-C6-cycloalkenyl" means a monovalent monocyclic or bicyclic hydrocarbon ring containing 5 or 6 carbon atoms and one double bond. The C5-C6-cycloalkenyl group is, for example, a monocyclic hydrocarbon ring, such as a cyclopentenyl- or cyclohexenyl-group. More particularly, the cycloalkenyl group is a C5-C6-cycloalkenyl group.

[0037] The term "4-6 membered heterocycloalkyl" means a monocyclic saturated or partially unsaturated heterocycle having a total of 4, 5 or 6 ring atoms containing one or two of the same or different series: N, O and S ring heteroatoms; said heterocycloalkyl group can be attached to the remainder of the molecule via any one of the carbon atoms or, if present, the nitrogen atom.

[0038] The heterocycloalkyl group may be, but is not limited to, a four-membered ring, such as, for example, an azetidinyl-, oxetanyl-, or thietanyl group; or a five-membered ring, such as, for example, a tetrahydrofuranyl-, 1,3-dioxolanyl-, thiolanyl-, pyrrolidinyl-, imidazolidinyl-, pyrazolidinyl-, 1,1-dioxidothiolanyl-, 1,2-oxazolidinyl-, 1,3-oxazolidinyl-, or 1,3-thiazolidinyl group; or a six-membered ring, such as, for example, a tetrahydropyranyl-, tetrahydrothiopyranyl-, piperidinyl-, morpholinyl-, dithianyl-, thiomorpholinyl-, piperazinyl-, 1,3-dioxanyl-, 1,4-dioxanyl-, or 1,2-oxazinanyl group.

[0039] The term "aryl" means a phenyl-, naphthyl-, 5,6-dihydronaphthyl-, 7,8-dihydronaphthyl-, 5,6,7,8-tetrahydronaphthyl-, indanyl- or indenyl group which is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents, each of which is independently selected from halogen atoms, cyano groups, C1-C3-alkyl groups, C1-C3-haloalkyl groups, C1-C3-alkoxy groups, C1-C3-thioalkyl groups, C1-C3-haloalkoxy groups, C1-C3-halothioalkyl groups, C3-C5-cycloalkyl groups, in particular halogen atoms, C1-C3-alkyl groups, C1-C3-haloalkyl groups, C1-C3-alkoxy groups and C1-C3-haloalkoxy groups. In particular, "aryl" is phenyl. Furthermore, R 3 The ortho-substituted phenyl group R 3 " is a phenyl substituent R 3 means that the phenyl group has a substituent directly on the carbon atom following the bond that connects it to the rest of the molecule.

[0040] The term "heteroaryl" means a monovalent monocyclic, bicyclic or tricyclic aromatic ring having 5, 6, 8, 9 or 10 ring atoms ("5-10 membered heteroaryl" groups) containing at least one ring heteroatom and optionally one, two or three additional ring heteroatoms of the series: N, O and / or S, bonded via a ring carbon atom or optionally a ring nitrogen atom (where permitted by valence).

[0041] The heteroaryl-groups may be 5-membered heteroaryl-groups, such as thienyl-, furanyl-, pyrrolyl-, oxazolyl-, thiazolyl-, imidazolyl-, pyrazolyl-, isoxazolyl-, isothiazolyl-, oxadiazolyl-, triazolyl-, thiadiazolyl- or tetrazolyl-groups; or 6-membered heteroaryl-groups, such as pyridyl-, pyridazinyl-, pyrimidyl-, pyrazinyl- or triazinyl-groups; or benzo-fused 5-membered heteroaryl-groups, such as benzofuranyl-, benzothienyl-, benzoxazolyl-, benzoisoxazolyl-, benzimidazolyl-, benzothiazolyl-, benzotriazolyl-, indazolyl-, indolyl- or isoindo- or a benzo-fused 6-membered heteroaryl-group, such as a quinolinyl-, quinazolinyl-, isoquinolinyl-, cinnolinyl-, phthalazinyl- or quinoxalinyl-; or another bicyclic group, such as an indolizinyl-, purinyl- or pteridinyl group; or a tricyclic heteroaryl-group, such as a carbazolyl-, acridinyl- or phenazinyl group; or a 9-membered heteroaryl group, such as a benzofuranyl-, benzothienyl-, benzoxazolyl-, benzisoxazolyl-, benzimidazolyl-, benzothiazolyl-, benzotriazolyl-, indazolyl-, indolyl-, isoindolyl-, indolizinyl- or purinyl group.

[0042] In general, unless otherwise stated, a heteroaryl or heteroarylene group includes all possible isomeric forms thereof, such as tautomers and positional isomers, with respect to the point of attachment to the remainder of the molecule. Thus, for some illustrative non-limiting examples, the term pyridinyl includes pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl; or the term thienyl includes thien-2-yl and thien-3-yl.

[0043] Throughout the text, the term "C1-C6" as used in the context of the definitions, for example, of "C1-C6-alkyl-", "C1-C6-haloalkyl-", "C1-C6-alkoxy-" or "C1-C6-haloalkoxy-", is to be understood to mean an alkyl group having a total number of carbon atoms of 1 to 6, i.e. 1, 2, 3, 4, 5 or 6 carbon atoms. It is further to be understood that the term "C1-C6" is to be interpreted as disclosing any subrange contained therein, for example, C1-C6, C2-C5, C3-C4, C1-C2, C1-C3, C1-C4, C1-C5, C1-C6; particularly C1-C2, C1-C3, C1-C4, C1-C5, C1-C6; more particularly C1-C4; and even more particularly C1-C2 in the case of "C1-C6-haloalkyl-" or "C1-C6-haloalkoxy-".

[0044] Similarly, as used herein, and throughout the text, for example, the term "C2-C6" used in the context of the definitions of "C2-C6-alkenyl-" and "C2-C6-alkynyl-" shall be understood to mean an alkenyl- or alkynyl group having a total number of carbon atoms from 2 to 6, i.e., 2, 3, 4, 5 or 6 carbon atoms. It shall be further understood that said term "C2-C6" shall be interpreted as disclosing any subrange contained therein, for example, C2-C6, C3-C5, C3-C4, C2-C3, C2-C4, C2-C5; in particular C2-C3.

[0045] Furthermore, as used herein, and throughout the text, for example, the term "C3-C7" used in the context of the definition of "C3-C7-cycloalkyl-" is to be understood to mean a cycloalkyl- group having a total number of carbon atoms from 3 to 7, i.e., 3, 4, 5, 6 or 7 carbon atoms. It is further to be understood that said term "C3-C7" is to be interpreted as disclosing any subrange contained therein, for example, C3-C6, C4-C5, C3-C5, C3-C4, C4-C6, C5-C7; in particular C3-C6.

[0046] As used herein, the term "leaving group" refers to an atom or group of atoms that is displaced in a chemical reaction as a stable species with the bonding electrons. In particular, such leaving groups are selected from the group comprising halides, in particular chloro-, bromo- or iodo-groups, (methylsulfonyl)oxy-, [(4-methylphenyl)sulfonyl]oxy-, [(trifluoromethyl)sulfonyl]oxy-, [(nona-fluorobutyl)sulfonyl]oxy-, [[(4-bromophenyl)sulfonyl]oxy-, [(4-nitrophenyl)sulfonyl]oxy-, [(2-nitro-phenyl)sulfonyl]oxy-, [(4-isopropylphenyl)sulfonyl]oxy-, [(2,4,6-triisopropylphenyl)sulfonyl]oxy-, [(2,4,6-trimethylphenyl)sulfonyl]oxy-, [(4-tert-butylphenyl)sulfonyl]oxy-, (phenylsulfonyl)oxy- and [(4-methoxyphenyl)sulfonyl]oxy groups.

[0047] As used herein, the term "protecting group" refers to a protective group attached to an oxygen or nitrogen atom in an intermediate used to prepare a compound of general formula (I). Such groups are introduced, for example, by chemical modification of the respective hydroxy or amino groups in order to obtain chemoselectivity in subsequent chemical reactions. Protective groups for hydroxy and amino groups are described, for example, in Protective Groups in Organic Synthesis, 4th Edition, Wiley 2006, by TW Greene and PG M Huts; more specifically, protective groups for amino groups can be selected from substituted sulfonyl groups, for example, mesyl-, tosyl- or phenylsulfonyl groups, acyl groups, for example, benzoyl-, acetyl- or tetrahydropyranoyl groups, or carbamate-based groups, for example, tert-butoxycarbonyl groups (Boc). Protecting groups for hydroxy groups may be selected from acyl groups, for example benzoyl-, acetyl, pivaloyl- or tetrahydropyranoyl groups, or may contain silicon, such as, for example, the tert-butyldimethylsilyl-, tert-butyldiphenylsilyl-, triethylsilyl- or triisopropylsilyl groups.

[0048] The term "substituents" refers to a group "substituted" on an alkyl, haloalkyl, cycloalkyl, heterocyclyl, heterocycloalkenyl, cycloalkenyl, aryl or heteroaryl group at any atom of the group, for example replacing one or more hydrogen atoms therein. In one aspect, one or more substituents on a group are independently any combination of just one or more of the permissible atoms or groups of atoms depicted for that substituent. In another aspect, the substituent itself may be substituted with any one of the above substituents. Additionally, as used herein, the phrase "optionally substituted" means unsubstituted (e.g., substituted with H) or substituted.

[0049] It will be understood that the description of compounds herein is limited by the principles of chemical bonding known to those skilled in the art.Therefore, when a group may be substituted by one or more of several substituents, such substitutions are selected to give a compound that is compatible with the principles of chemical bonding in terms of valence, etc., and is not inherently unstable.For example, any carbon atom will be bonded to two, three or four other atoms, in agreement with the four valence electrons of carbon.

[0050] By "subject" is meant a mammal, including, but not limited to, a human or a non-human mammal, such as a cow, horse, dog, sheep, rodent or cat.

[0051] An "oxo" substituent in the context of this invention means an oxygen atom which is attached to a carbon atom via a double bond.

[0052] It is possible for compounds of formula (I) to exist in isotopic variations, and therefore the present invention includes one or more isotopic variations of compounds of formula (I), particularly deuterium-containing compounds of formula (I).

[0053] The term "isotopic variant" of a compound or reagent is defined as a compound that exhibits an unnatural ratio of one or more isotopes that constitute such compound.

[0054] The term "isotopic variant of a compound of general formula (I)" is defined as a compound of general formula (I) that exhibits unnatural proportions of one or more isotopes as a component of such compound.

[0055] The expression "unnatural ratio" means a ratio of such isotope that is greater than its natural abundance. Natural abundance ratios of isotopes as applied in this context are described in "Isotopic Compositions of the Elements 1997", Pure Appl. Chem., 70(1), 217-235, 1998.

[0056] Examples of such isotopes include stable radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine and iodine, e.g., 2 H (deuterium), 3 H (tritium), 11 C. 13 C. 14 C. 15 N, 17 O. 18 O. 32 P, 33 P, 33 S, 34 S, 35 S, 36 S, 18 F, 36 Cl, 82 Br, 123 I, 124 I, 125 I, 129 I and 131 I can be mentioned.

[0057] For the treatment and / or prevention of the diseases specified herein, one or more isotopic variants of the compounds of general formula (I) in particular contain deuterium ("deuterium-containing compounds of general formula (I)"). One or more radioisotopes, e.g. 3 H or 14 Isotopic variations of compounds of general formula (I), such as those incorporating C, are useful, for example, in drug and / or substrate tissue distribution studies. These isotopes are particularly preferred for their ease of incorporation and detectability. 18 F or 11 Positron-emitting isotopes, such as C, can be incorporated into the compounds of general formula (I). These isotopic variants of the compounds of general formula (I) are useful for in vivo imaging applications. 13 C-containing compounds can be used in mass spectrometry in preclinical or clinical research settings (HJ Leis et al., Curr. Org. Chem., 1998, 2, 131).

[0058] Isotopic variants of compounds of general formula (I) can generally be prepared by methods known to those skilled in the art, such as those described in the schemes and / or examples herein, by substituting a reagent, particularly a deuterium-containing reagent, for the reagent isotopic variant. Depending on the desired location of deuteration, in some cases, the deuterium of DO can be directly incorporated into the compound or incorporated into a reagent useful for synthesizing such a compound (Esaki et al., Tetrahedron, 2006, 62, 10954; Esaki et al., Chem. Eur. J., 2007, 13, 4052). Deuterium gas is also a useful reagent for incorporating deuterium into molecules. Catalytic deuteration of olefinic bonds (HJ Leis et al., Curr. Org. Chem., 1998, 2, 131; JR Morandi et al., J. Org. Chem., 1969, 34(6), 1889) and acetylenic bonds (H.H. Han, J. Am. Chem. Soc., 1952, 74(12), 3018; S. Chandrasekhar et al., Tetrahedron Letters, 2011, 52, 3865) is a fast route for the incorporation of deuterium. Metal catalysts (i.e., Pd, Pt, and Rh) can be used to directly exchange deuterium for hydrogen in hydrocarbon-containing functional groups in the presence of deuterium gas (JG Atkinson et al., U.S. Pat. No. 3,966,781). A variety of deuterated reagents and synthetic building blocks are commercially available from companies such as, for example, C / D / N Isotopes, Quebec, Canada; Cambridge Isotope Laboratories Inc., Andover, Mass., USA; and CombiPhos Catalysts, Inc., Princeton, NJ, USA.Further information on the prior art regarding deuterium-hydrogen exchange is given, for example, in Hanzlik et al., J. Org. Chem. 55, 3992-3997, 1990; RP Hanzlik et al., Biochem. Biophys. Res. Commun. 160, 844, 1989; PJ Reider et al., J. Org. Chem. 52, 3326-3334, 1987; M. Jarman et al., Carcinogenesis 16(4), 683-688, 1995; J. Atzrodt et al., Angew. Chem., Int. Ed. 2007, 46, 7744; K. Matoishi et al., Chem. Commun. 2000, 1519-1520; K. Kassahun et al., WO 2012 / 112363.

[0059] The term "deuterium-containing compound of general formula (I)" is defined as a compound of general formula (I) in which one or more hydrogen atoms are replaced by one or more deuterium atoms, and the abundance of deuterium at each deuterated position of the compound of general formula (I) is higher than the natural abundance of deuterium, which is about 0.015%. In particular, in the deuterium-containing compound of general formula (I), the abundance of deuterium at each deuterated position of the compound of general formula (I) is higher than 10%, 20%, 30%, 40%, 50%, 60%, 70% or 80% at one or more of said positions, particularly higher than 90%, 95%, 96% or 97%, and even more particularly higher than 98% or 99%. It is understood that the abundance of deuterium at each deuterated position is independent of the abundance of deuterium at one or more other deuterated positions.

[0060] The selective incorporation of one or more deuterium atoms into the compounds of general formula (I) can have an effect on the physicochemical properties of the molecule, such as acidity [CL Perrin et al., J. Am. Chem. Soc., 2007, 129, 4490; A. Streitwieser et al., J. Am. Chem. Soc., 1963, 85, 2759], basicity [CL Perrin et al., J. Am. Chem. Soc., 2005, 127, 9641; CL Perrin et al., J. Am. Chem. Soc., 2003, 125, 15008; CL Perrin in Advances in Physical Organic Synthesis Chemistry, 44, 144;], lipophilicity [B. Testa et al., Int. J. Pharm., 1984, 19(3), 271]) and / or metabolic profile, leading to changes in the parent compound to metabolite ratio or the amount of metabolite produced. Such changes may result in certain therapeutic advantages and therefore may be desirable in some circumstances. Decreased rates of metabolism and metabolic switching, with altered metabolite ratios, have been reported (AE Mutlib et al., Toxicol. Appl. Pharmacol., 2000, 169, 102; DJ Kushner et al., Can. J. Physiol. Pharmacol., 1999, 77, 79). These changes in exposure to parent drug and metabolites may have important consequences for the pharmacokinetics, tolerability and efficacy of deuterium-containing compounds of general formula (I). In some instances, deuterium substitution reduces or eliminates the formation of undesirable or toxic metabolites and enhances the formation of desirable metabolites (e.g. Nevirapine: AM Sharma et al., Chem. Res. Toxicol., 2013, 26, 410; Efavirenz: AEMutlib et al., Toxicol. Appl. Pharmacol., 2000, 169, 102). In other instances, the primary effect of deuteration is to decrease the rate of systemic clearance. As a result, the biological half-life of the compound is increased. Potential clinical benefits would include the ability to maintain similar systemic exposure with reduced peak levels and increased trough levels.This can result in reduced side effects and enhanced efficacy, depending on the pharmacokinetic / pharmacodynamic relationship of the particular compound. ML-337 (CJ Wenthur et al., J. Med. Chem., 2013, 56, 5208) and odanacatib (K. Kassahun et al., WO 2012 / 112363) are examples of this deuterium effect. Still other cases have been reported where a reduction in metabolic rate increases exposure of a drug without altering the systemic clearance rate (e.g. rofecoxib: F. Schneider et al., Arzneim. Forsch. / Drug. Res., 2006, 56, 295; telaprevir: F. Maltais et al., J. Med. Chem., 2009, 52, 7993). Deuterated drugs that exhibit this effect may reduce dosing requirements (e.g., a lower number of doses or a lower dosage to achieve the desired effect) and / or may result in a lower amount of metabolites.

[0061] A compound of general formula (I) may have multiple possible sites of attack on metabolism. In order to optimize the above effects on physicochemical properties and metabolic profiles, a deuterium-containing compound of general formula (I) can be selected that has a certain pattern of one or more deuterium-hydrogen exchanges. In particular, one or more deuterium atoms of one or more deuterium-containing compounds of general formula (I) are bonded to a carbon atom and / or bonded to a cytochrome P, for example. 450 It is located at the position of the compound of general formula (I) which is the site of attack for metabolic enzymes such as.

[0062] When the plural of words such as compounds, salts, polymorphs, hydrates, solvates, etc. are used herein, this is taken to mean also a single compound, salt, polymorph, isomer, hydrate, solvate, etc.

[0063] By "stable compound" or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

[0064] The compounds of the present invention may contain one or more asymmetric centers, depending on the position and nature of various desired substituents.It is possible that one or more asymmetric carbon atoms are present in (R) or (S) configuration, which can result in racemic mixtures in the case of a single asymmetric center, and diastereomeric mixtures in the case of multiple asymmetric centers.In certain cases, asymmetry may exist due to restricted rotation around a given bond, for example, the central bond that joins two substituted aromatic rings of a specified compound.

[0065] Preferred compounds are those which provide the more desirable biological activity. Also included within the scope of the present invention are separated, pure or partially purified isomers and stereoisomers or racemic or diastereomeric mixtures of the compounds of the present invention. Purification and separation of such materials can be accomplished by standard techniques known in the art.

[0066] Preferred isomers are those that provide more desirable biological activity, when biological activity differs between isomers.These separated, pure or partially purified isomers or racemic mixtures of the compounds of the present invention are also included within the scope of the present invention.The purification and separation of such substances can be achieved by standard techniques known in the art, including chiral high pressure liquid chromatography (HPLC), formation and crystallization of chiral salts, or can be prepared by asymmetric synthesis.

[0067] Optical isomers can be obtained by conventional resolution of racemic mixtures, for example, formation of diastereoisomeric salts or formation of covalent diastereomers with optically active acids or bases. Examples of suitable acids include tartaric acid, diacetyltartaric acid, ditoluoyltartaric acid and camphorsulfonic acid. Mixtures of diastereoisomers can be separated into individual diastereomers based on their physical and / or chemical differences by methods known in the art, for example, chromatography or fractional crystallization. The optically active base or acid is then liberated from the separated diastereomeric salts. Another method for separating optical isomers includes the use of chiral chromatography (e.g., HPLC columns using chiral phases), with or without conventional derivatization, which may be selected to maximize the separation of the enantiomers. Suitable HPLC columns using chiral phases are commercially available, for example, those manufactured by Daicel, among others, such as Chiracel OD and Chiracel OJ, all of which are routinely selectable. Enzymatic separations, with or without derivatization, are also useful. The optically active compounds of this invention can also be obtained by chiral syntheses utilizing optically active starting materials.

[0068] To distinguish different types of isomers from one another, reference is made to IUPAC Rules Section E (Pure Appl Chem 45, 11-30, 1976).

[0069] The present invention includes all possible stereoisomers of the compounds of the present invention as single stereoisomers or as any mixture of said stereoisomers in any ratio, e.g., (R)- or (S)-isomers. Isolation of a single stereoisomer of a compound of the present invention, e.g., a single enantiomer or a single diastereomer, can be achieved by any suitable prior art method, e.g., chromatography, in particular chiral chromatography.

[0070] Additionally, it is possible for the compounds of the invention to exist as tautomers. For example, any compound of the invention that includes a pyrazole moiety as a heteroaryl group may exist as, for example, a 1H tautomer or a 2H tautomer, or two tautomers, i.e.: [ka] may be present in any amount of mixture.

[0071] The present invention includes all possible tautomers of the compounds of the present invention as single tautomers or any mixture of tautomers in any ratio.

[0072] Additionally, the compounds of the present invention can exist as N-oxides, which are defined in that at least one nitrogen of the compounds of the present invention is oxidized, and the present invention includes all such possible N-oxides.

[0073] The present invention also includes useful forms of the compounds of the invention, such as metabolites, hydrates, solvates, prodrugs, salts, particularly pharma- ceutically acceptable salts, and / or coprecipitates.

[0074] The compounds of the present invention can exist as hydrates or solvates, and for example, the compounds of the present invention contain polar solvents, particularly water, methanol or ethanol, as structural elements of the crystal lattice of the compounds. The amount of polar solvent, particularly water, can exist in stoichiometric or non-stoichiometric ratios. In the case of stoichiometric solvates, for example, hydrates, hemi-, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta-isosolvates, or hydrates are respectively possible. The present invention includes all such hydrates or solvates.

[0075] It is further possible for the compounds of the invention to exist in free form, e.g., as a free base or free acid or zwitterion, or in salt form, which may be any salt, either an organic or inorganic addition salt, in particular any pharma- ceutically acceptable organic or inorganic addition salt customarily used in pharmacology or used, e.g., to isolate or purify the compounds of the invention.

[0076] The term "pharmaceutically acceptable salt" refers to an inorganic or organic acid addition salt of a compound of the present invention. See, for example, SM Berge et al., "Pharmaceutical Salts," J. Pharm. Sci. 1977, 66, 1-19.

[0077] Suitable pharma- ceutically acceptable salts of the compounds of the present invention include, for example, acid addition salts of compounds of the present invention having a nitrogen atom, e.g., sufficiently basic, in the chain or in the ring, e.g., with inorganic or "mineral acids", such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, bisulfuric acid, phosphoric acid or nitric acid, or with organic acids, such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, bisulfuric acid, phosphoric acid and nitric acid, or with organic acids, such as formic acid, acetic acid, acetoacetic acid, pyruvic acid, trifluoroacetic acid, propionic acid, butyric acid, hexanoic acid, heptanoic acid, undecanoic acid, lauric acid, benzoic acid, salicylic acid, 2-(4-hydroxybenzoyl)benzoic acid, camphoric acid, cinnamic acid, cyclopentanepropionic acid, digluconic acid, 3-hydroxy-2-naphthalene acid, benzoic ...2-(4-hydroxybenzoyl)benzoic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, 2-( The acid addition salts may be with phthoic acid, nicotinic acid, pamoic acid, pectic acid, persulfuric acid, 3-phenylpropionic acid, picric acid, pivalic acid, 2-hydroxyethanesulfonic acid, itaconic acid, sulfamic acid, trifluoromethanesulfonic acid, dodecylsulfuric acid, ethanesulfonic acid, benzenesulfonic acid, para-toluenesulfonic acid, methanesulfonic acid, 2-naphthalenesulfonic acid, naphthalenedisulfonic acid, camphorsulfonic acid, citric acid, tartaric acid, stearic acid, lactic acid, oxalic acid, malonic acid, succinic acid, malic acid, adipic acid, alginic acid, maleic acid, fumaric acid, D-gluconic acid, mandelic acid, ascorbic acid, glucoheptanoic acid, glycerophosphoric acid, aspartic acid, sulfosalicylic acid, hemisulfuric acid and thiocyanic acid.

[0078] "Pharmaceutically acceptable anion" refers to the deprotonated form of a conventional acid, such as, for example, a hydroxide, carboxylate, sulfate, halide, phosphate, or nitrate.

[0079] Physiologically acceptable salts of the compounds according to the invention also include salts of customary bases, such as, by way of example and preferably, the alkali metal salts (e.g. lithium, sodium and potassium salts), alkaline earth metal salts (e.g. calcium, strontium and magnesium salts) or the aluminium salts or zinc salts, or ammonium salts derived from ammonia or from organic primary, secondary or tertiary amines having 1 to 20 carbon atoms, such as, by way of example and preferably, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, These include, but are not limited to, ethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, diethylaminoethanol, tris(hydroxymethyl)aminomethane, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, 1,2-ethylenediamine, N-methylpiperidine, N-methylglucamine, N,N-dimethylglucamine, N-ethylglucamine, 1,6-hexanediamine, glucosamine, sarcosine, serinol, 2-amino-1,3-propanediol, 3-amino-1,2-propanediol, and 4-amino-1,2,3-butanetriol.

[0080] In addition, the compounds according to the invention may form salts with quaternary ammonium ions, which may be obtained by quaternization of basic nitrogen-containing groups with agents such as lower alkyl halides, e.g. alkyl chlorides, e.g. methyl chloride, ethyl chloride, propyl chloride and butyl chloride; alkyl bromides, e.g. methyl bromide, ethyl bromide, propyl bromide and butyl bromide; and alkyl iodides, e.g. methyl iodide, ethyl iodide, propyl iodide and butyl iodide; dialkyl sulfates, e.g. dimethyl sulfate, diethyl sulfate, dibutyl sulfate and diamyl sulfate, long chain halides, e.g. decyl chloride, lauryl chloride, myristyl chloride and stearyl chloride, decyl bromide, lauryl bromide, myristyl bromide and stearyl bromide, decyl iodide, lauryl iodide, myristyl iodide and stearyl iodide, aralkyl halides, e.g. benzyl chloride, benzyl bromide, benzyl iodide and phenethyl bromide. Examples of suitable quaternary ammonium ions include tetramethylammonium, tetraethylammonium, tetra(n-propyl)ammonium, tetra(n-butyl)ammonium or N-benzyl-N,N,N-trimethylammonium.

[0081] Those skilled in the art will further recognize that acid addition salts of the claimed compounds can be prepared by reacting the compounds with the appropriate inorganic or organic acid via any of a number of known methods. Alternatively, alkali and alkaline earth metal salts of acidic compounds of the invention are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods.

[0082] The present invention includes all possible salts of the compounds of the present invention, either as a single salt or as any mixture of said salts in any ratio.

[0083] When compounds are referred to herein, particularly in the experimental section, for the synthesis of intermediates and examples of the present invention as salt forms with the corresponding bases or acids, the exact stoichiometric composition of said salt forms obtained by the respective preparation and / or purification steps is in most cases unknown.

[0084] Unless otherwise specified, for example, "hydrochloride", "trifluoroacetate", "sodium salt" or "xHCl", "xCF3COOH", "xNa + A suffix to a chemical name or structural formula for a salt, such as "," denotes the salt form and does not specify the stoichiometry of the salt form.

[0085] This also applies if the synthetic intermediates or example compounds or their salts are obtained by the preparation and / or purification steps as solvates, such as hydrates of unknown stoichiometric composition (if defined).

[0086] Solvates and hydrates of the disclosed intermediates or example compounds or their salts obtained by the preparation and / or purification methods described herein may be formed in any ratio.

[0087] Furthermore, the present invention includes all possible crystalline forms or polymorphs of the compounds of the present invention, either as a single polymorph or as a mixture of two or more polymorphs in any ratio.

[0088] Furthermore, the present invention also includes prodrugs of the compounds according to the present invention. The term "prodrug" refers to a compound that may be biologically active or inactive per se, but is converted (e.g., metabolically or hydrolytically) into the compound according to the present invention during its residence time in the body. For example, the prodrug may be in the form of an in vivo hydrolyzable ester of a particular compound. The derivatives (biological precursors or prodrugs) of the compounds of formula (I) and their salts that are converted into the compounds of formula (I) and their salts in a biological system are covered by the present invention. The biological system may be, for example, a mammalian organism, in particular a human subject. The biological precursor is, for example, converted into the compounds of formula (I) or their salts by metabolic processes.

[0089] explanation According to a first aspect, the present invention relates to a compound of general formula (I) as above: [ka] (In the formula, R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 teeth, C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups and NR 5 R 6 C1-C3-alkyl groups substituted one or more times with groups independently selected from the groups; C2-C6-alkenyl groups optionally substituted by C1-C3-alkoxy groups, C5-C6-cycloalkenyl group, a phenyl group substituted one or more times by a group independently selected from halogen atoms, C1-C3-alkyl groups and C1-C3-haloalkyl groups, a 4- to 6-membered heterocycloalkyl group substituted one or more times with a group independently selected from a fluorine atom, a hydroxy group, and a C1-C3 alkyl group; [ka] base, [ka] base, [ka] base, a 5- to 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a halogen atom, and a C1-C3-haloalkyl group; C1-C6-alkoxy groups optionally substituted with groups independently selected from C1-C3-haloalkyl groups, hydroxy groups, C1-C3-alkoxy groups, C4-C6-cycloalkyl groups, 4- to 6-membered heterocycloalkyl groups, and 5- to 6-membered heteroaryl groups, excluding unsubstituted methoxy groups; NR 5 R 6 Groups, and [ka] basis is selected from R 4 is a hydrogen atom or a C1-C3 alkyl group, R 5 is a hydrogen atom, R 6 teeth, C1-C3-alkyl groups which are substituted one or more times by groups independently selected from 5-6 membered heteroaryl groups, C1-C3-alkoxy groups, hydroxy groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group (selected from or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

[0090] According to an embodiment of the first aspect, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2cannot both be hydrogen atoms at the same time; R 3 but, C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups and NR 5 R 6 C1-C3-alkyl groups substituted one or more times with groups independently selected from the groups; C2-C6-alkenyl groups optionally substituted by C1-C3-alkoxy groups, C5-C6-cycloalkenyl group, a phenyl group substituted one or more times by a group independently selected from halogen atoms, C1-C3-alkyl groups and C1-C3-haloalkyl groups, a 4- to 6-membered heterocycloalkyl group substituted one or more times with a group independently selected from a fluorine atom, a hydroxy group, and a C1-C3 alkyl group; [ka] base, [ka] base, [ka] base, a 5- to 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; C1-C6-alkoxy groups optionally substituted with groups independently selected from C1-C3-haloalkyl groups, hydroxy groups, C1-C3-alkoxy groups, C4-C6-cycloalkyl groups, 4- to 6-membered heterocycloalkyl groups, and 5- to 6-membered heteroaryl groups, excluding unsubstituted methoxy groups; NR 5 R 6 Groups, and [ka] basis is selected from R 4 is a hydrogen atom or a C1-C3 alkyl group; R 5 is a hydrogen atom, R 6 but, C1-C3-alkyl groups which are substituted one or more times by groups independently selected from 5-6 membered heteroaryl groups, C1-C3-alkoxy groups, hydroxy groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group Selected from: The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0091] According to an embodiment of the first aspect, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 but, C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups and NR 5 R 6 C1-C3-alkyl groups substituted one or more times with groups independently selected from the groups; C2-C6-alkenyl groups optionally substituted by C1-C3-alkoxy groups, C5-C6-cycloalkenyl group, a phenyl group substituted one or more times by a group independently selected from halogen atoms, C1-C3-alkyl groups and C1-C3-haloalkyl groups, a 4- to 6-membered heterocycloalkyl group substituted one or more times with a group independently selected from a fluorine atom, a hydroxy group, and a C1-C3 alkyl group; [ka] base, [ka] base, [ka] base, a 5- to 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a halogen atom, and a C1-C3-haloalkyl group; C1-C6-alkoxy groups optionally substituted with groups independently selected from C1-C3-haloalkyl groups, hydroxy groups, C1-C3-alkoxy groups, C4-C6-cycloalkyl groups, 4- to 6-membered heterocycloalkyl groups, and 5- to 6-membered heteroaryl groups, excluding unsubstituted methoxy groups; NR 5 R 6 Groups, and [ka] basis is selected from R 4 is a hydrogen atom; R 5 is a hydrogen atom, R 6 but, C1-C3-alkyl groups which are substituted one or more times by groups independently selected from 5-6 membered heteroaryl groups, C1-C3-alkoxy groups, hydroxy groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group Selected from: The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0092] According to an embodiment of the first aspect, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom, However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 but, C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups and NR 5 R 6 C1-C3-alkyl groups substituted one or more times with groups independently selected from the groups; C2-C6-alkenyl groups optionally substituted by C1-C3-alkoxy groups, C5-C6-cycloalkenyl group, a phenyl group substituted one or more times by a group independently selected from halogen atoms, C1-C3-alkyl groups and C1-C3-haloalkyl groups, a 4- to 6-membered heterocycloalkyl group substituted one or more times with a group independently selected from a fluorine atom, a hydroxy group, and a C1-C3 alkyl group; [ka] base, [ka] base, [ka] base, a 5- to 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; C1-C6-alkoxy groups optionally substituted with groups independently selected from C1-C3-haloalkyl groups, hydroxy groups, C1-C3-alkoxy groups, C4-C6-cycloalkyl groups, 4- to 6-membered heterocycloalkyl groups, and 5- to 6-membered heteroaryl groups, excluding unsubstituted methoxy groups; NR 5 R 6 Groups, and [ka] basis is selected from R 4 is a hydrogen atom, R 5 is a hydrogen atom, R 6 but, C1-C3-alkyl groups which are substituted one or more times by groups independently selected from 5-6 membered heteroaryl groups, C1-C3-alkoxy groups, hydroxy groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group Selected from: The compound of the above general formula (I) [ka] or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

[0093] According to an embodiment of the first aspect, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: R1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom, However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 but, C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups and NR 5 R 6 C1-C3-alkyl groups substituted one or more times with groups independently selected from the groups; C2-C6-alkenyl groups optionally substituted by C1-C3-alkoxy groups, C5-C6-cycloalkenyl group, a phenyl group substituted one or more times by a group independently selected from halogen atoms, C1-C3-alkyl groups and C1-C3-haloalkyl groups, a 4- to 6-membered heterocycloalkyl group substituted one or more times with a group independently selected from a fluorine atom, a hydroxy group, and a C1-C3 alkyl group; [ka] base, [ka] base, [ka] base, a 5- to 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a halogen atom, and a C1-C3-haloalkyl group; C1-C6-alkoxy groups optionally substituted with groups independently selected from C1-C3-haloalkyl groups, hydroxy groups, C1-C3-alkoxy groups, C4-C6-cycloalkyl groups, 4- to 6-membered heterocycloalkyl groups, and 5- to 6-membered heteroaryl groups, excluding unsubstituted methoxy groups; NR 5 R 6 Groups, and [ka] basis is selected from R 4 is a C1-C3 alkyl group; R 5 is a hydrogen atom, R 6 but, C1-C3-alkyl groups which are substituted one or more times by groups independently selected from 5-6 membered heteroaryl groups, C1-C3-alkoxy groups, hydroxy groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group Selected from: The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0094] According to an embodiment of the first aspect, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2cannot both be hydrogen atoms at the same time; R 3 but, C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups and NR 5 R 6 C1-C3-alkyl groups substituted one or more times with groups independently selected from the groups; C2-C6-alkenyl groups optionally substituted by C1-C3-alkoxy groups, C5-C6-cycloalkenyl group, a phenyl group substituted one or more times by a group independently selected from halogen atoms, C1-C3-alkyl groups and C1-C3-haloalkyl groups, a 4- to 6-membered heterocycloalkyl group substituted one or more times with a group independently selected from a fluorine atom, a hydroxy group, and a C1-C3 alkyl group; [ka] base, [ka] base, [ka] base, a 5- to 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; C1-C6-alkoxy groups optionally substituted with groups independently selected from C1-C3-haloalkyl groups, hydroxy groups, C1-C3-alkoxy groups, C4-C6-cycloalkyl groups, 4- to 6-membered heterocycloalkyl groups, and 5- to 6-membered heteroaryl groups, excluding unsubstituted methoxy groups; NR 5 R 6 Groups, and [ka] basis is selected from R 4 is a C1-C3 alkyl group; R 5 is a hydrogen atom, R 6 but, C1-C3-alkyl groups which are substituted one or more times by groups independently selected from 5-6 membered heteroaryl groups, C1-C3-alkoxy groups, hydroxy groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group Selected from: The compound of the above general formula (I) [ka] or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

[0095] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group, or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 but, C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups and NR 5 R 6 C1-C3-alkyl groups substituted one or more times with groups independently selected from the groups; C2-C6-alkenyl groups optionally substituted by C1-C3-alkoxy groups, C5-C6-cycloalkenyl group, a phenyl group substituted one or more times by a group independently selected from a halogen atom, a C1-C3-alkyl group and a C1-C3-haloalkyl group; a 4- to 6-membered heterocycloalkyl group substituted one or more times with a group independently selected from a fluorine atom, a hydroxy group, and a C1-C3 alkyl group; [ka] base, [ka] base, [ka] base, a 5- to 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a halogen atom, and a C1-C3-haloalkyl group; C1-C6-alkoxy groups optionally substituted with groups independently selected from C1-C3-haloalkyl groups, hydroxy groups, C1-C3-alkoxy groups, C4-C6-cycloalkyl groups, 4- to 6-membered heterocycloalkyl groups, and 5- to 6-membered heteroaryl groups, excluding unsubstituted methoxy groups; NR 5 R 6 Groups, and [ka] basis is selected from R 4 is a hydrogen atom or a C1-C3 alkyl group; R 5 is a hydrogen atom, R 6 but, C1-C3-alkyl groups which are substituted one or more times by groups independently selected from 5-6 membered heteroaryl groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group Selected from: The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0096] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group, or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 but, C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups and NR 5 R 6 C1-C3-alkyl groups substituted one or more times with groups independently selected from the groups; C2-C6-alkenyl groups optionally substituted by C1-C3-alkoxy groups, C5-C6-cycloalkenyl group, a phenyl group substituted one or more times by a group independently selected from a halogen atom, a C1-C3-alkyl group and a C1-C3-haloalkyl group; a 4- to 6-membered heterocycloalkyl group substituted one or more times with a group independently selected from a fluorine atom, a hydroxy group, and a C1-C3 alkyl group; [ka] base, [ka] base, [ka] base, a 5- to 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; C1-C6-alkoxy groups optionally substituted with groups independently selected from C1-C3-haloalkyl groups, hydroxy groups, C1-C3-alkoxy groups, C4-C6-cycloalkyl groups, 4- to 6-membered heterocycloalkyl groups, and 5- to 6-membered heteroaryl groups, excluding unsubstituted methoxy groups; NR 5 R 6 Groups, and [ka] basis is selected from R 4 is a hydrogen atom or a C1-C3 alkyl group; R 5 is a hydrogen atom, R 6 but, C1-C3-alkyl groups which are substituted one or more times by groups independently selected from 5-6 membered heteroaryl groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group Selected from: The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0097] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group, or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 but, C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups and NR 5 R 6 C1-C3-alkyl groups substituted one or more times with groups independently selected from the groups; C2-C6-alkenyl groups optionally substituted by C1-C3-alkoxy groups, C5-C6-cycloalkenyl group, a phenyl group substituted one or more times by a group independently selected from a halogen atom, a C1-C3-alkyl group and a C1-C3-haloalkyl group; a 4- to 6-membered heterocycloalkyl group substituted one or more times with a group independently selected from a fluorine atom, a hydroxy group, and a C1-C3 alkyl group; [ka] base, [ka] base, [ka] base, a 5- to 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a halogen atom, and a C1-C3-haloalkyl group; C1-C6-alkoxy groups optionally substituted with groups independently selected from C1-C3-haloalkyl groups, hydroxy groups, C1-C3-alkoxy groups, C4-C6-cycloalkyl groups, 4- to 6-membered heterocycloalkyl groups, and 5- to 6-membered heteroaryl groups, excluding unsubstituted methoxy groups; NR 5 R 6 Groups, and [ka] basis is selected from R 4 is a hydrogen atom; R 5 is a hydrogen atom, R 6 but, C1-C3-alkyl groups which are substituted one or more times by groups independently selected from 5-6 membered heteroaryl groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group Selected from: The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0098] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 3is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 but, C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups and NR 5 R 6 C1-C3-alkyl groups substituted one or more times with groups independently selected from the groups; C2-C6-alkenyl groups, optionally substituted by C1-C3-alkoxy groups, C5-C6-cycloalkenyl group, a phenyl group substituted one or more times by a group independently selected from a halogen atom, a C1-C3-alkyl group and a C1-C3-haloalkyl group; a 4- to 6-membered heterocycloalkyl group substituted one or more times with a group independently selected from a fluorine atom, a hydroxy group, and a C1-C3 alkyl group; [ka] base, [ka] base, [ka] base, a 5- to 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; C1-C6-alkoxy groups optionally substituted with groups independently selected from C1-C3-haloalkyl groups, hydroxy groups, C1-C3-alkoxy groups, C4-C6-cycloalkyl groups, 4- to 6-membered heterocycloalkyl groups, and 5- to 6-membered heteroaryl groups, excluding unsubstituted methoxy groups; NR 5 R 6 Groups, and [ka] basis is selected from R 4 is a hydrogen atom; R 5 is a hydrogen atom, R 6 but, C1-C3-alkyl groups which are substituted one or more times by groups independently selected from 5-6 membered heteroaryl groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group Selected from: The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0099] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group, or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 but, C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups and NR 5 R 6 C1-C3-alkyl groups substituted one or more times with groups independently selected from the groups; C2-C6-alkenyl groups, optionally substituted by C1-C3-alkoxy groups, C5-C6-cycloalkenyl group, a phenyl group substituted one or more times by a group independently selected from a halogen atom, a C1-C3-alkyl group and a C1-C3-haloalkyl group; a 4- to 6-membered heterocycloalkyl group substituted one or more times with a group independently selected from a fluorine atom, a hydroxy group, and a C1-C3 alkyl group; [ka] base, [ka] base, [ka] base, a 5- to 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a halogen atom, and a C1-C3-haloalkyl group; C1-C6-alkoxy groups optionally substituted with groups independently selected from C1-C3-haloalkyl groups, hydroxy groups, C1-C3-alkoxy groups, C4-C6-cycloalkyl groups, 4- to 6-membered heterocycloalkyl groups, and 5- to 6-membered heteroaryl groups, excluding unsubstituted methoxy groups; NR 5 R 6 Groups, and [ka] basis is selected from R 4 is a C1-C3 alkyl group, R 5 is a hydrogen atom, R 6 but, C1-C3-alkyl groups which are substituted one or more times by groups independently selected from 5-6 membered heteroaryl groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group Selected from: The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0100] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 but, C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups and NR 5 R 6 C1-C3-alkyl groups substituted one or more times with groups independently selected from the groups; C2-C6-alkenyl groups, optionally substituted by C1-C3-alkoxy groups, C5-C6-cycloalkenyl group, a phenyl group substituted one or more times by a group independently selected from a halogen atom, a C1-C3-alkyl group and a C1-C3-haloalkyl group; a 4- to 6-membered heterocycloalkyl group substituted one or more times with a group independently selected from a fluorine atom, a hydroxy group, and a C1-C3 alkyl group; [ka] base, [ka] base, [ka] base, a 5- to 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; C1-C6-alkoxy groups optionally substituted with groups independently selected from C1-C3-haloalkyl groups, hydroxy groups, C1-C3-alkoxy groups, C4-C6-cycloalkyl groups, 4- to 6-membered heterocycloalkyl groups, and 5- to 6-membered heteroaryl groups, excluding unsubstituted methoxy groups; NR 5 R 6 Groups, and [ka] basis and R 4 is a C1-C3 alkyl group; R 5 is a hydrogen atom, R 6 but, C1-C3-alkyl groups which are substituted one or more times by groups independently selected from 5-6 membered heteroaryl groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group Selected from: The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0101] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 but, a phenyl group substituted one or more times by a group independently selected from halogen atoms, C1-C3-alkyl groups and C1-C3-haloalkyl groups, a 4- to 6-membered heterocycloalkyl group substituted one or more times with a group independently selected from a fluorine atom, a hydroxy group, and a C1-C3 alkyl group; [ka] base, [ka] base, [ka] base, a 5- to 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; NR 5 R 6 Groups, and [ka] basis and R 4is a hydrogen atom or a C1-C3 alkyl group; R 5 is a hydrogen atom, R 6 but, C1-C3-alkyl groups which are substituted one or more times by groups selected from 5-6-membered heteroaryl groups, C1-C3-alkoxy groups, hydroxy groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which themselves are optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group Selected from: The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0102] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group, or a trifluoromethyl group; R 2 is a hydrogen atom, a fluorine atom or a chlorine atom; However, R 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 -(CH2)-CH(CH3)2 group, -(CH2)3-O-CH3 group, -CH2-(morpholin-4-yl) group, -CH2-N(CH3)2 group, -CH=C(CH3)2 group, -CH=CH-CH2-O-CH3 group, -CH=CH-CH2-O-CH2-CH3 group, cyclopent-1-en-1-yl group, 4-chlorophenyl group, 4-fluoro-phenyl group, 4-fluoro-2-methyl-phenyl group, 3-fluoro-4-methyl-phenyl group, 4-fluoro-2-trifluoromethyl-phenyl group, piperidin-1-yl group, 3-hydroxy-piperidin-1-yl group, 4,4-difluoro-piperidin-1-yl group, 4-ethyl-4-hydroxy-piperidin-1-yl group, [ka] base, [ka] base, [ka] group, 3-hydroxy-3-methyl-pyrrolidin-1-yl group, 4-methyl-piperazin-1-yl group, morpholin-4-yl group, pyridin-4-yl group, 2-amino-pyridin-4-yl group, 3-chloro-pyridin-6-yl group, 3-fluoro-pyrazol-1-yl group, 3-trifluoromethyl-pyrazol-1-yl group, 1-difluoromethylpyrazol-4-yl group, 4-trifluoromethyl-1,2,3-triazol-2-yl group, -NH-CH2-(pyrazol-3-yl) group, -NH-CH2-(pyrazol-5-yl) group, -NH-CH2-pyrazin-2-yl group, -NH-(CH2)2-O-CH3 group, -NH-CH2-CH(OH)CF3 group, [ka] group, NH-cyclopentyl group, -O-(CH2)2-CH3 group, -O-(CH2)2-C(CH3)3 group, -O-(CH2)-CH(CH3)-OH group, -O-(CH2)-C(CH3)2-OH group, -O-CH2-(pyrazol-3-yl) group, -O-(CH2)2-O-CH3 group, -O-CH2-cyclobutyl group, -O-CH2-tetrahydrofuran-2-yl group, -O-(CH2)2-CF3 group and -O-(CH2)3CH3 group. is selected from R 4 is a hydrogen atom or a methyl group; The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0103] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group, or a trifluoromethyl group; R 2 is a hydrogen atom, a fluorine atom or a chlorine atom; However, R 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 -(CH2)-CH(CH3)2 group, -(CH2)3-O-CH3 group, -CH2-(morpholin-4-yl) group, -CH2-N(CH3)2 group, -CH=C(CH3)2 group, -CH=CH-CH2-O-CH3 group, -CH=CH-CH2-O-CH2-CH3 group, cyclopent-1-en-1-yl group, 4-chlorophenyl group, 4-fluoro-phenyl group, 4-fluoro-2-methyl-phenyl group, 3-fluoro-4-methyl-phenyl group, 4-fluoro-2-trifluoromethyl-phenyl group, piperidin-1-yl group, 3-hydroxy-piperidin-1-yl group, 4,4-difluoro-piperidin-1-yl group, 4-ethyl-4-hydroxy-piperidin-1-yl group, [ka] base, [ka] base, [ka] group, 3-hydroxy-3-methyl-pyrrolidin-1-yl group, 4-methyl-piperazin-1-yl group, morpholin-4-yl group, pyridin-4-yl group, 2-amino-pyridin-4-yl group, 3-chloro-pyridin-6-yl group, 3-fluoro-pyrazol-1-yl group, 3-trifluoromethyl-pyrazol-1-yl group, 1-difluoromethylpyrazol-4-yl group, 4-trifluoromethyl-1,2,3-triazol-2-yl group, -NH-CH2-(pyrazol-3-yl) group, -NH-CH2-(pyrazol-5-yl) group, -NH-CH2-pyrazin-2-yl group, -NH-(CH2)2-O-CH3 group, -NH-CH2-CH(OH)CF3 group, [ka] group, NH-cyclopentyl group, -O-(CH2)2-CH3 group, -O-(CH2)2-C(CH3)3 group, -O-(CH2)-CH(CH3)-OH group, -O-(CH2)-C(CH3)2-OH group, -O-CH2-(pyrazol-3-yl) group, -O-(CH2)2-O-CH3 group, -O-CH2-cyclobutyl group, -O-CH2-tetrahydrofuran-2-yl group, -O-(CH2)2-CF3 group and -O-(CH2)3CH3 group. is selected from R 4 is a hydrogen atom, The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0104] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group, or a trifluoromethyl group; R 2 is a hydrogen atom, a fluorine atom or a chlorine atom; However, R 1 and R 2 cannot both be hydrogen atoms at the same time; R 3-(CH2)-CH(CH3)2 group, -(CH2)3-O-CH3 group, -CH2-(morpholin-4-yl) group, -CH2-N(CH3)2 group, -CH=C(CH3)2 group, -CH=CH-CH2-O-CH3 group, -CH=CH-CH2-O-CH2-CH3 group, cyclopent-1-en-1-yl group, 4-chlorophenyl group, 4-fluoro-phenyl group, 4-fluoro-2-methyl-phenyl group, 3-fluoro-4-methyl-phenyl group, 4-fluoro-2-trifluoromethyl-phenyl group, piperidin-1-yl group, 3-hydroxy-piperidin-1-yl group, 4,4-difluoro-piperidin-1-yl group, 4-ethyl-4-hydroxy-piperidin-1-yl group, [ka] base, [ka] base, [ka] group, 3-hydroxy-3-methyl-pyrrolidin-1-yl group, 4-methyl-piperazin-1-yl group, morpholin-4-yl group, pyridin-4-yl group, 2-amino-pyridin-4-yl group, 3-chloro-pyridin-6-yl group, 3-fluoro-pyrazol-1-yl group, 3-trifluoromethyl-pyrazol-1-yl group, 1-difluoromethylpyrazol-4-yl group, 4-trifluoromethyl-1,2,3-triazol-2-yl group, -NH-CH2-(pyrazol-3-yl) group, -NH-CH2-(pyrazol-5-yl) group, -NH-CH2-pyrazin-2-yl group, -NH-(CH2)2-O-CH3 group, -NH-CH2-CH(OH)CF3 group, [ka] group, NH-cyclopentyl group, -O-(CH2)2-CH3 group, -O-(CH2)2-C(CH3)3 group, -O-(CH2)-CH(CH3)-OH group, -O-(CH2)-C(CH3)2-OH group, -O-CH2-(pyrazol-3-yl) group, -O-(CH2)2-O-CH3 group, -O-CH2-cyclobutyl group, -O-CH2-tetrahydrofuran-2-yl group, -O-(CH2)2-CF3 group and -O-(CH2)3CH3 group. is selected from R 4 is a methyl group; The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0105] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group, or a trifluoromethyl group; R 2 is a hydrogen atom, a fluorine atom or a chlorine atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 -(CH2)3-O-CH3 group, -CH2-(morpholin-4-yl) group, -CH2-N(CH3)2 group, -CH=C(CH3)2 group, -CH=CH-CH2-O-CH3 group, -CH=CH-CH2-O-CH2-CH3 group, cyclopent-1-en-1-yl group, 4-chlorophenyl group, 4-fluoro-phenyl group, 4-fluoro-2-methyl-phenyl group, 3-fluoro-4-methyl-phenyl group, 4-fluoro-2-trifluoromethyl-phenyl group, 3-hydroxy-piperidin-1-yl group, 4,4-difluoro-piperidin-1-yl group, 4-ethyl-4-hydroxy-piperidin-1-yl group, [ka] base, [ka] base, [ka] base, 3-hydroxy-3-methyl-pyrrolidin-1-yl group, 4-methyl-piperazin-1-yl group, 2-amino-pyridin-4-yl group, 3-chloro-pyridin-6-yl group, 3-fluoro-pyrazol-1-yl group, 3-trifluoromethyl-pyrazol-1-yl group, 1-difluoromethylpyrazol-4-yl group, 4-trifluoromethyl-1,2,3-triazol-2-yl group, -NH-CH2-(pyrazol-3-yl) group, -NH-CH2-(pyrazol-5-yl) group, -NH-CH2-pyrazin-2-yl group, -NH-CH2-CH(OH)CF3 group, [ka] group, NH-cyclopentyl group, -O-(CH2)2-CH3 group, -O-(CH2)2-C(CH3)3 group, -O-(CH2)-CH(CH3)-OH group, -O-(CH2)-C(CH3)2-OH group, -O-CH2-(pyrazol-3-yl) group, -O-(CH2)2-O-CH3 group, -O-CH2-cyclobutyl group, -O-CH2-tetrahydrofuran-2-yl group, -O-(CH2)2-CF3 group and -O-(CH2)3CH3 group. is selected from R 4 is a hydrogen atom or a methyl group; The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0106] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group, or a trifluoromethyl group; R 2 is a hydrogen atom, a fluorine atom or a chlorine atom; R 3 -(CH2)3-O-CH3 group, -CH2-(morpholin-4-yl) group, -CH2-N(CH3)2 group, -CH=C(CH3)2 group, -CH=CH-CH2-O-CH3 group, -CH=CH-CH2-O-CH2-CH3 group, cyclopent-1-en-1-yl group, 4-chlorophenyl group, 4-fluoro-phenyl group, 4-fluoro-2-methyl-phenyl group, 3-fluoro-4-methyl-phenyl group, 4-fluoro-2-trifluoromethyl-phenyl group, 3-hydroxy-piperidin-1-yl group, 4,4-difluoro-piperidin-1-yl group, 4-ethyl-4-hydroxy-piperidin-1-yl group, [ka] base, [ka] base, [ka] base, 3-hydroxy-3-methyl-pyrrolidin-1-yl group, 4-methyl-piperazin-1-yl group, 2-amino-pyridin-4-yl group, 3-chloro-pyridin-6-yl group, 3-fluoro-pyrazol-1-yl group, 3-trifluoromethyl-pyrazol-1-yl group, 1-difluoromethylpyrazol-4-yl group, 4-trifluoromethyl-1,2,3-triazol-2-yl group, -NH-CH2-(pyrazol-3-yl) group, -NH-CH2-(pyrazol-5-yl) group, -NH-CH2-pyrazin-2-yl group, -NH-CH2-CH(OH)CF3 group, [ka] group, NH-cyclopentyl group, -O-(CH2)2-CH3 group, -O-(CH2)2-C(CH3)3 group, -O-(CH2)-CH(CH3)-OH group, -O-(CH2)-C(CH3)2-OH group, -O-CH2-(pyrazol-3-yl) group, -O-(CH2)2-O-CH3 group, -O-CH2-cyclobutyl group, -O-CH2-tetrahydrofuran-2-yl group, -O-(CH2)2-CF3 group and -O-(CH2)3CH3 group. is selected from R 4 is a hydrogen atom or a methyl group; The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0107] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group, or a trifluoromethyl group; R 2 is a hydrogen atom, a fluorine atom or a chlorine atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 -(CH2)3-O-CH3 group, -CH2-(morpholin-4-yl) group, -CH2-N(CH3)2 group, -CH=C(CH3)2 group, -CH=CH-CH2-O-CH3 group, -CH=CH-CH2-O-CH2-CH3 group, cyclopent-1-en-1-yl group, 4-chlorophenyl group, 4-fluoro-phenyl group, 4-fluoro-2-methyl-phenyl group, 3-fluoro-4-methyl-phenyl group, 4-fluoro-2-trifluoromethyl-phenyl group, 3-hydroxy-piperidin-1-yl group, 4,4-difluoro-piperidin-1-yl group, 4-ethyl-4-hydroxy-piperidin-1-yl group, [ka] base, [ka] base, [ka] base, 3-hydroxy-3-methyl-pyrrolidin-1-yl group, 4-methyl-piperazin-1-yl group, 2-amino-pyridin-4-yl group, 3-chloro-pyridin-6-yl group, 3-fluoro-pyrazol-1-yl group, 3-trifluoromethyl-pyrazol-1-yl group, 1-difluoromethylpyrazol-4-yl group, 4-trifluoromethyl-1,2,3-triazol-2-yl group, -NH-CH2-(pyrazol-3-yl) group, -NH-CH2-(pyrazol-5-yl) group, -NH-CH2-pyrazin-2-yl group, -NH-CH2-CH(OH)CF3 group, [ka] group, NH-cyclopentyl group, -O-(CH2)2-CH3 group, -O-(CH2)2-C(CH3)3 group, -O-(CH2)-CH(CH3)-OH group, -O-(CH2)-C(CH3)2-OH group, -O-CH2-(pyrazol-3-yl) group, -O-(CH2)2-O-CH3 group, -O-CH2-cyclobutyl group, -O-CH2-tetrahydrofuran-2-yl group, -O-(CH2)2-CF3 group and -O-(CH2)3CH3 group. is selected from R 4 is a hydrogen atom, The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0108] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group, or a trifluoromethyl group; R 2 is a hydrogen atom, a fluorine atom or a chlorine atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 -(CH2)3-O-CH3 group, -CH2-(morpholin-4-yl) group, -CH2-N(CH3)2 group, -CH=C(CH3)2 group, -CH=CH-CH2-O-CH3 group, -CH=CH-CH2-O-CH2-CH3 group, cyclopent-1-en-1-yl group, 4-chlorophenyl group, 4-fluoro-phenyl group, 4-fluoro-2-methyl-phenyl group, 3-fluoro-4-methyl-phenyl group, 4-fluoro-2-trifluoromethyl-phenyl group, 3-hydroxy-piperidin-1-yl group, 4,4-difluoro-piperidin-1-yl group, 4-ethyl-4-hydroxy-piperidin-1-yl group, [ka] base, [ka] base, [ka] base, 3-hydroxy-3-methyl-pyrrolidin-1-yl group, 4-methyl-piperazin-1-yl group, 2-amino-pyridin-4-yl group, 3-chloro-pyridin-6-yl group, 3-fluoro-pyrazol-1-yl group, 3-trifluoromethyl-pyrazol-1-yl group, 1-difluoromethylpyrazol-4-yl group, 4-trifluoromethyl-1,2,3-triazol-2-yl group, -NH-CH2-(pyrazol-3-yl) group, -NH-CH2-(pyrazol-5-yl) group, -NH-CH2-pyrazin-2-yl group, -NH-CH2-CH(OH)CF3 group, [ka] group, NH-cyclopentyl group, -O-(CH2)2-CH3 group, -O-(CH2)2-C(CH3)3 group, -O-(CH2)-CH(CH3)-OH group, -O-(CH2)-C(CH3)2-OH group, -O-CH2-(pyrazol-3-yl) group, -O-(CH2)2-O-CH3 group, -O-CH2-cyclobutyl group, -O-CH2-tetrahydrofuran-2-yl group, -O-(CH2)2-CF3 group and -O-(CH2)3CH3 group. is selected from R 4 is a methyl group; The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0109] According to another embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group or a trifluoromethyl group, R 2 is a hydrogen atom, a fluorine atom or a chlorine atom, However, R 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 a 5- to 6-membered heteroaryl group substituted with a trifluoromethyl group; Substituted with a group independently selected from a hydroxy group or a C1-C3 alkyl group. 4-6 membered heterocycloalkyl groups, C4-C6-heterocycloalkyl groups optionally substituted by one or two groups independently selected from C1-C3-alkyl groups and hydroxy groups; And NR 5 R 6 basis is selected from R 4 is a methyl group; R 5 is a hydrogen atom; R 6 but, C1-C3-alkyl groups which are themselves substituted one or more times with groups independently selected from heteroaryl groups, C1-C3-haloalkyl groups and hydroxy groups. And C5-C6-Cycloalkyl group That is, The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0110] According to another embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group or a trifluoromethyl group, R 2 is a hydrogen atom, a fluorine atom or a chlorine atom, However, R 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 a 5- to 6-membered heteroaryl group substituted with a trifluoromethyl group; Substituted with a group independently selected from a hydroxy group or a C1-C3 alkyl group. 4-6 membered heterocycloalkyl groups, C4-C6-heterocycloalkyl groups optionally substituted by one or two groups independently selected from C1-C3-alkyl groups and hydroxy groups; And NR 5 R 6 basis is selected from R 4 is a methyl group; R 5 is a hydrogen atom; R 6 but, C1-C3-alkyl groups which are themselves optionally substituted one or more times with groups independently selected from heteroaryl groups, C1-C3-haloalkyl groups and hydroxy groups. (However, pyridyl or furanyl groups as single substituents and C1-C3-alkyl groups substituted with hydroxyl groups are excluded.) And C5-C6-Cycloalkyl group That is, The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0111] According to yet another embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group; R 2 is a hydrogen atom, R 3 is selected from the group -NH-CH2-CH(OH)CF3, -NH-cyclopentyl, -NH-CH2-(pyrazol-5-yl), -NH-CH2-pyrazin-2-yl, 3-hydroxy-3-methyl-azetidin-1-yl and 3-trifluoromethyl-pyrazol-1-yl; R 4 is a methyl group; The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0112] According to yet another embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group; R 2 is a hydrogen atom, R 3 is selected from the group -NH-CH2-CH(OH)CF3, -NH-cyclopentyl, -NH-CH2-(pyrazol-5-yl), -NH-CH2-pyrazin-2-yl, 3-hydroxy-3-methyl-azetidin-1-yl, 3-trifluoromethyl-pyrazol-1-yl, 3-difluoromethyl-pyrazol-1-yl, R 4 is a methyl group; The compounds include compounds of the above general formula (I) or their stereoisomers, tautomers, N-oxides, hydrates, solvates or salts, or salts of the stereoisomers, tautomers, N-oxides or mixtures thereof.

[0113] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: (5S)-6-{4-[(2-methoxyethyl)amino]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(2-azaspiro[3.3]heptan-2-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-{[(2S)-3,3,3-trifluoro-2-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(morpholin-4-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-{3-(trifluoromethyl)-4-[4-(trifluoromethyl)-2H-1,2,3-triazol-2-yl]phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-{3-(trifluoromethyl)-4-[3-(difluoromethyl)-1H-pyrazol-1-yl]phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one, rel-(5R)-6-{4-[(1R,5R)-3-azabicyclo[3.1.0]hexan-3-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-({[1-(hydroxymethyl)cyclobutyl]methyl}amino)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(3-fluoro-1H-pyrazol-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(4-ethyl-4-hydroxypiperidin-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(3S)-3-hydroxypiperidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(3R)-3-hydroxypiperidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(piperidin-1-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(3R)-3-hydroxy-3-methylpyrrolidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(3S)-3-hydroxy-3-methylpyrrolidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(4,4-difluoropiperidin-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-Methyl-6-{3-(trifluoromethyl)-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or a mixture thereof.

[0114] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: (5S)-6-{4-[(2-methoxyethyl)amino]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(2-azaspiro[3.3]heptan-2-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-{[(2S)-3,3,3-trifluoro-2-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(morpholin-4-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-{3-(trifluoromethyl)-4-[4-(trifluoromethyl)-2H-1,2,3-triazol-2-yl]phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-{3-(trifluoromethyl)-4-[3-(difluoromethyl)-1H-pyrazol-1-yl]phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one, rel-(5R)-6-{4-[(1R,5R)-3-azabicyclo[3.1.0]hexan-3-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-({[1-(hydroxymethyl)cyclobutyl]methyl}amino)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(3-fluoro-1H-pyrazol-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(4-ethyl-4-hydroxypiperidin-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(3S)-3-hydroxypiperidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(3R)-3-hydroxypiperidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(piperidin-1-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(3R)-3-hydroxy-3-methylpyrrolidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(3S)-3-hydroxy-3-methylpyrrolidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(4,4-difluoropiperidin-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4'-fluoro-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(2-aminopyridin-4-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(5-chloropyridin-2-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4 triazin-3(2H)-one, (5S)-5-methyl-6-[4-(2-methylprop-1-en-1-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(1E)-3-methoxyprop-1-en-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(E)-2-ethoxyvinyl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(pyridin-4-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(morpholin-4-ylmethyl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(cyclopent-1-en-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4'-chloro-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[3'-fluoro-4'-methyl-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(dimethylamino)methyl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(2R)-2-hydroxypropoxy]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(2-hydroxy-2-methylpropoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(2S)-2-hydroxypropoxy]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-propoxy-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(2-methoxyethoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(cyclobutylmethoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-{4-[(2S)-tetrahydrofuran-2-ylmethoxy]-3-(trifluoromethyl)phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-{4-[(2R)-tetrahydrofuran-2-ylmethoxy]-3-(trifluoromethyl)phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[3-(trifluoromethyl)-4-(3,3,3-trifluoropropoxy)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-butoxy-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(3,3-dimethylbutoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(3-methoxypropyl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-isobutyl-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(1H-pyrazol-3-ylmethoxy)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-(4'-fluoro-2'-methyl[biphenyl]-4-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4'-fluoro-2'-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-{3-(trifluoromethyl)-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-{[(1H-pyrazol-5-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(3-hydroxy-3-methylazetidin-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(cyclopentylamino)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-Methyl-6-[4-{[(2R)-3,3,3-trifluoro-2-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one and (5S)-5-Methyl-6-[4-{[(pyrazin-2-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or a mixture thereof.

[0115] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: (5S)-6-[4'-fluoro-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(2-aminopyridin-4-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(5-chloropyridin-2-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4 triazin-3(2H)-one, (5S)-5-methyl-6-[4-(2-methylprop-1-en-1-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(1E)-3-methoxyprop-1-en-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(E)-2-ethoxyvinyl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(pyridin-4-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(morpholin-4-ylmethyl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(cyclopent-1-en-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4'-chloro-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[3'-fluoro-4'-methyl-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(dimethylamino)methyl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(2R)-2-hydroxypropoxy]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(2-hydroxy-2-methylpropoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(2S)-2-hydroxypropoxy]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-propoxy-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(2-methoxyethoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(cyclobutylmethoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-{4-[(2S)-tetrahydrofuran-2-ylmethoxy]-3-(trifluoromethyl)phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-{4-[(2R)-tetrahydrofuran-2-ylmethoxy]-3-(trifluoromethyl)phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[3-(trifluoromethyl)-4-(3,3,3-trifluoropropoxy)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-butoxy-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(3,3-dimethylbutoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(3-methoxypropyl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-isobutyl-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(1H-pyrazol-3-ylmethoxy)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-(4'-fluoro-2'-methyl[biphenyl]-4-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4'-fluoro-2'-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-{3-(trifluoromethyl)-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-{3-(trifluoromethyl)-4-[3-(difluoromethyl)-1H-pyrazol-1-yl]phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-{[(1H-pyrazol-5-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(3-hydroxy-3-methylazetidin-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(cyclopentylamino)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-Methyl-6-[4-{[(2R)-3,3,3-trifluoro-2-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one and (5S)-5-methyl-6-[4-{[(pyrazin-2-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or a mixture thereof.

[0116] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: (5S)-6-{4-[(2-methoxyethyl)amino]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(2-azaspiro[3.3]heptan-2-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-{[(2S)-3,3,3-trifluoro-2-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(morpholin-4-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-{3-(trifluoromethyl)-4-[4-(trifluoromethyl)-2H-1,2,3-triazol-2-yl]phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one, rel-(5R)-6-{4-[(1R,5R)-3-azabicyclo[3.1.0]hexan-3-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-({[1-(hydroxymethyl)cyclobutyl]methyl}amino)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(3-fluoro-1H-pyrazol-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(4-ethyl-4-hydroxypiperidin-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(3S)-3-hydroxypiperidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(3R)-3-hydroxypiperidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(piperidin-1-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(3R)-3-hydroxy-3-methylpyrrolidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(3S)-3-hydroxy-3-methylpyrrolidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(4,4-difluoropiperidin-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4'-fluoro-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(2-aminopyridin-4-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(5-chloropyridin-2-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4 triazin-3(2H)-one, (5S)-5-methyl-6-[4-(2-methylprop-1-en-1-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(1E)-3-methoxyprop-1-en-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(E)-2-ethoxyvinyl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(pyridin-4-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(morpholin-4-ylmethyl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(cyclopent-1-en-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4'-chloro-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[3'-fluoro-4'-methyl-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(dimethylamino)methyl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(2R)-2-hydroxypropoxy]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(2-hydroxy-2-methylpropoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-{4-[(2S)-2-hydroxypropoxy]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-propoxy-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(2-methoxyethoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(cyclobutylmethoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-{4-[(2S)-tetrahydrofuran-2-ylmethoxy]-3-(trifluoromethyl)phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-{4-[(2R)-tetrahydrofuran-2-ylmethoxy]-3-(trifluoromethyl)phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[3-(trifluoromethyl)-4-(3,3,3-trifluoropropoxy)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-butoxy-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(3,3-dimethylbutoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-(3-methoxypropyl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-[4-isobutyl-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-5-methyl-6-[4-(1H-pyrazol-3-ylmethoxy)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one, (5S)-6-(4'-fluoro-2'-methyl[biphenyl]-4-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one and (5S)-6-[4'-fluoro-2'-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

[0117] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: (5S)-6-{4-[(2-methoxyethyl)amino]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(2-azaspiro[3.3]heptan-2-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-{[(2S)-3,3,3-trifluoro-2-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(morpholin-4-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-{3-(trifluoromethyl)-4-[4-(trifluoromethyl)-2H-1,2,3-triazol-2-yl]phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one rel-(5R)-6-{4-[(1R,5R)-3-azabicyclo[3.1.0]hexan-3-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-({[1-(hydroxymethyl)cyclobutyl]methyl}amino)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(3-fluoro-1H-pyrazol-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(4-ethyl-4-hydroxypiperidin-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(3S)-3-hydroxypiperidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(3R)-3-hydroxypiperidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(piperidin-1-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(3R)-3-hydroxy-3-methylpyrrolidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(3S)-3-hydroxy-3-methylpyrrolidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(4,4-difluoropiperidin-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

[0118] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: (5S)-6-[4'-fluoro-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(2-aminopyridin-4-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(5-chloropyridin-2-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(2-methylprop-1-en-1-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(1E)-3-methoxyprop-1-en-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(E)-2-ethoxyvinyl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(pyridin-4-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(morpholin-4-ylmethyl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(cyclopent-1-en-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4'-chloro-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[3'-fluoro-4'-methyl-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(dimethylamino)methyl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(2R)-2-hydroxypropoxy]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(2-hydroxy-2-methylpropoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(2S)-2-hydroxypropoxy]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-propoxy-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(2-methoxyethoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(cyclobutylmethoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-{4-[(2S)-tetrahydrofuran-2-ylmethoxy]-3-(trifluoromethyl)phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-{4-[(2R)-tetrahydrofuran-2-ylmethoxy]-3-(trifluoromethyl)phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[3-(trifluoromethyl)-4-(3,3,3-trifluoropropoxy)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-butoxy-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(3,3-dimethylbutoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(3-methoxypropyl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-isobutyl-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(1H-pyrazol-3-ylmethoxy)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-(4'-fluoro-2'-methyl[biphenyl]-4-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4'-fluoro-2'-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

[0119] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: (5S)-6-[4'-fluoro-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(2-aminopyridin-4-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(5-chloropyridin-2-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(2-methylprop-1-en-1-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(1E)-3-methoxyprop-1-en-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(E)-2-ethoxyvinyl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(pyridin-4-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(morpholin-4-ylmethyl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(cyclopent-1-en-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4'-chloro-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[3'-fluoro-4'-methyl-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(dimethylamino)methyl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(2R)-2-hydroxypropoxy]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(2-hydroxy-2-methylpropoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(2S)-2-hydroxypropoxy]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-propoxy-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(2-methoxyethoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(cyclobutylmethoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-{4-[(2S)-tetrahydrofuran-2-ylmethoxy]-3-(trifluoromethyl)phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-{4-[(2R)-tetrahydrofuran-2-ylmethoxy]-3-(trifluoromethyl)phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[3-(trifluoromethyl)-4-(3,3,3-trifluoropropoxy)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-butoxy-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(3,3-dimethylbutoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(3-methoxypropyl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-isobutyl-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(1H-pyrazol-3-ylmethoxy)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

[0120] According to a further embodiment of the first aspect, the present invention relates to a compound of general formula (I) as above: (5S)-6-(4'-fluoro-2'-methyl[biphenyl]-4-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4'-fluoro-2'-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

[0121] According to a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: (5S)-5-Methyl-6-{3-(trifluoromethyl)-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-{[(1H-pyrazol-5-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(3-hydroxy-3-methylazetidin-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(cyclopentylamino)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-{[(2R)-3,3,3-trifluoro-2-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-{[(pyrazin-2-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

[0122] According to a further embodiment of the first aspect, the present invention relates to a compound of general formula (I) (5S)-5-Methyl-6-{3-(trifluoromethyl)-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

[0123] According to a further embodiment of the first aspect, the present invention relates to a compound of general formula (I) (5S)-5-Methyl-6-[4-{[(1H-pyrazol-5-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

[0124] According to a further embodiment of the first aspect, the present invention relates to a compound of general formula (I) as defined above, (5S)-6-[4-(3-hydroxy-3-methylazetidin-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

[0125] According to a further embodiment of the first aspect, the present invention relates to a compound of general formula (I) as defined above, (5S)-6-[4-(cyclopentylamino)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

[0126] According to a further embodiment of the first aspect, the present invention relates to a compound of general formula (I) as defined above, (5S)-5-Methyl-6-[4-{[(2R)-3,3,3-trifluoro-2-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

[0127] According to a further embodiment of the first aspect, the present invention relates to a compound of general formula (I) as defined above, (5S)-5-Methyl-6-[4-{[(pyrazin-2-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

[0128] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; R 3 but, A phenyl group substituted one or more times with a group independently selected from a halogen atom, a C1-C3-alkyl group, and a C1-C3-haloalkyl group. That is, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0129] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; R 3 but, A phenyl group substituted one or more times with a group independently selected from a halogen atom, a C1-C3 alkyl group, and a C1-C3 fluoroalkyl group. That is, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0130] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 but, A phenyl group substituted one or more times with a group independently selected from a halogen atom, a C1-C3-alkyl group, and a C1-C3-haloalkyl group. That is, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0131] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 but, A phenyl group substituted one or more times with a group independently selected from a halogen atom, a C1-C3 alkyl group, and a C1-C3 fluoroalkyl group. That is, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0132] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 is a phenyl group substituted one or more times with a group independently selected from a fluorine atom, a chlorine atom, a methyl group, a trifluoromethyl group and a difluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0133] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group, R 2 is a hydrogen atom, R 3 is a phenyl group substituted one or more times by radicals independently selected from halogen atoms, C1-C3-alkyl groups and C1-C3-haloalkyl groups, R 4 is a methyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0134] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group, R 2 is a hydrogen atom, R 3is a phenyl group substituted one or more times with a group independently selected from a fluorine atom, a chlorine atom, a methyl group, a trifluoromethyl group and a difluoromethyl group; R 4 is a methyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0135] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group, R 2 is a hydrogen atom, R 3 is selected from the 4-chlorophenyl group, the 4-fluoro-phenyl group, the 4-fluoro-2-methyl-phenyl group, the 3-fluoro-4-methyl-phenyl group and the 4-fluoro-2-trifluoromethyl-phenyl group, R 4 is a methyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0136] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group, R 2 is a hydrogen atom, R 3 is a phenyl group substituted one or more times with a group independently selected from a fluorine atom, a chlorine atom, a methyl group, and a trifluoromethyl group; R 4 is a methyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0137] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group, R 2 is a hydrogen atom, R 3 is a C1-C6 alkyl group, or a C1-C3 alkoxy group, a heterocycloalkyl group, or a NR 5 R 6 is a C1-C3-alkyl group, optionally substituted one or more times with radicals independently selected from the groups R 4 is a methyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0138] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a C1-C3 haloalkyl group, R 2 is a hydrogen atom, R 3 is a C1-C6 alkyl group, or a C1-C3 alkoxy group, a heterocycloalkyl group, or a NR 5 R 6 is a C1-C3-alkyl group, optionally substituted one or more times with radicals independently selected from the groups R 4 is a methyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0139] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group, R 2 is a hydrogen atom, R3 is a C2-C6-alkenyl group optionally substituted by a C1-C3-alkoxy group, R 4 is a methyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0140] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group, R 2 is a hydrogen atom, R 3 is a C5-C6 cycloalkenyl group, R 4 is a methyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0141] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group, R 2 is a hydrogen atom, R 3 is a 4- to 6-membered heterocycloalkyl group, which is optionally substituted one or more times with groups independently selected from fluorine atoms, hydroxy groups, and C1-C3-alkyl groups; [ka] base, [ka] Group or [ka] It is based on R 4is a methyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0142] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a C1-C3 haloalkyl group, R 2 is a hydrogen atom or a halogen atom; R 3 is a 5-10 membered heteroaryl group optionally substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; R 4 is a C1-C3 alkyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0143] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a C1-C3 haloalkyl group, R 2 is a hydrogen atom; R 3 is a 5-10 membered heteroaryl group optionally substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; R 4 is a C1-C3 alkyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0144] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a C1-C3 haloalkyl group, R 2 is a halogen atom; R 3 is a 5-10 membered heteroaryl group optionally substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; R 4 is a C1-C3 alkyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0145] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a C1-C3 haloalkyl group, R 2 is a hydrogen atom; R 3 is a 5-10 membered heteroaryl group optionally substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; R 4 is a methyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0146] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group, R 2 is a hydrogen atom; R 3 is a 5-10 membered heteroaryl group optionally substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; R 4 is a C1-C3 alkyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0147] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group, R 2 is a hydrogen atom, R 3 is a 5-10 membered heteroaryl group optionally substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; R 4 is a methyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0148] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group, R 2 is a hydrogen atom, R 3 is a 5- to 6-membered heteroaryl group optionally substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group, and a difluoromethyl group; R 4 is a methyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0149] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group, R 2 is a hydrogen atom, R 3 is a 5-membered heteroaryl group optionally substituted one or more times with groups independently selected from amino groups, chlorine atoms, fluorine atoms, trifluoromethyl groups and difluoromethyl groups; R 4 is a methyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0150] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group, R 2 is a hydrogen atom, R 3 is a 6-membered heteroaryl group optionally substituted one or more times with groups independently selected from amino groups, chlorine atoms, fluorine atoms, trifluoromethyl groups and difluoromethyl groups; R 4 is a methyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0151] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group, R 2 is a hydrogen atom, R 3is a C1-C6 alkoxy group optionally substituted by groups independently selected from a C1-C3 haloalkyl group, a hydroxy group, a C1-C3 alkoxy group, a C4-C6 cycloalkyl group, a 4- to 6-membered heterocycloalkyl group and a 5- to 6-membered heteroaryl group, R 4 is a methyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0152] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group, R 2 is a hydrogen atom, R 3 But, NR 5 R 6 Group or [ka] It is based on R 4 is a methyl group; R 5 is a hydrogen atom, R 6 but, C1-C3-alkyl groups which are optionally substituted one or more times by groups independently selected from 5-6 membered heteroaryl groups, C1-C3-alkoxy groups, hydroxy groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which themselves are optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group Selected from: This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0153] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group, R 2 is a hydrogen atom, R 3 NR 5 R 6 It is based on R 4 is a methyl group; R 5 is a hydrogen atom, R 6 but, C1-C3-alkyl groups which are optionally substituted one or more times by groups independently selected from 5-6 membered heteroaryl groups, C1-C3-alkoxy groups, hydroxy groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which themselves are optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group Selected from: This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0154] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group, R 2 is a hydrogen atom, R 3 but [ka] It is based on R 4 is a methyl group; R 5 is a hydrogen atom, R 6 but, C1-C3-alkyl groups which are optionally substituted one or more times by groups independently selected from 5-6 membered heteroaryl groups, C1-C3-alkoxy groups, hydroxy groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which themselves are optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group Selected from: This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0155] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group or a C1-C3-haloalkyl group; However, R 1 and R 2 cannot both be hydrogen atoms at the same time. This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0156] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group or a C1-C3-haloalkyl group; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time. This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0157] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group, or a trifluoromethyl group; However, R 1 and R 2 cannot both be hydrogen atoms at the same time. This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0158] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group, or a trifluoromethyl group; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time. This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0159] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a halogen atom or a C1-C3-haloalkyl group; However, R 1 and R 2 cannot both be hydrogen atoms at the same time. This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0160] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a halogen atom or a C1-C3-haloalkyl group; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time. This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0161] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom; However, R 1 and R 2 cannot both be hydrogen atoms at the same time. This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0162] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time. This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0163] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a C1-C3 alkyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0164] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a C1-C3-alkyl group or a C1-C3-haloalkyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0165] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a halogen atom or a C1-C3 haloalkyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0166] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a halogen atom; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0167] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a C1-C3 haloalkyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0168] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group, or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 1 and R 2 cannot both be hydrogen atoms at the same time. This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0169] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group, or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time. This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0170] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 2 is a hydrogen atom or a halogen atom; However, R1 and R 2 cannot both be hydrogen atoms at the same time. This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0171] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 2 is a hydrogen atom or a halogen atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time. This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0172] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 2 is a hydrogen atom, a fluorine atom or a chlorine atom; However, R 1 and R 2 cannot both be hydrogen atoms at the same time. This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0173] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 2 is a hydrogen atom, a fluorine atom or a chlorine atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time. This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0174] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a trifluoromethyl group; R 2 is a hydrogen atom, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0175] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 1 is a hydrogen atom, R 2 is a trifluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0176] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a C1-C3-alkyl group substituted one or more times by groups independently selected from a C1-C3-alkyl group, a C1-C3-alkoxy group, a heterocycloalkyl group, and an amino group substituted one or two times by a C1-C3-alkyl group, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0177] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a C1-C3-alkyl group substituted one or more times by groups independently selected from C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups and amino groups optionally substituted one or two times by a C1-C3-alkyl group, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0178] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a C1-C3-alkyl group substituted one or more times by radicals independently selected from C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups and amino groups optionally substituted one or two times by a C1-C3-alkyl group, However, methyl groups are excluded. This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0179] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a C1-C3-alkyl group substituted one or more times by groups independently selected from C1-C3-alkoxy groups, heterocycloalkyl groups and amino groups optionally substituted one or two times by a C1-C3-alkyl group, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0180] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3is selected from the group -(CH2)3-O-CH3, -CH2-(morpholin-4-yl) and -CH2-N(CH3)2; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0181] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a C2-C6-alkenyl group optionally substituted by a C1-C3-alkoxy group, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0182] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a phenyl group substituted one or more times by radicals independently selected from halogen atoms, C1-C3-alkyl groups and C1-C3-haloalkyl groups, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0183] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a phenyl group independently substituted one or more times with halogen atoms; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0184] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3is a phenyl group substituted one or more times by radicals independently selected from C1-C3-alkyl and C1-C3-haloalkyl groups, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0185] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a phenyl group which is independently substituted one or more times with a C1-C3-alkyl group, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0186] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a phenyl group substituted independently one or more times by C1-C3-haloalkyl groups, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0187] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a phenyl group substituted one or more times with a group independently selected from a fluorine atom, a chlorine atom, a methyl group, a trifluoromethyl group and a difluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0188] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3is a phenyl group substituted one or more times with a group independently selected from a fluorine atom, a chlorine atom, a methyl group, and a trifluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0189] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a phenyl group substituted one or more times with a group independently selected from a fluorine atom, a chlorine atom and a trifluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0190] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a phenyl group substituted with a chlorine atom or a trifluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0191] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a phenyl group substituted with a fluorine atom or a trifluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0192] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3is a phenyl group substituted one or more times with a group independently selected from fluorine and chlorine atoms; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0193] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a phenyl group substituted one or more times with fluorine atoms, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0194] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a phenyl group substituted with a fluorine atom; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0195] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a phenyl group substituted with a chlorine atom; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0196] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a phenyl group substituted with a trifluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0197] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a 4- to 6-membered heterocycloalkyl group, which is substituted one or more times by a group independently selected from a fluorine atom, a hydroxy group, and a C1-C3 alkyl group; [ka] base, [ka] base, [ka] basis That is, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0198] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a 5-10 membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0199] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3is a 5-10 membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; A compound of the above formula (I) or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or a mixture thereof, provided that unsubstituted R 3 (Excluding piperidine, morpholine, and pyridine) Includes.

[0200] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a 5- to 6-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group, and a difluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0201] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a 5- to 6-membered heteroaryl group substituted one or more times with a group independently selected from a chlorine atom, a fluorine atom, a trifluoromethyl group, and a difluoromethyl group; A compound of the above formula (I) or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or a mixture thereof, provided that unsubstituted R 3 (Excluding piperidine, morpholine, and pyridine) Includes.

[0202] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3is a 5- to 6-membered heteroaryl group substituted one or more times with a group independently selected from a chlorine atom, a fluorine atom, a trifluoromethyl group, and a difluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0203] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a 5- to 6-membered heteroaryl group substituted one or more times with a group independently selected from a trifluoromethyl group and a difluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0204] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a 5-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0205] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a 6-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0206] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a 7-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0207] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is an 8-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0208] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a 9-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0209] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group, and a difluoromethyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0210] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 is a C1-C6 alkoxy group optionally substituted by a group independently selected from a C1-C3 haloalkyl group, a hydroxy group, a C1-C3 alkoxy group, a C4-C6 cycloalkyl group, a 4- to 6-membered heterocycloalkyl group and a 5- to 6-membered heteroaryl group, excluding an unsubstituted methoxy group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0211] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 NR 5 R 6 It is based on R 5 is a hydrogen atom; R 6 but, C1-C3-alkyl groups substituted one or more times by groups independently selected from 5- to 6-membered heteroaryl groups, C1-C3-haloalkyl groups, and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups. (However, unsubstituted pyridyl or furanyl groups as single substituents and C1-C3-alkyl groups substituted with hydroxy groups are excluded.) And C5-C6-Cycloalkyl group Selected from: This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0212] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 but [ka] Based on This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0213] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 3 -(CH2)3-O-CH3 group, -CH2-(morpholin-4-yl) group, -CH2-N(CH3)2 group, -CH=C(CH3)2 group, -CH=CH-CH2-O-CH3 group, -CH=CH-CH2-O-CH2-CH3 group, cyclopent-1-en-1-yl group, 4-chlorophenyl group, 4-fluoro-phenyl group, 4-fluoro-2-methyl-phenyl group, 3-fluoro-4-methyl-phenyl group, 4-fluoro-2-trifluoromethyl-phenyl group, 3-hydroxy-piperidin-1-yl group, 4,4-difluoro-piperidin-1-yl group, 4-ethyl-4-hydroxy-piperidin-1-yl group, [ka] group, 3-hydroxy-3-methyl-pyrrolidin-1-yl group, 4-methyl-piperazin-1-yl group, 2-amino-pyridin-4-yl group, 3-chloro-pyridin-6-yl group, 3-fluoro-pyrazol-1-yl group, 3-trifluoromethyl-pyrazol-1-yl group, 1-difluoromethylpyrazol-4-yl group, 4-trifluoromethyl-1,2,3-triazol-2-yl group, -NH-CH2-(pyrazol-3-yl) group, -NH-CH2-(pyrazol-5-yl) group, -NH-CH2-pyrazin-2-yl group, -NH-CH2-CH(OH)CF3 group, [ka] group, an NH-cyclopentyl group, an -O-(CH2)2-CH3 group, an -O-(CH2)2-C(CH3)3 group, an -O-(CH2)-CH(CH3)-OH group, an -O-(CH2)-C(CH3)2-OH group, an -O-CH2-(pyrazol-3-yl) group, an -O-(CH2)2-O-CH3 group, an -O-CH2-cyclobutyl group, an -O-CH2-tetrahydrofuran-2-yl group, an -O-(CH2)2-CF3 group and an -O-(CH2)3CH3 group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0214] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 4 is a hydrogen atom or a C1-C3 alkyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0215] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 4 is a hydrogen atom, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0216] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 4 is a C1-C3 alkyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0217] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 4 is a methyl group; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0218] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 4 is a methyl group having an S configuration; This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0219] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 6 but, C1-C3-alkyl groups substituted one or more times by groups independently selected from 5- to 6-membered heteroaryl groups, C1-C3-alkoxy groups, hydroxy groups, C1-C3-haloalkyl groups, and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups. That is, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0220] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 6 but, C1-C3-alkyl groups substituted one or more times by groups independently selected from 5- to 6-membered heteroaryl groups, C1-C3-alkoxy groups, hydroxy groups, C1-C3-haloalkyl groups, and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups. (However, C1-C3-alkyl groups substituted with an unsubstituted pyridyl group or an unsubstituted furanyl group or a hydroxy group as the sole substituent are excluded.) That is, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0221] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 6 but, C1-C3-alkyl groups substituted one or more times by groups independently selected from 5- to 6-membered heteroaryl groups, C1-C3-haloalkyl groups, and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups. That is, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0222] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 6 but, C1-C3-alkyl groups substituted one or more times by groups independently selected from 5- to 6-membered heteroaryl groups, C1-C3-haloalkyl groups, and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups. (However, unsubstituted pyridyl or furanyl groups as single substituents and C1-C3-alkyl groups substituted with hydroxy groups are excluded.) That is, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0223] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 6 but, C1-C3-alkyl groups substituted one or more times by groups independently selected from 5- to 6-membered heteroaryl groups, C1-C3-haloalkyl groups, and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups. (However, C1-C3-alkyl groups substituted with an unsubstituted pyridyl group or an unsubstituted furanyl group as the sole substituent are excluded.) That is, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0224] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 6 but, C1-C3-alkyl groups substituted one or more times by groups independently selected from 5- to 6-membered heteroaryl groups, C1-C3-haloalkyl groups, and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups. (However, C1-C3-alkyl groups substituted with an unsubstituted pyridyl group as the sole substituent are excluded.) That is, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0225] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 6 but, C1-C3-alkyl groups substituted one or more times by groups independently selected from 5- to 6-membered heteroaryl groups, C1-C3-haloalkyl groups, and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups. (However, C1-C3-alkyl groups substituted with an unsubstituted furanyl group as the sole substituent are excluded.) That is, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0226] In a further embodiment of the first aspect, the present invention provides a method for producing a composition comprising the steps of: R 6 but, C1-C3-Alkyl groups substituted one or more times by groups independently selected from C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups. (However, C1-C3 alkyl groups substituted with a hydroxyl group as the only substituent are excluded.) That is, This includes compounds of formula (I) above or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of stereoisomers, tautomers, N-oxides or mixtures thereof.

[0227] In a further embodiment, the present invention comprises a compound of formula (I) or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or a mixture thereof.

[0228] In a further embodiment, the invention includes a compound of formula (I) or a tautomer, N-oxide or salt thereof, or a salt of the tautomer or a salt of the N-oxide, or a mixture thereof.

[0229] In a further embodiment, the present invention includes a compound of formula (I) or a tautomer or salt thereof, or a salt of a tautomer, or a mixture thereof.

[0230] In yet a further embodiment, the present invention comprises a compound of formula (I), or a salt thereof, or a mixture thereof.

[0231] In a further embodiment, the present invention includes compounds of formula (I) that are salts.

[0232] In a further embodiment, the present invention includes compounds of formula (I) that are amine salts or salts with organic acids.

[0233] In a further embodiment, the present invention includes compounds of formula (I) that are salts with organic acids, particularly formed with pharma- ceutically acceptable organic acids.

[0234] In a further embodiment, the present invention includes compounds of formula (I) that are amine salts, particularly formed with pharma- ceutically acceptable amines.

[0235] In a further embodiment, the invention includes compounds of formula (I) that are tautomers or salts thereof, or salts of tautomers, or mixtures thereof.

[0236] In a further embodiment, the invention includes a compound of formula (I) that is an N-oxide or a salt thereof, or a salt of an N-oxide, or a mixture thereof.

[0237] In certain further embodiments of the first aspect, the invention comprises a combination of two or more of the above embodiments under the heading "Further embodiments of the first aspect of the invention".

[0238] It is further understood that the present invention includes any subcombination of the single embodiments disclosed herein with respect to certain residues of formula (I) or in combination with subcombinations of residues as outlined in the claims.

[0239] The present invention includes any subcombination within any embodiment or aspect of the invention of the compounds of general formula (I) above.

[0240] The present invention includes any subcombination within any embodiment or aspect of the invention of intermediate compounds of general formulas (IV) and (V).

[0241] The present invention includes compounds of general formula (I) that are disclosed in the Examples section of the text below.

[0242] General synthesis of compounds of formula (I) A. General synthetic route The compounds according to the present invention of general formula (I) can be prepared according to the following schemes 1, 2 and 3. The schemes and procedures described below show synthetic routes to the compounds of general formula (I) of the present invention, but are not intended to be limiting. It is clear to those skilled in the art that the order of the transformations illustrated in schemes 1, 2 and 3 can be modified in various ways. Thus, the order of the transformations illustrated in these schemes is not intended to be limiting. Furthermore, the substituent R may be replaced before and / or after the illustrated transformations. 1 , R 2 , R 3 or R 4 These modifications can be, for example, the introduction of protecting groups, cleavage of protecting groups, reduction or oxidation of functional groups, halogenation, metallation, substitution or other reactions known to those skilled in the art. These transformations include those that introduce functional groups that allow further interconversion of substituents. Suitable protecting groups and their introduction and cleavage are well known to those skilled in the art (see, for example, TW Greene and PG M Huts, Protective Groups in Organic Synthesis, 3rd Edition, Wiley 1999). Specific examples are described in the following paragraphs.

[0243] Five routes for the preparation of compounds of general formula (I) are described in Schemes 1, 2 and 3. Route 1 (Grignard route) [ka] Especially R 4 About =CH3: [ka]

[0244] Scheme 1 Scheme 1: Route for the preparation of compounds of general formula (I) from compounds of formula (II) and compounds of formula (III), where R 1 , R 2 , R 3 (which may contain suitably protected functional groups) and R 4 has the meaning defined above, M is a metal-containing group such as Li, or MgBr, or MgCl; DG is a group displaceable from a compound of formula (III) by a reactant of formula (II), in particular but not limited to N(OCH3)CH3 (Weinreb amide); PG is a suitable protecting group for an amine group, for example a carbamate group such as tert-butyl-carbamate (Boc). Compounds of formula (II) and formula (III) are known to those skilled in the art and can be easily prepared from commercially available precursors by known methods.

[0245] (a) THF, -20°C to 20°C, 1 h to 24 h, (b) 1. H2NNHCOOCH3, HCl, MeOH; 2. TFA, DCM, 0°C to 20°C; 3. NaOEt / EtOH or NaOMe / MeOH, 20°C; Compounds of formula (I) that contain chiral centers can optionally be separated to give individual enantiomers or diastereomers by methods known to those skilled in the art, for example, chiral chromatography.

[0246] Compound (II) is commercially available or can be prepared according to procedures available in the public domain, as will be appreciated by those skilled in the art. Specific examples are described in the experimental section.

[0247] Route 2: Alternative synthesis of a subset of compounds of general formula (I), compounds of general formula (Ia) Part I: Synthesis of intermediate compounds of formula (V) [ka] Scheme 2 Scheme 2: Route for preparing intermediate compounds of formula (V) 1 , R 2 and R 4 has the meaning defined above; the meaning of X is as defined below in the context of Scheme 3 and paragraphs (i), (j), (k) for compounds of formula (V).

[0248] (a) THF, -20°C to 20°C, 1 h to 24 h, (b) 1. H2NNHCOOCH3, HCl, MeOH; 2. TFA, DCM, 0°C to 20°C; 3. NaOEt / EtOH or NaOMe / MeOH, 20°C; Compounds of formula (V) that contain chiral centers can optionally be separated to give individual enantiomers or diastereomers by methods known to those skilled in the art, for example, chiral chromatography.

[0249] Part II: Conversion of intermediate compounds of formula (V) to compounds of general formula (Ia): [ka] (i)R 3 = a substituted alkyl group, an optionally substituted alkenyl group, a cycloalkenyl group, a substituted phenyl group, or a substituted heteroaryl group (j), (k): R 3 =NR 5 R 6 , optionally substituted N-linked heterocycloalkyl, or substituted N-linked heteroaryl; Scheme 3 Scheme 3: Route for the preparation of compounds of general formula (I) via formula (V), where R 1 , R 2 and R 4 has the meaning defined above, and R in general formula (Ia) 3 is R x is selected from substituted methyl groups, optionally substituted alkenyl groups, cycloalkenyl groups, substituted phenyl groups, and substituted heteroaryl groups, as defined in more detail below in paragraph (i) for R 3NR, as defined in more detail below in paragraphs (j) and (k), respectively. 5 R 6 or an optionally substituted N-linked heterocycloalkyl group, or a substituted N-linked heteroaryl group; the terms "N-linked heterocycloalkyl" and "N-linked heteroaryl" refer to the above R which is bonded to the remainder of the molecule through a nitrogen atom which constitutes a ring atom of said heterocycloalkyl or heteroaryl group. 3 (R 2 -R 3 ) refers to a 4- to 6-membered heterocycloalkyl or heteroaryl group as defined above.

[0250] (i) Route 2 via Suzuki coupling with organoboron compounds General formula (I) (wherein, R 3 is R as defined below for formulae (VIa), (VIb) and (VIc). x The compound of formula (V) (In the formula, X is Cl, Br (reflected in Scheme 3) or a group selected from (C1-C4-alkylsulfonyl)oxy, (C1-C4-fluoroalkylsulfonyl)oxy and (phenylsulfonyl)oxy, where the phenyl present in (phenylsulfonyl)oxy is optionally substituted with 1, 2, 3, 4 or 5 substituents, each of which is independently selected from halogen, nitro, cyano, C1-C4-alkyl and C1-C4-alkoxy; R 1 or R 2 is as defined above, but unlike Cl, Br, and I, R 4 is as defined above) to boronic acid R x B(OH)2 (formula (VIa)), or a boronic ester R x B(OR y ) 2 (formula (VIb)), or a tetrafluoroborate salt R x BF4 (formula (VIc)) a base such as potassium carbonate or potassium acetate, Dichlorobis(triphenylphosphine)palladium, Tetrakistriphenylphosphinepalladium(0), Palladium(II) acetate / triscyclohexylphosphine, Tris(dibenzylideneacetone)dipalladium, Bis(diphenylphosphineferrocenyl)palladium(II) chloride, 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene(1,4-naphthoquinone)palladium dimer, Allyl(chloro)(1,3-dimesityl-1,3-dihydro-2H-imidazol-2-ylidene)palladium, Palladium(II) acetate / dicyclohexyl(2',4',6'-triisopropyl-biphenyl-2-yl)phosphine, [1,1-bis(diphenylphosphino)ferrocene]palladium Palladium catalysts such as palladium(II) chloride monodichloromethane adduct, [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II), palladium(II) acetate and (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II), especially chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II). and, optionally, an additional ligand such as 2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl. In the presence of In a solvent such as dioxane, toluene, or water, or a mixture thereof, under a nitrogen or argon atmosphere, at 80°C to 120°C for 2 hours to 7 days. It can be obtained by reacting (In the formula, R x teeth a methyl group which is substituted one or more times by a group selected from C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups, and amino groups which are substituted one or two times by a C1-C3-alkyl group, C2-C6-alkenyl groups optionally substituted by C1-C3-alkoxy groups, C5-C6-cycloalkenyl group, a phenyl group substituted one or more times with a group independently selected from a fluorine atom, a chlorine atom, a methyl group, and a trifluoromethyl group; A 5- to 10-membered heteroaryl group optionally substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group, and a difluoromethyl group. and R y is C1-C6-alkyl, or two R y The residues taken together form a C2-C6-alkylene group, in particular -C(CH3)2-C(CH3)2-, forming a pinacol ester.

[0251] As will be readily understood by those skilled in the art, for example, R 3 is characterized by a group containing an olefinic double bond (e.g., R 3 is alkenyl, cycloalkenyl), the compound of general formula (I) prepared by Suzuki coupling can be converted to R by methods known to those skilled in the art, such as catalytic hydrogenolysis using a suitable catalyst, such as palladium on carbon. 3 can be readily converted to compounds featuring the corresponding saturated groups (eg, alkyl, cycloalkyl, heterocycloalkyl).

[0252] (j) via nucleophilic aromatic substitution, -NR 5 R 6 R is selected from N-linked heterocycloalkyl groups and N-linked heteroaryl groups (wherein the term "N-linked" is to be understood as described in the context of Scheme 3). 3 Route 2 for introducing substituents. A compound of general formula (I) R 3 -NR 5 R 6 , N-linked 4-6 membered heterocycloalkyl groups and N-linked heteroaryl groups (wherein the term "N-linked" is to be understood as described in the context of Scheme 3 and the terms "4-6 membered heterocycloalkyl" and "heteroaryl" are defined as above in R 3 and optionally substituted) is an intermediate compound of formula (V), R 4 has the meaning defined above, X is F, Cl or Br (as reflected in Scheme 3), and when X is Cl or Br, R 1 or R 2 cannot be F; in particular X is F; R 1 and R 2 has the meaning defined above, except that when X is Cl or Br, R 1 or R 2 cannot be F, except that R 1 and R 2 At least one of the following has an electron-withdrawing effect; in particular, R 1 is selected from fluorine and -CF3, R 2 is hydrogen or fluorine; more particularly, R 1 is -CF3, R 2 is hydrogen) , HNR 5 R 6 and a cyclic amine characterized by one NH as a ring atom, said cyclic amine being selected from 4-6 membered heterocycloalkanes and heteroarenes, each containing one NH as a ring atom, optionally as a free base or a salt, e.g., a hydrochloride salt, Optionally, it can be obtained by reacting in the presence of a base such as triethylamine, DIPEA or cesium carbonate in an inert solvent such as THF, CH3CN, DMF or DMSO at RT to 160°C, preferably at a higher temperature in the range of 60°C to 150°C, for 2 hours to 7 days. (In the formula, R 5 is H and R 6 teeth, C1-C3-alkyl groups which are substituted one or more times by groups independently selected from 5- to 6-membered heteroaryl groups, C1-C3-alkoxy groups, hydroxy groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups, and C5-C6-Cycloalkyl group selected from);

[0253] (k) via transition metal catalyzed, particularly palladium catalyzed amination, to give -NR 5 R 6 R is selected from N-linked heterocycloalkyl groups and N-linked heteroaryl groups (wherein the term "N-linked" is to be understood as described in the context of Scheme 3). 3 Alternative routes to introduce substituents. A compound of general formula (I) 3 -NR 5 R 6 , N-linked 4-6 membered heterocycloalkyl groups and N-linked heteroaryl groups (wherein the term "N-linked" is to be understood as described in the context of Scheme 3 and the terms "4-6 membered heterocycloalkyl" and "heteroaryl" are defined as above in R 3 and optionally substituted) is an intermediate compound of formula (V), X is Cl, Br (as reflected in Scheme 3), or a group selected from (C1-C4-alkylsulfonyl)oxy, (C1-C4-fluoroalkylsulfonyl)oxy and (phenylsulfonyl)oxy, in which the phenyl present in (phenylsulfonyl)oxy is optionally substituted with 1, 2, 3, 4 or 5 substituents, each of which is independently selected from halogen, nitro, cyano, C1-C4-alkyl and C1-C4-alkoxy; R1 or R 2 is as defined above, but different from Cl, Br; in particular, R 1 is -CF3, R 2 is hydrogen; R 4 has the meaning defined above) , HNR 5 R 6 and a cyclic amine characterized by one NH as a ring atom, said cyclic amine being selected from 4-6 membered heterocycloalkanes and heteroarenes, each containing one NH as a ring atom, optionally as a free base or a salt, e.g., a hydrochloride salt, It can be obtained by reacting in the presence of a base such as potassium phosphate or cesium carbonate, a palladium catalyst such as tris(dibenzylideneacetone)dipalladium(0), and a ligand such as 2-(dicyclohexylphosphino)-2',4',6'-triisopropyl-1,1'-biphenyl or 2,2'-bis(diphenylphosphino)-1,1'-binaphthalene in an inert solvent such as dioxane or toluene at a high temperature in the range of 60 to 160°C for 2 hours to 7 days. (In the formula, R 5 is H and R 6 teeth, C1-C3-alkyl groups which are substituted one or more times by groups independently selected from 5- to 6-membered heteroaryl groups, C1-C3-alkoxy groups, hydroxy groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which are themselves optionally substituted by C1-C3-hydroxyalkyl groups, and C5-C6-Cycloalkyl group selected from); The compounds of formula (I) thus obtained that contain a chiral center can optionally be separated by chiral chromatography to give the individual enantiomers or diastereomers.

[0254] Route 3: A subset of compounds of general formula (I), compounds of general formula (Ib) (wherein R 3Alternative synthesis of Part I: Synthesis of intermediate compounds of formula (V) [ka] Especially R 4 For =CH3: [ka] Scheme 4 Scheme 4: Route for preparing intermediate compounds of formula (V) 1 , R 2 and R 4 has the meaning defined above; the meaning of X is as defined below in the context of Scheme 5 and paragraphs (m), (n), (o) for compounds of formula (V). (a) THF, -20°C to 20°C, 1 hour to 24 hours, (b) 1. H2NNHCOOCH3, HCl, MeOH; 2. TFA, DCM, 0°C-20°C; 3. NaOEt / EtOH or NaOMe / MeOH, 20°C; Compounds of formula (V) that contain chiral centers can optionally be separated to give individual enantiomers or diastereomers by methods known to those skilled in the art, for example, chiral chromatography.

[0255] Part II: Conversion of intermediate compounds of formula (V) to compounds of general formula (Ib): [ka] (m), (n), (o): R 7 = a C1-C6-alkyl group optionally substituted by groups independently selected from a C1-C3-haloalkyl group, a hydroxy group, a C1-C3-alkoxy group, a C4-C6-cycloalkyl group, a 4- to 6-membered heterocycloalkyl group, a 5- to 6-membered heteroaryl group, excluding an unsubstituted methyl group; Pg2 is a suitable protecting group for a hydroxy group, for example a benzyl group. Scheme 5 Scheme 5: Route to prepare compounds of general formula (Ib) via formula (V) 1 , R 2 and R 4 has the meaning defined above, and R in general formula (I) 3 is a C1-C6-alkoxy group optionally substituted with a group selected from a C1-C3-haloalkyl group, a hydroxy group, a C1-C3-alkoxy group, a C4-C6-cycloalkyl group, a 4- to 6-membered heterocycloalkyl group and a 5- to 6-membered heteroaryl group, with the exception of an unsubstituted methoxy group.

[0256] (m) via nucleophilic aromatic substitution to R 3 Route 3 for introducing a substituent (wherein, R 3 is an optionally substituted alkoxy group. The compound of general formula (Ib) can be prepared by reacting an intermediate compound of formula (V) R 4 has the meaning defined above, X is F or Cl (reflected in Scheme 5), and when X is Cl, R1 or R2 cannot be F; particularly particularly X is F; R 1 and R 2 has the meaning defined above, except that when X is Cl, R 1 or R 2 cannot be F, except that R 1 and R 2 At least one of the following has an electron-withdrawing effect; in particular, R 1 is selected from fluorine and -CF3, R 2 is hydrogen or fluorine; more particularly, R 1 is -CF3, R 2 is hydrogen) with the corresponding alcohol R, optionally as an alcohol or alkoxide salt, e.g., as a sodium or potassium salt. 7 -OH(R 7 is defined above), and Optionally in the presence of a strong base such as potassium tert-butoxide, or sodium hydride, or sodium metal, Optionally in an inert solvent such as THF or DMF, Optionally in the presence of a base such as cesium carbonate, in a solvent such as DMSO, optionally at elevated temperatures in the range of RT to 160°C, particularly 60°C to 150°C, for 2 hours to 7 days It can be obtained by reacting (In the formula, R 7 is a C1-C6-alkyl group optionally substituted with a group independently selected from a C1-C3-haloalkyl group, a hydroxy group, a C1-C3-alkoxy group, a C4-C6-cycloalkyl group, a 4- to 6-membered heterocycloalkyl group, and a 5- to 6-membered heteroaryl group, with the exception of an unsubstituted methyl group.

[0257] (n) via transition metal catalysis, particularly palladium catalyzed amination of R 3 An alternative route for introducing substituents (wherein R 3 is an optionally substituted alkoxy group. The compound of general formula (Ib) can be prepared by reacting an intermediate compound of formula (V) X is Cl, Br, I (as reflected in Scheme 5), or a group selected from (C1-C4-alkylsulfonyl)oxy, (C1-C4-fluoroalkylsulfonyl)oxy and (phenylsulfonyl)oxy, in which the phenyl present in (phenylsulfonyl)oxy is optionally substituted with 1, 2, 3, 4 or 5 substituents, each of which is independently selected from halogen, nitro, cyano, C1-C4-alkyl and C1-C4-alkoxy; R 1 or R 2 is as defined above, but different from Cl, Br, and I; in particular, R 1 is -CF3, R 2 is hydrogen; R 4 has the meaning defined above) to the corresponding alcohol R 7 -OH and Bases such as potassium phosphate or cesium carbonate, [(2-di-tert-butylphosphino-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate or [(2-di-tert-butylphosphino-3-methoxy-6-methyl-2',4',6'-triisopropyl-1,1'-biphenyl)-2-(2-aminobiphenyl)]palladium(II) methanesulfonate The product can be obtained by reacting the product in the presence of a palladium catalyst such as ethanesulfonate, and optionally a ligand such as 2-di(tert-butyl)phosphino-2',4',6'-triisopropyl-3-methoxy-6-methylbiphenyl or 2-(di-tert-butylphosphino)-2',4',6'-triisopropyl-3,6-dimethoxy-1,1'-biphenyl, in an inert solvent such as dioxane or toluene at a high temperature in the range of 60 to 160°C for 2 hours to 7 days. (In the formula, R 7 = a C1-C6-alkyl group optionally substituted with a group selected from a C1-C3-haloalkyl group, a hydroxy group, a C1-C3-alkoxy group, a C4-C6-cycloalkyl group, a 4- to 6-membered heterocycloalkyl group and a 5- to 6-membered heteroaryl group, with the exception of unsubstituted methyl groups. The compounds of formula (I) thus obtained that contain a chiral center can optionally be separated by chiral chromatography to give the individual enantiomers or diastereomers.

[0258] (o) R via Mitsunobu reaction 3 An alternative route for introducing substituents (wherein R 3 is an optionally substituted alkoxy group. Compounds of general formula (Ib) can be obtained in a two-step procedure: step o-1 (removal of the protecting group Pg2), followed by step o-2 (Mitsunobu reaction).

[0259] (o-1) The compound of general formula (V) (wherein X is -OH) can be converted into an intermediate compound of formula (V) (wherein X is OPg2, Pg2 is a suitable protecting group for a hydroxy group, e.g., a benzyl group; R 1 , R 2 and R 4 has the meaning defined above) can be obtained by reacting with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon in a solvent such as ethanol at a temperature ranging from room temperature to 60° C. for 2 hours to 3 days at a hydrogen pressure ranging from 1 bar to 10 bar, in particular 1 bar.

[0260] (o-2) The compound of general formula (Ib) is an intermediate compound of formula (V) (wherein X is -OH, R 1 , R 2 and R 4 has the meaning defined above) to the corresponding alcohol R 7 -OH and Dialkyl azodicarboxylates, in particular diisopropyl azodicarboxylate; It can be obtained by reacting in the presence of a phosphine such as triphenylphosphine in an inert solvent such as THF at a temperature ranging from 0°C to room temperature for 2 hours to 3 days. (In the formula, R 7 = a C1-C6-alkyl group optionally substituted with a group selected from a C1-C3-haloalkyl group, a hydroxy group, a C1-C3-alkoxy group, a C4-C6-cycloalkyl group, a 4- to 6-membered heterocycloalkyl group and a 5- to 6-membered heteroaryl group, with the exception of unsubstituted methyl groups.

[0261] The compounds of formula (I) thus obtained that contain a chiral center can optionally be separated by chiral chromatography to give the individual enantiomers or diastereomers.

[0262] According to a second aspect, the present invention relates to a process for preparing a compound of general formula (I) as defined above, comprising reacting an intermediate compound of general formula (IV): [ka] (In the formula, R 1 , R 2 and R 3 is as defined for the compounds of general formula (I) defined above, and Pg represents a readily suitable protecting group for an amine group, such as a carbamate group, more particularly a tert-butoxycarbamate group. of, In step 1): with H2NNHCOOCH3 under acidic conditions (e.g., hydrochloric acid) in an alcoholic solution, e.g., methanol; and In step 2): with trifluoroacetic acid (TFA) in dichloromethane (DCM) at 0° C. to 20° C.; and In step 3): under basic conditions at room temperature, in particular with NaOEt / EtOH or NaOMe / MeOH at 20°C React, Thereby, compounds of general formula (I) [ka] (In the formula, R 1 , R 2 , R 3 and R 4 is as defined in any one of claims 1 to 8 or any embodiment above) The method includes the step of obtaining

[0263] According to a third aspect, the present invention relates to a method for preparing a compound of general formula (I) as defined above, comprising reacting an intermediate compound of general formula (II): [ka] (In the formula, R 1 , R 2 and R 3 is as defined for the compounds of general formula (I) according to claim 1, and R 3 The functional groups contained in are optionally appropriately protected, for example, hydroxy groups are protected by PG2 as defined above, Pg meaning a protecting group for an amine group. of, In step 1): with H2NNHCOOCH3 under acidic conditions in an alcoholic solution, and In step 2): with trifluoroacetic acid (TFA) in dichloromethane (DCM) at 0° C. to 20° C.; and In step 3): under basic conditions at room temperature, in particular with NaOEt / EtOH or NaOMe / MeOH at 20°C React, Optionally deprotecting any still protected functional groups; Thereby, compounds of general formula (I) [ka] (In the formula, R 1 , R 2 , R 3 and R 4 is as defined in any one of claims 1 to 8 or any embodiment above) And Then, optionally, converting said compound into a solvate, salt and / or solvate of such a salt using a corresponding (i) solvent and / or (ii) base or acid.

[0264] In a further embodiment, the present invention provides a process for preparing a compound of formula (I) above, further comprising the step of separating the enantiomers or diastereoisomers.

[0265] In yet a further embodiment, the present invention relates to a compound of formula (Ia) [ka] to provide.

[0266] In yet a further embodiment, the present invention relates to a compound of formula (Ib) [ka] to provide.

[0267] Methods for obtaining compounds of formula (Ia) and compounds of formula (Ib) from compounds of formula (I) are known to those skilled in the art, for example by chromatography, optionally chiral chromatography.

[0268] The present invention includes a process for preparing the compounds of the present invention of general formula (I), comprising the steps described in the experimental section herein.

[0269] According to a fourth aspect, the present invention comprises intermediate compounds useful in the preparation of compounds of general formula (I) above.

[0270] In particular, the present invention relates to an intermediate compound of general formula (IV): [ka] (In the formula, R 1 , R 2 , R 3 and R 4 are as defined above for compounds of general formula (I). Includes.

[0271] According to a fifth aspect, the present invention comprises the use of said intermediate compound for the preparation of a compound of general formula (I) as defined above.

[0272] In particular, the present invention relates to an intermediate compound of general formula (I) for preparing a compound of general formula (I) as defined above: [ka] (In the formula, R 1 , R 2 , R 3 and R 4 and Pg is as defined for compounds of general formula (I) above. Includes the use of.

[0273] In particular, the present invention relates to an intermediate compound of general formula (V): [ka] (In the formula, R1 , R 2 , R 3 and R 4 is as defined for compounds of general formula (I) above, X is a halogen atom or OPg2, and Pg2 is a suitable protecting group such as a benzyl group. Includes.

[0274] According to a fifth aspect, the present invention comprises the use of said intermediate compound for the preparation of a compound of general formula (I) as defined above.

[0275] In particular, the present invention relates to an intermediate compound of general formula (V) for preparing a compound of general formula (I) as defined above: [ka] (In the formula, R 1 , R 2 and R 4 is as defined for the compounds of general formula (I) above, X is a halogen atom or OPg2, and Pg2 is a benzyl group. Includes the use of.

[0276] The present invention includes intermediate compounds disclosed in the Examples section of the text below.

[0277] The present invention includes any subcombination within any embodiment or aspect of the invention of intermediate compounds of general formula (IV) and (V) above.

[0278] The compounds of the general formula (I) of the present invention can be converted into any salt, in particular the pharma- ceutically acceptable salts described herein, by any method known to those skilled in the art.Similarly, any salt of the compounds of the general formula (I) of the present invention can be converted into the free compounds by any method known to those skilled in the art.

[0279] Methods and Administration The compounds of general formula (I) of the present invention exhibit an unexpectedly beneficial pharmacological spectrum of action.Surprisingly, the compounds of the present invention have been found to effectively inhibit cell proliferation, which makes it likely that said compounds can be used for the treatment or prevention of diseases, particularly hyperproliferative disorders, in humans and animals.

[0280] More particularly, the compounds of formula (I) are suitable for treating such patients by detecting the co-expression of PDE3A and / or PDE3B and Schlafen 12 (SLFN12) and / or SLFN12L mRNA, polynucleotide or polypeptide, and / or the lack of reduction in the expression of CREB3L1 mRNA, polynucleotide or polypeptide in cancer cells derived from patients with cancers known to be sensitive to treatment with phosphodiesterase 3A / B (PDE3A and / or B)-SLF12 complex modulators. The compounds of formula (I) are selective for cancer cell killing while minimizing the enzyme inhibition of PDE3A and PDE3B.

[0281] The compounds of the present invention can be used to inhibit tumor growth by inducing SLFN 12 complex formation. The method includes administering a disease-treating effective amount of the compound of general formula (I) of the present invention, or its pharma- ceutically acceptable salt, isomer, polymorph, metabolite, hydrate, solvate or ester to a mammal in need thereof, including a human.

[0282] Further definitions "Alteration" refers to a change (increase or decrease) in the expression level, structure or activity of a gene or polypeptide as detected by standard art-known methods, such as those described herein. As used herein, in one embodiment, the alteration includes about a 10% change in expression level, particularly about a 25% change, more particularly about a 40% change, and most particularly about a 50% or greater change in expression level. In certain embodiments, the alteration includes a 10% or less change in expression level, particularly a 25% or less change, more particularly a 40% or less change, and most particularly a 50% or less change in expression level or greater. In other embodiments, the modification comprises a 9% to 11% (including 9% and 11%) change in expression levels, particularly a 10% to 25% (including 10% and 25%) change, more particularly a 25% to 40% (including 25% and 40%) change, and most particularly a 40% to 50% (including 40% to 50%) or greater than 50% (including 50%) change in expression levels. In certain other embodiments, the modification comprises a 9% to 11% (including 9% and 11%) change in expression levels, particularly a 22% to 28% (including 22% and 28%) change, more particularly a 35% to 45% (including 35% and 45%) change, and most particularly a 45% to 55% (including 45% to 55%) or greater than 55% change in expression levels.

[0283] By "fragment" is meant a portion of a polypeptide or nucleic acid molecule, particularly one that contains at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% of the entire length of a reference nucleic acid molecule or polypeptide. In certain embodiments, this portion contains, inter alia, at least 9%-11% (including 9% and 11%), 18%-22% (including 18% and 22%), 27%-33% (including 27% and 33%), 36%-44% (including 36% and 44%), 45%-55% (including 45% and 55%), 54%-66% (including 54% and 66%), 63%-77% (including 63% and 77%), 72%-88% (including 72% and 88%), or 81%-99% (including 81% and 99%) of the entire length of the reference nucleic acid molecule or polypeptide. The fragment may contain about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 200, about 300, about 400, about 500, about 600, about 700, about 800, about 900 or about 1000 nucleotides or amino acids. In certain embodiments, a fragment may contain between 9 and 11, about 18 and 22, 27 and 33, 36 and 44, 45 and 55, 54 and 66, 63 and 77, 72 and 88, 81 and 99, 90 and 110, 180 and 220, 270 and 330, 360 and 440, 450 and 550, 540 and 660, 630 and 770, 720 and 880, 810 and 990, or 900 and 1100 nucleotides or amino acids (in each case inclusive of the stated limits, e.g., "9 and 11" means inclusive of 9 and 11).

[0284] "Modulator" refers to any agent that binds to a polypeptide and changes the biological function or activity of the polypeptide. Modulators include, but are not limited to, agents that reduce or eliminate the biological function or activity of a polypeptide (e.g., "inhibitors"). For example, a modulator can inhibit the catalytic activity of a polypeptide. Modulators include, but are not limited to, agents that increase or decrease the binding of a polypeptide to another agent. For example, a modulator can promote the binding of a polypeptide to another polypeptide. In some embodiments, a modulator of a PDE3A and / or PDE3B polypeptide is a compound of formula (I).

[0285] By "hyperproliferative disease" is meant a disease, such as cancer, that is associated with inappropriately high levels of cell division, inappropriately low levels of apoptosis, or both.

[0286] Hyperproliferative disorders include, but are not limited to, hematopoietic and benign hyperproliferative disorders.

[0287] "Hematopoietic hyperproliferative disorders", also known as myoproliferative disorders, include, for example, polycythemia vera, essential thrombocytosis, thrombocytosis, primary myelofibrosis, and the like.

[0288] "Benign hyperproliferative diseases" include, for example, endometriosis, leiomyomas and benign prostatic hyperplasia.

[0289] Hyperproliferative diseases include, but are not limited to, for example, psoriasis, keloids and other hyperplasias affecting the skin, benign prostatic hyperplasia (BPH), solid tumors, such as cancers of the brain, breast, gastrointestinal tract, eye, head and neck, liver, respiratory tract, reproductive organs, skin, thyroid, parathyroid, urinary tract, and distant metastases thereof. These diseases also include leukemias, lymphomas, and sarcomas.

[0290] "Solid tumors" include, for example, breast cancer, brain cancer, gastrointestinal cancer, eye cancer, head and neck cancer, liver cancer, parathyroid cancer, reproductive cancer, respiratory tract cancer, skin cancer, thyroid cancer, urinary tract cancer, and distant metastases thereof. These diseases also include lymphoma, sarcoma, and leukemia.

[0291] Examples of breast cancer include, but are not limited to, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.

[0292] Examples of brain cancers include, but are not limited to, brain stem and hypothalamic glioma, glioblastoma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, and neuroectodermal and pineal tumors. In one embodiment, brain cancers include glioblastoma, astrocytoma, anaplastic astrocytoma, and primitive neuroectodermal tumors, among others.

[0293] Tumors of the digestive tract include, but are not limited to, anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small intestine, and salivary gland cancer.

[0294] Eye cancers include, but are not limited to, intraocular melanoma and retinoblastoma.

[0295] Head and neck cancers include, but are not limited to laryngeal, hypopharyngeal, nasopharyngeal, oropharyngeal, and oral cavity cancer and squamous cell.

[0296] Examples of liver cancer include, but are not limited to, hepatocellular carcinoma (liver cell carcinoma with or without fibrolamellar transformation), cholangiocarcinoma (intrahepatic cholangiocarcinoma), and mixed hepatocellular-cholangiocarcinoma.

[0297] Examples of cancers of the respiratory tract include, but are not limited to, small cell and non-small cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.

[0298] Tumors of the male reproductive organs include, but are not limited to, prostate and testicular cancer.

[0299] Tumors of the female reproductive organs include, but are not limited to, endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.

[0300] Tumors of the urinary tract include, but are not limited to bladder, penile, kidney, renal pelvis, ureter, urethral, ​​and human papillary renal cancer.

[0301] Skin cancer includes, but is not limited to, squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.

[0302] Leukemias include, but are not limited to, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia. More particularly, leukemias include, but are not limited to, acute lymphoblastic leukemia, acute myeloid leukemia, (acute) T-cell leukemia, acute lymphoblastic leukemia, acute lymphocytic leukemia (ALL), acute monocytic leukemia (AML), acute promyelocytic leukemia (APL), bisphenotypic B myelomonocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), large granular lymphocytic leukemia, plasma cell leukemia, and myelodysplastic syndromes (MDS) that can progress to acute myeloid leukemia.

[0303] Lymphomas include, but are not limited to AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin's disease, and lymphoma of the central nervous system. In particular, lymphomas include, but are not limited to, AIDS-related lymphoma, chronic lymphocytic lymphoma (CLL), non-Hodgkin's lymphoma (NHL), T non-Hodgkin's lymphoma (T-NHL), subtypes of NHL such as diffuse large cell lymphoma (DLBCL), activated B cell DLBCL, germinal center B cell lymphoma DLBCL, double hit lymphoma and double expressor lymphoma; anaplastic large cell lymphoma, B cell lymphoma, cutaneous T cell lymphoma, Burkitt's lymphoma, follicular lymphoma, hairy cell lymphoma, Hodgkin's disease, mantle cell lymphoma (MCL), lymphoma of the central nervous system, small lymphocytic lymphoma and chronic lymphocytic lymphoma and Sezary syndrome.

[0304] Sarcomas include, but are not limited to, sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.

[0305] Any composition or method provided herein can be combined with one or more of any of the other compositions and methods provided herein.

[0306] The term "treating" or "treatment" as mentioned throughout this document is used conventionally and includes the management or care of a subject for the purpose of combating, alleviating, reducing, ameliorating and / or ameliorating a disease state or disorder, such as, for example, cancer. These disorders are well characterized in humans, but also exist with similar etiology in other mammals and can be treated by administering the pharmaceutical compositions of the present invention. Although not excluded, it will be recognized that treating a disease or condition does not require that the disease, condition or symptoms associated therewith be completely eliminated.

[0307] The compounds of the invention can be used in particular for the treatment and prevention, ie prophylaxis, of tumor growth and metastasis, in particular of solid tumors of all indications and stages, with or without prior treatment of the tumor growth.

[0308] In general, the use of chemotherapeutic and / or anticancer agents in combination with the compounds or pharmaceutical compositions of the present invention includes: 1. Provides superior efficacy in reducing tumor growth or even eliminating tumors compared to administration of either agent alone; 2. resulting in the administration of smaller doses of chemotherapeutic and / or anticancer drugs; 3. Providing chemotherapy treatments that are better tolerated by patients with fewer adverse pharmacological complications than are observed with single agent chemotherapy and certain other combination therapies; 4. Providing treatment for a wide range of different cancer types in mammals, particularly humans; 5. Providing a high response rate among treated patients; 6. Providing longer survival times among treated patients compared to standard chemotherapy treatments; 7. Leads to longer time to tumor progression, and / or 8. Produce efficacy and tolerability results that are at least as good as those of the drugs used alone, compared with known antagonistic effects of other anticancer drug combinations It is useful.

[0309] Furthermore, the compounds of general formula (I) according to the invention can also be used in combination with radiation therapy and / or surgical intervention.

[0310] In a further embodiment of the present invention, the compounds of general formula (I) of the present invention can be used to sensitize cells to radiation, i.e., treatment of cells with a compound of the present invention prior to radiotherapy of the cells renders the cells more susceptible to DNA damage and cell death than if the cells had not been treated with a compound of the present invention. In one aspect, the cells are treated with at least one compound of general formula (I) of the present invention.

[0311] Thus, the present invention also provides a method of killing cells, in which the cells are administered one or more compounds of the present invention in combination with conventional radiation therapy.

[0312] The present invention also provides a method of rendering a cell more susceptible to cell death, wherein the cell is treated with one or more compounds of general formula (I) of the present invention prior to treatment of the cell to cause or induce cell death.

[0313] In one embodiment, cells are treated with one or more compounds of general formula (I) of the present invention followed by treatment with at least one compound or at least one method, or a combination thereof, to induce DNA damage in order to inhibit normal cell function or kill the cells.

[0314] In another embodiment of the present invention, cells are killed by treating cells with at least one DNA damaging agent, i.e., cells are treated with one or more compounds of the present invention of general formula (I) to sensitize cells to cell death, and then cells are treated with at least one DNA damaging agent to kill cells.DNA damaging agents useful in the present invention include, but are not limited to, chemotherapeutic agents (e.g., cisplatin), ionizing radiation (X-rays, ultraviolet radiation), carcinogens and mutagens.

[0315] In other embodiments, cells are killed by treating them with at least one method to cause or induce DNA damage.Such methods include, but are not limited to, activating cell signaling pathways that cause DNA damage when the pathways are activated, inhibiting cell signaling pathways that cause DNA damage when the pathways are inhibited, and inducing biochemical changes in cells, where the changes cause DNA damage.As a non-limiting example, it can inhibit the DNA repair pathways of cells, thereby preventing DNA damage repair, and causing abnormal accumulation of DNA damage in cells.

[0316] In one embodiment of the present invention, the compound of the present invention is administered to the cell before radiation or other induction of DNA damage in the cell. In another embodiment of the present invention, the compound of the present invention is administered to the cell simultaneously with radiation or other induction of DNA damage in the cell. In yet another embodiment of the present invention, the compound of the present invention is administered to the cell immediately after radiation or other induction of DNA damage in the cell begins.

[0317] In another aspect, the cell is in vitro. In another embodiment, the cell is in vivo.

[0318] Thus, in some embodiments, the present invention includes a method of inhibiting cell proliferation and / or inducing apoptosis in a cell, comprising contacting a cell with a compound of formula (I) as defined in any one of claims 1 to 6.

[0319] The compounds of the present invention can be used to inhibit tumor growth by inducing SLFN 12 complex formation. The method includes administering to a mammal, including a human, in need thereof a disease-treating amount of a compound of the present invention, or a pharma- ceutically acceptable salt, isomer, polymorph, metabolite, hydrate, solvate, or ester thereof.

[0320] The present invention also includes methods of treating hyperproliferative diseases, cancer diseases.

[0321] Although these diseases are well characterized in humans, they also exist in other mammals with similar etiologies and can be treated by administering the pharmaceutical compositions of the present invention.

[0322] The compounds of the present invention can be used in the treatment and prevention, ie prophylaxis, of hyperproliferative diseases, cancer diseases in particular.

[0323] Another aspect of the present invention is a method of controlling (e.g., via treatment and / or prevention) cancer in a subject (e.g., a human, other mammal such as a rat, etc.) by administering to the subject an effective amount of at least one compound of general formula (I), or a pharma-ceutically acceptable salt, polymorph, metabolite, hydrate, solvate, or ester thereof.

[0324] In particular, in some embodiments, the present invention comprises a method for treating a hyperproliferative disease, more particularly cancer, comprising administering an effective amount of at least one compound of general formula (I) as defined in any one of claims 1 to 6.

[0325] Also provided is a method of inhibiting hyperproliferation of cancer cells, comprising contacting the cancer cells with a compound of general formula (I). The cancer cells can be in vitro or in vivo.

[0326] According to a further aspect, the present invention comprises a method for treating or preventing a disease, in particular a hyperproliferative disease, in particular a cancer disease, using an effective amount of a compound of general formula (I) as above, or its stereoisomers, tautomers, N-oxides, hydrates, solvates and salts, in particular a pharma-ceutically acceptable salt thereof, or a mixture thereof.

[0327] In some embodiments, the method of treating and / or preventing hyperproliferative disease in a subject may comprise administering to the subject an effective amount of a compound of general formula (I).The hyperproliferative disease may be, for example, cancer, for example, anal tumor, brain tumor, breast tumor, bone tumor, central and peripheral nervous system tumor, colon tumor, eye tumor, kidney tumor, endocrine gland (e.g., thyroid and adrenal cortex) tumor, endometrial tumor, esophageal tumor, gastrointestinal tumor (including gastrointestinal stromal tumor), germ cell tumor, head and neck tumor, kidney tumor, liver tumor, larynx and hypopharynx tumor, lung tumor, mesothelioma, pancreatic tumor, prostate tumor, rectal tumor, reproductive organ (e.g., cervix, ovary, prostate) tumor, airway tumor, small intestine tumor, skin tumor, soft tissue tumor, stomach tumor, testicular tumor, thyroid tumor, parathyroid tumor, ureter tumor, genitourinary tumor, vaginal and vulvar tumor, and connective tissue tumor, and metastasis of these tumors. Malignant neoplasms include hereditary cancers exemplified by retinoblastoma and Wilms' tumor.

[0328] In some embodiments, a method for treating and / or preventing a hyperproliferative disease in a subject may comprise administering to the subject an effective amount of a compound of general formula (I). The hyperproliferative disease may be, for example, cancer (e.g., cervical cancer, melanoma, etc.).

[0329] Furthermore, in some embodiments, the present invention includes a method for treating cancer, particularly anal tumor, brain tumor, breast tumor, bone tumor, central and peripheral nervous system tumor, colon tumor, eye tumor, kidney tumor, endocrine gland (e.g., thyroid and adrenal cortex) tumor, endometrial tumor, esophageal tumor, gastrointestinal tumor (including gastrointestinal stromal tumor), germ cell tumor, head and neck tumor, kidney tumor, liver tumor, larynx and hypopharynx tumor, lung tumor, mesothelioma, pancreatic tumor, prostate tumor, rectal tumor, reproductive organ (e.g., cervix, ovary, prostate) tumor, airway tumor, small intestine tumor, skin tumor, soft tissue tumor, stomach tumor, testicular tumor, thyroid tumor, parathyroid tumor, ureter tumor, genitourinary tumor, vaginal and vulvar tumor, and connective tissue tumor, as well as metastasis of these tumors. Malignant neoplasms include hereditary cancers exemplified by retinoblastoma and Wilms' tumor. The method includes administering an effective amount of at least one compound of formula (I) according to any one of claims 1 to 6.

[0330] Further, in some embodiments, the present invention includes a method for treating cancer, particularly cervical cancer and melanoma, comprising administering an effective amount of at least one compound of formula (I) according to any one of claims 1 to 6.

[0331] Furthermore, in some embodiments, the present invention includes a method for treating cancer, particularly anal tumor, brain tumor, breast tumor, bone tumor, central and peripheral nervous system tumor, colon tumor, eye tumor, kidney tumor, endocrine gland (e.g., thyroid and adrenal cortex) tumor, endometrial tumor, esophageal tumor, gastrointestinal tumor (including gastrointestinal stromal tumor), germ cell tumor, head and neck tumor, kidney tumor, liver tumor, larynx and hypopharynx tumor, lung tumor, mesothelioma, pancreatic tumor, prostate tumor, rectal tumor, reproductive organ (e.g., cervix, ovary, prostate) tumor, airway tumor, small intestine tumor, skin tumor, soft tissue tumor, stomach tumor, testicular tumor, thyroid tumor, parathyroid tumor, ureter tumor, genitourinary tumor, vaginal and vulvar tumor, and connective tissue tumor, as well as metastasis of these tumors. Malignant neoplasms include hereditary cancers exemplified by retinoblastoma and Wilms' tumor. The method includes administering an effective amount of at least one compound of formula (I) according to any one of claims 1 to 6.

[0332] Further, in some embodiments, the present invention includes a method for treating cancer, particularly cervical cancer and melanoma, comprising administering an effective amount of at least one compound of formula (I) according to any one of claims 1 to 6.

[0333] According to a further aspect, the present invention comprises a compound of general formula (I) as defined above, or its stereoisomers, tautomers, N-oxides, hydrates, solvates and salts, in particular its pharma- ceutically acceptable salts, or mixtures thereof, for use in the treatment or prevention of diseases, in particular hyperproliferative diseases.

[0334] In some embodiments, the present invention includes methods of using compounds of general formula (I) to treat diseases.

[0335] The pharmaceutical activity of the compounds according to the invention can be explained by their activity as SLFN12 complex inducers.

[0336] According to a further aspect, the present invention comprises the use of a compound of general formula (I) as defined above, or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, in particular a pharma- ceutically acceptable salt thereof, or a mixture thereof, for preventing or treating a disease, in particular a hyperproliferative disease, in particular a cancer disease.

[0337] According to a further aspect, the present invention comprises a compound of formula (I) according to any one of claims 1 to 6 without a disclaimer for use in the treatment of cancer, in particular for use in the treatment of brain cancer, cervical cancer, skin cancer and ovarian cancer, more in particular for use in the treatment of brain cancer, cervical cancer and skin cancer.

[0338] According to another aspect, the present invention provides a method for producing a method for manufacturing a pharmaceutical composition comprising: R 1 is a hydrogen atom, a halogen atom, a C1-C3-alkyl group or a C1-C3-haloalkyl group; R 2 is a hydrogen atom or a halogen atom; R 3 but, C1-C3-alkyl groups substituted one or more times with groups independently selected from C1-C3-alkyl groups, C1-C3-alkoxy groups, heterocycloalkyl groups, and amino groups substituted one or two times with C1-C3-alkyl groups; C2-C6-alkenyl groups optionally substituted by C1-C3-alkoxy groups, C5-C6-cycloalkenyl group, a phenyl group substituted one or more times by a group independently selected from halogen atoms, C1-C3-alkyl groups and C1-C3-haloalkyl groups, a 4- to 6-membered heterocycloalkyl group substituted one or more times with a group independently selected from a fluorine atom, a hydroxy group, and a C1-C3 alkyl group; [ka] base, [ka] base, [ka] base, a 5- to 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a halogen atom, and a C1-C3-haloalkyl group; C1-C6-alkoxy groups optionally substituted by groups independently selected from C1-C3-haloalkyl groups, hydroxy groups, C1-C3-alkoxy groups, C4-C6-cycloalkyl groups, 4- to 6-membered heterocycloalkyl groups, and 5- to 6-membered heteroaryl groups; NR 5 R 6 Groups, and [ka] basis and R 4 is a hydrogen atom or a C1-C3 alkyl group, R 5 is a hydrogen atom, R 6 but, C1-C3-alkyl groups which are substituted one or more times by groups selected from 5-6-membered heteroaryl groups, C1-C3-alkoxy groups, hydroxy groups, C1-C3-haloalkyl groups and C4-C6-cycloalkyl groups which themselves are optionally substituted by C1-C3-hydroxyalkyl groups, And C5-C6-Cycloalkyl group Selected from: Includes compounds of formula (I) or stereoisomers, tautomers, N-oxides, hydrates, solvates or salts thereof, or salts of a stereoisomer, a tautomer, an N-oxide or mixtures thereof.

[0339] According to a further aspect, the present invention comprises the use of a compound of general formula (I) as defined above, or its stereoisomers, tautomers, N-oxides, hydrates, solvates and salts, in particular its pharma- ceutically acceptable salts, or mixtures thereof, in a method for treating or preventing a disease, in particular a hyperproliferative disease, in particular a cancer disease.

[0340] In some embodiments, the present invention comprises the use of the compound of general formula (I) for the manufacture of medicaments for treating hyperproliferative diseases, particularly cancer, more particularly anal tumor, brain tumor, breast tumor, bone tumor, central and peripheral nervous system tumor, colon tumor, eye tumor, kidney tumor, endocrine gland (e.g. thyroid and adrenal cortex) tumor, endometrial tumor, esophageal tumor, gastrointestinal tumor (including gastrointestinal stromal tumor), germ cell tumor, head and neck tumor, kidney tumor, liver tumor, larynx and hypopharynx tumor, lung tumor, mesothelioma, pancreatic tumor, prostate tumor, rectal tumor, reproductive organ (e.g. cervix, ovary, prostate) tumor, airway tumor, small intestine tumor, skin tumor, soft tissue tumor, stomach tumor, testicular tumor, thyroid tumor, parathyroid tumor, ureter tumor, genitourinary tumor, vaginal and vulvar tumor, and connective tissue tumor, and metastasis of these tumors. Malignant neoplasms include hereditary cancers exemplified by retinoblastoma and Wilms' tumor.

[0341] In some embodiments, the present invention comprises the use of a compound of general formula (I) for the manufacture of a medicament for the treatment of a hyperproliferative disease, particularly cancer, more particularly cervical cancer and melanoma.

[0342] In some embodiments, the present invention comprises the use of a compound of general formula (I) for the manufacture of a medicament for the treatment of a hyperproliferative disease, particularly cancer, more particularly brain cancer, cervical cancer and melanoma.

[0343] In some embodiments, the present invention comprises the use of a compound of general formula (I) for the manufacture of a medicament for the treatment of a hyperproliferative disease, particularly cancer, more particularly brain cancer, cervical cancer, melanoma and ovarian cancer.

[0344] In some embodiments, the present invention comprises a compound of general formula (I) for use in a method of inhibiting cell proliferation and / or inducing apoptosis in a cell, the method comprising contacting a cell with a compound of formula (I) as defined in any one of claims 1 to 6.

[0345] In some embodiments, the present invention comprises a compound of general formula (I) as defined in any one of claims 1 to 6 for use in a method for treating or preventing a disease.

[0346] In particular, in some embodiments, the present invention comprises a compound of general formula (I) for use in a method for treating a hyperproliferative disease, more particularly wherein the hyperproliferative disease is cancer, and even more particularly wherein the cancer disease is cervical cancer and melanoma.

[0347] In particular, in some embodiments, the present invention comprises a compound of general formula (I) for use in a method for treating a hyperproliferative disease, more particularly wherein the hyperproliferative disease is cancer, even more particularly wherein the cancer disease is brain cancer, cervical cancer, melanoma and ovarian cancer.

[0348] In some embodiments, the present invention provides compounds of general formula (I) for use in a method for treating cancer, particularly where the cancer disease is cervical cancer and melanoma.

[0349] In some embodiments, the present invention provides compounds of general formula (I) for use in a method for treating cancer, particularly where the cancer disease is brain cancer, cervical cancer, melanoma and ovarian cancer.

[0350] According to a further aspect, the present invention comprises the use of a compound of general formula (I) as defined above, or its stereoisomers, tautomers, N-oxides, hydrates, solvates and salts, in particular its pharma- ceutically acceptable salts, or mixtures thereof, for preparing a pharmaceutical composition, in particular a medicament, for preventing or treating a disease, in particular a hyperproliferative disease, in particular a cancer disease.

[0351] According to a further aspect, the present invention includes a pharmaceutical composition, in particular a pharmaceutical product, comprising a compound of general formula (I) as above, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, salt, in particular a pharma- ceutically acceptable salt thereof, or a mixture thereof, and one or more excipients, in particular one or more pharma- ceutically acceptable excipients. Conventional procedures for preparing such pharmaceutical compositions in suitable dosage forms can be utilized.

[0352] The present invention further comprises pharmaceutical compositions, in particular medicinal products, comprising at least one compound according to the invention, conventionally together with one or more pharma- ceutically suitable excipients, and the use thereof for the above-mentioned purposes.

[0353] The compounds according to the invention can have systemic and / or local activity, and for this purpose they can be administered in any suitable manner, for example via the oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, vaginal, dermal, transdermal, conjunctival, auricular route or as an implant or stent.

[0354] For these administration routes, the compounds according to the invention can be administered in suitable dosage forms.

[0355] For oral administration, the compounds according to the invention can be formulated into dosage forms known in the art that deliver the compounds of the invention in a rapid and / or modified manner, such as tablets (uncoated or coated, e.g., with a delayed dissolving or soluble enteric or controlled release coating), orally disintegrating tablets, films / wafers, films / lyophilisates, capsules (e.g., hard or soft gelatin capsules), dragees, granules, pellets, powders, emulsions, suspensions, aerosols or solutions. The compounds according to the invention can be incorporated into said dosage forms in crystalline and / or amorphous and / or dissolved form.

[0356] Parenteral administration can be achieved by avoiding the absorption step (e.g., intravenously, intraarterially, intracardially, intrathecally or intralumbarly) or by including absorption (e.g., intramuscularly, subcutaneously, intradermally, transdermally or intraperitoneally). Suitable dosage forms for parenteral administration are, inter alia, injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.

[0357] Examples suitable for other administration routes include pharmaceutical forms for inhalation (in particular powder inhalers, nebulizers), nose drops, nasal solutions or nasal sprays; tablets / films / wafers / capsules for lingual, sublingual or buccal administration; suppositories; eye drops, eye ointments, eye baths, eye inserts, ear drops, ear sprays, ear powders, ear rinses, ear tampons; vaginal capsules, aqueous suspensions (lotions, shaking mixtures), lipophilic suspensions, emulsions, ointments, creams, transdermal therapeutic systems (e.g. patches, etc.), milks, pastes, foams, powders, implants or stents.

[0358] The compounds according to the invention can be incorporated into the mentioned dosage forms. This can be done in a manner known per se by mixing with pharma- ceutically suitable excipients. Pharmaceutically suitable excipients include, in particular: fillers and carriers (e.g. cellulose, microcrystalline cellulose (e.g. Avicel®), lactose, mannitol, starch, calcium phosphates (e.g. Di-Cafos®), Ointment bases (e.g., petrolatum, paraffin, triglycerides, wax, wool wax, wool wax alcohol, lanolin, hydrophilic ointments, polyethylene glycols), Suppository bases (e.g., polyethylene glycol, cocoa butter, hard fats), Solvents (e.g., water, ethanol, isopropanol, glycerol, propylene glycol, medium-chain triglyceride fatty oils, liquid polyethylene glycols, paraffin), surfactants, emulsifiers, dispersants or wetting agents (e.g. sodium dodecyl sulfate, lecithin, phospholipids, fatty alcohols (e.g. Lanette®, etc.), sorbitan fatty acid esters (e.g. Span®, etc.), polyoxyethylene sorbitan fatty acid esters (e.g. Tween®, etc.), polyoxyethylene fatty acid glycerides (e.g. Cremophor®, etc.), polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, glycerol fatty acid esters, poloxamers (e.g. Pluronic®, etc.), Buffers, acids and bases (e.g. phosphates, carbonates, citric acid, acetic acid, hydrochloric acid, sodium hydroxide solution, ammonium carbonate, trometamol, triethanolamine), Isotonic agents (e.g., glucose, sodium chloride), Adsorbents (e.g. highly dispersible silica), viscosity enhancing agents, gel formers, thickeners and / or binders (e.g. polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, starch, carbomer, polyacrylic acid (e.g. Carbopol®), alginates, gelatin), Disintegrants (e.g. modified starch, sodium carboxymethylcellulose, sodium starch glycolate (e.g. Explotab®, etc.), cross-linked polyvinylpyrrolidone, croscarmellose sodium (e.g. AcDiSol®, etc.)), flow regulators, lubricants, glidants and release agents (e.g. magnesium stearate, stearic acid, talc, highly disperse silica (e.g. Aerosil®, etc.)); coating materials (e.g. sugars, shellac) and film formers or dispersions which dissolve rapidly or in a modified manner (e.g. polyvinylpyrrolidones (e.g. Kollidon®), polyvinyl alcohols, hydroxypropyl methylcellulose, hydroxypropyl cellulose, ethyl cellulose, hydroxypropyl methylcellulose phthalate, cellulose acetate, cellulose acetate phthalate, polyacrylates, polymethacrylates (e.g. Eudragit®), capsule materials (e.g., gelatin, hydroxypropyl methylcellulose), synthetic polymers (e.g. polylactides, polyglycolides, polyacrylates, polymethacrylates (e.g. Eudragit®, etc.), polyvinylpyrrolidones (e.g. Kollidon®, etc.), polyvinyl alcohols, polyvinyl acetates, polyethylene oxides, polyethylene glycols and their copolymers and block copolymers); Plasticizers (e.g. polyethylene glycol, propylene glycol, glycerol, triacetin, triacetyl citrate, dibutyl phthalate), Penetration enhancers, stabilizers (e.g. antioxidants, e.g. ascorbic acid, ascorbyl palmitate, sodium ascorbate, butylhydroxyanisole, butylhydroxytoluene, propyl gallate), Preservatives (e.g., parabens, sorbic acid, thiomersal, benzalkonium chloride, chlorhexidine acetate, sodium benzoate), colorants (e.g. inorganic pigments, e.g. iron oxide, titanium dioxide), Flavoring, sweetening, flavoring and / or odor masking agents.

[0359] The present invention further relates to pharmaceutical compositions comprising at least one compound according to the invention, conventionally together with one or more pharma- ceutically suitable excipients, and to their uses according to the invention.

[0360] According to another aspect, the present invention comprises a pharmaceutical combination, in particular a medicinal product, comprising at least one compound of general formula (I) according to the invention and at least one or more further active ingredients, in particular for the treatment and / or prevention of hyperproliferative diseases, cancer.

[0361] In particular, the present invention provides one or more first active ingredients, in particular compounds of general formula (I) as defined above, and one or more further active ingredients, in particular one or more anti-cancer drugs The pharmaceutical combination includes

[0362] The term "combination" in the present invention is used as known to those skilled in the art, and the combination can be a fixed combination, a loose combination or a kit-of-parts.

[0363] "Fixed combination" in the present invention is used as known to those skilled in the art, and is defined as, for example, the combination in which the first active ingredient, for example, one or more compounds of the present invention's general formula (I) and the further active ingredient are present together in one unit dosage or single entity.One example of "fixed combination" is the pharmaceutical composition in which the first active ingredient and the further active ingredient are present in a mixture, for example, a formulation, for simultaneous administration.Another example of "fixed combination" is the pharmaceutical combination in which the first active ingredient and the further active ingredient are not mixed but are present in one unit.

[0364] In the present invention, non-fixed combination or "kit of parts" is used as known to those skilled in the art and is defined as the combination in which the first active ingredient and the further active ingredient are present in two or more units.One example of non-fixed combination or kit of parts is the combination in which the first active ingredient and the further active ingredient are present separately.The components of non-fixed combination or kit of parts can be administered separately, sequentially, simultaneously, simultaneously or chronologically staggered.

[0365] The compound of the present invention can be administered as the only pharmaceutical agent or in combination with one or more other pharmaceutical active ingredients, where the combination does not cause unacceptable adverse effects.The present invention also includes such pharmaceutical combinations.For example, the compound of the present invention can be combined with known anticancer agents.

[0366] Examples of anti-cancer drugs include: 131I-chTNT, abarelix, abemaciclib, abiraterone, acalabrutinib, aclarubicin, adalimumab, ado-trastuzumab emtansine, afatinib, aflibercept, aldesleukin, alectinib, alemtuzumab, alendronate, alitretinoin, alpharadin, altretamine, amifostine, aminoglutethimide, hexylaminolevulinic acid, amrubicin, amsacrine, anastrozole, ancestim, anetholedithiolthione, anetumab ravtansine, angiotensin II, anti-thrombotic Rhombomodulin III, apalutamide, aprepitant, arcitumomab, aruglavin, arsenic trioxide, asparaginase, atezolizumab, avelumab, axicabtagene ciloleucel, axitinib, azacitidine, basiliximab, belotecan, bendamustine, besilesomab, belinostat, bevacizumab, bexarotene, bicalutamide, bisantrene, bleomycin, blinatumomab, bortezomib, bosutinib, buserelin, brentuximab vedotin, brigatinib, busulfan, cabazitaxel, cabozantinib, calcitonin, folinic acid calcium levofolinate, calcium levofolinate, capecitabine, capromab, carbamazepine, carboplatin, carboquin, carfilzomib, carmofur, carmustine, catumaxomab, celecoxib, cermoleukin, cemiplimab, ceritinib, cetuximab, chlorambucil, chlormadinone, chlormethine, cidofovir, cinacalcet, cisplatin, cladribine, clodronic acid, clofarabine, cobimetinib, copanlisib, crisantaspase, crizotinib, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dacarbazine Tinomycin, daratumumab, darbepoetin alfa, dabrafenib, dasatinib, daunorubicin, decitabine, degarelix, denileukin diftitox, denosumab, depreotide, deslorelin, dianhydrogalactitol, dexrazoxane, dibrospidium chloride, dianhydrogalactitol, diclofenac, dinutuximab, docetaxel, dolasetron, doxifluridine, doxorubicin, doxorubicin + estrone, dronabinol, durvalumab, eculizumab, edrecolomab, elliptinium acetate, elotuzumab,Eltrombopag, enasidenib, endostatin, enocitabine, enzalutamide, epirubicin, epithiostanol, epoetin alfa, epoetin beta, epoetin zeta, eptaplatin, eribulin, erlotinib, esomeprazole, estradiol, estramustine, ethinyl estradiol, etoposide, everolimus, exemestane, fadrozole, fentanyl, filgrastim, fluoxymesterone, flocc Suridine, fludarabine, fluorouracil, flutamide, folinic acid, formestane, fosaprepitant, fotemustine, fulvestrant, gadobutrol, gadoteridol, gadoterate meglumine, gadoversetamide, gadoxetic acid, gallium nitrate, ganirelix, gefitinib, gemcitabine, gemtuzumab, glucarpidase, glutoxim, GM-CSF, goserelin, granisetron, granulocyte colony-stimulating factor, Histamine dihydrochloride, histrelin, hydroxycarbamide, I-125 seed, lansoprazole, ibandronic acid, ibritumomab tiuxetan, ibrutinib, idarubicin, ifosfamide, imatinib, imiquimod, improsulfan, indisetron, incadronic acid, ingenol mebutate, inotuzumab ozogamicin, interferon alpha, interferon beta, interferon gamma, iobitridol, io Benguan (123I), Iomeprol, Ipilimumab, Irinotecan, Itraconazole, Ixabepilone, Ixazomib, Lanreotide, Lansoprazole, Lapatinib, Iasocholine, Lenalidomide, Lenvatinib, Lenograstim, Lentinan, Letrozole, Leuprorelin, Levamisole, Levonorgestrel, Levothyroxine Sodium, Lisuride, Lobaplatin, Lomustine, Lonidamine, Lutetium Lu 177 Dotatate, Masoprocol, Medroxyprogesterone, Megestrol, Melarsoprol, Melphalan, Mepitiostane, Mercaptopurine, Mesna, Methadone, Methotrexate, Methoxsalen, Methylaminolevulinate, Methylprednisolone, Methyltestosterone, Metyrosine, Midostaurin, Mifamurtide, Miltefosine, Miriplatin, Mitobronitrol,Mitoguazone, Mitolactol, Mitomycin, Mitotane, Mitoxantrone, Mogamulizumab, Molgramostim, Mopidamol, Morphine hydrochloride, Morphine sulfate, Mvasi, Nabilone, Nabiximols, Nafarelin, Naloxone + Pentazocine, Naltrexone, Nartograstim, Necitumumab, Nedaplatin, Nelarabine, Neratinib, Neridronic acid, Netupitant + Palonosetron, Nivolumabpentetreotide, Nilotinib, Nilutamide, Nimorazole, Nimotuzumab, Nimustine , nintedanib, niraparib, nitracrine, nivolumab, obinutuzumab, octreotide, ofatumumab, olaparib, olaratumab, omacetaxine mepesuccinate, omeprazole, ondansetron, oprelvekin, orgotein, oritlotimod, osimertinib, oxaliplatin, oxycodone, oxymetholone, ozogamicin, p53 gene therapy, paclitaxel, palbociclib, palifermin, palladium-103 seed, palonosetron, pamidronate, panitumumab, panobinostat , pantoprazole, pazopanib, pegaspargase, PEG-epoetin beta (methoxy PEG-epoetin beta), pembrolizumab, begfilgrastim, peg interferon alfa-2b, pembrolizumab, pemetrexed, pentazocine, pentostatin, peplomycin, perflubutane, perfosfamide, pertuzumab, picibanil, pilocarpine, pirarubicin, pixantrone, plerixafor, plicamycin, poliglusum, polyestradiol phosphate, polyvinylpyrrolidone + sodium hyaluronate, Polysaccharide-K, pomalidomide, ponatinib, porfimer sodium, pralatrexate, prednimustine, prednisone, procarbazine, procodazole, propranolol, quinagolide, rabeprazole, racotumomab, radium-223 chloride, radotinib, raloxifene, raltitrexed, ramosetron, ramucirumab, ranimustine, rasburicase, razoxane, refametinib, regorafenib, ribociclib, risedronate, etidronate rhenium-186, rituximab, rolapitant, romidepsin, romiplostim,Romurtid, Le, Caparib, samarium (153Sm) lexidronam, sargramostim, sarilumab, satumomab, secretin, siltuximab, sipuleucel-T, sizofiran, sobuzoxane, glycididazole sodium, sonidegib, sorafenib, stanozolol, streptozocin, sunitinib, talaporfin, talimogene laherparepvec, tamibarotene, tamoxifen , tapentadol, tasonermin, teceleukin, technetium (99mTc) nofetumomab merpentane, 99mTc-HYNIC-[Tyr3]-octreotide, tegafur, tegafur + gimeracil + oteracil, temoporfin, temozolomide, temsirolimus, teniposide, testosterone, tetrofosmin, thalidomide, thiotepa, thymalfasin, sa Ilotropin alfa, thioguanine, tisagenlecleucel, tislelizumab, tocilizumab, topotecan, toremifene, tositumomab, trabectedin, trametinib, tramadol, trastuzumab, trastuzumab emtansine, treosulfan, tretinoin, trifluridine + tipiracil, trilostane, triptorelin, trametinib, trophosphamide, thrombopoietin, tryptophan, ubenimex, baratinib, valrubicin, vandetanib, vapreotide, vemurafenib, vinblastine, vincristine, vindesine, vinflunine, vinorelbine, vismodegib, vorinostat, vorozole, yttrium-90 glass microspheres, zinostatin, zinostatin stimalamer, zoledronic acid, zorubicin.

[0367] Effective dosages of the compounds of the present invention can be easily determined for treating each desired indication based on standard laboratory techniques known for evaluating compounds useful for treating hyperproliferative diseases, such as cancer diseases, by standard toxicity tests and standard pharmacological assays for determining the treatment of the above-identified conditions in mammals, and comparing the results with those of known active ingredients or pharmaceuticals used to treat these conditions. The amount of active ingredient to be administered in the treatment of any of these conditions can vary widely, depending on such considerations as the specific compound and dosage unit used, the mode of administration, the duration of treatment, the age and sex of the patient being treated, and the nature and severity of the condition being treated.

[0368] The total amount of active ingredient to be administered generally ranges from about 0.001 mg / kg to about 200 mg / kg body weight / day, particularly from about 0.01 mg / kg to about 20 mg / kg body weight / day. Clinically useful administration schedules range from 1 to 3 times / day administration to once every 4 weeks administration. In addition, "drug holidays" during which the patient does not receive the drug for a period of time can be beneficial to the overall balance between pharmacological effect and tolerability. A unit dose can contain from about 0.5 mg to about 1500 mg of active ingredient and can be administered once or multiple times per day or less than once per day. The average daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous and parenteral injections, as well as for use of infusion techniques, will particularly be 0.01 to 200 mg / kg total body weight. The average daily rectal administration regimen will particularly be 0.01 to 200 mg / kg total body weight. The average daily vaginal administration regimen will particularly be 0.01 to 200 mg / kg total body weight. The average daily topical dosage regimen will typically be 0.1-200 mg administered 1-4 times daily. The transdermal concentration will typically be that required to maintain a daily dose of 0.01-200 mg / kg. The average daily inhalation dosage regimen will typically be 0.01-100 mg / kg of total body weight.

[0369] Of course, the specific initial and subsequent dosing regimens for each patient will vary according to the nature and severity of the condition as determined by the attending diagnostician, the activity of the specific compound used, the age and general condition of the patient, the duration of administration, the route of administration, the excretion rate of the drug, the combination of drugs, etc. The desired mode of treatment and frequency of administration of the compounds of the invention or a pharmacologic acceptable salt or ester thereof or a composition thereof can be ascertained by one skilled in the art using conventional therapeutic trials.

[0370] Experimental Section Experimental section - NMR spectrum NMR peak forms are reported as they appear in the spectra and possible higher order effects have not been taken into account.

[0371] Nuclear magnetic resonance (NMR) spectra were obtained from a Bruker (300 or 400 MHz 1 H, 75 or 101MHz 13 C) Spectrometer. Proton, fluorine and carbon chemical shifts are reported in ppm (δ) relative to the NMR solvent. Data are reported as follows: chemical shift, multiplicity (br=broad, s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet; one or more coupling constants (Hz)).

[0372] Selected Compounds 1 H-NMR data 1 The peaks are listed in the form of a H-NMR peak list, in which for each signal peak, a δ value (ppm) is given followed by the signal intensity reported in parentheses. The δ value-signal intensity pairs of different peaks are separated by commas. Thus, the peak list is of the general form: δ1 (intensity 1), δ2 (intensity 2), ..., δ i (strength i ), ..., δ n (strength n ) should be used.

[0373] The intensity of a sharp signal correlates to the height (cm) of the signal in the printed NMR spectrum. When compared to other signals, this data can be correlated to the actual ratio of signal intensities. In the case of a broad signal, two or more peaks are shown, or the center of the signal together with its relative intensity compared to the most intense signal shown in the spectrum. 1 The H-NMR peak list is a classic 1 Since it is similar to a H-NMR reading, it usually includes all the peaks listed in the classical NMR interpretation. 1 Similar to a H-NMR printout, the peak list includes solvent signals, signals due to stereoisomers of a particular target compound, impurity peaks, 13 C satellite peaks and / or spinning side bands may be shown. Stereoisomers' and / or impurity peaks are typically shown at lower intensities compared to the target compound (e.g., with a purity of more than 90%). Since such stereoisomers and / or impurities may be typical for a particular manufacturing method, these peaks may help to confirm the reproduction of the manufacturing method based on the "by-product fingerprint". The expert who calculates the peaks of the target compound by known methods (MestReC, ACD simulation or using empirically evaluated expectation values) can optionally use further intensity filters to isolate the peaks of the required target compound. Such operations are classical 1 The peak picking procedure described in Research Disclosure Database No. 605005, 2014, August 1, 2014, the parameter "MinimumHeight" can be adjusted between 1% and 4%. However, depending on the chemical structure of the measured compound and / or depending on the concentration, it may be reasonable to set the parameter "MinimumHeight" below 1%.

[0374] Chemical names were generated using ACD / Name software from ACD / Labs. In some cases, commonly accepted names of commercially available reagents were used in place of the ACD / Name-generated names.

[0375] Experimental Section - Abbreviations Table 1 below lists the abbreviations used in this paragraph and in the Examples section unless otherwise explained in the text. Other abbreviations have their customary meanings per se to those of ordinary skill in the art.

[0376] [Table 1]

[0377] Various aspects of the invention described in this application are illustrated by the following examples, which are not intended to be limiting of the invention in any way.

[0378] The example test experiments described herein serve to illustrate the invention, but the invention is not limited to the examples shown.

[0379] Experimental section - general part All reagents whose synthesis is not described in the experimental section are commercially available or are known compounds or can be formed from known compounds by known methods by those skilled in the art. The reactions were set up and started by the addition of the reagents, e.g. at the temperatures specified in the protocols; if no temperature is specified, the respective working steps were carried out at ambient temperature, e.g. between 18 and 25 °C.

[0380] The compounds and intermediates produced by the method of the present invention may require purification. Purification of organic compounds is well known to those skilled in the art, and there may be several methods to purify the same. In some cases, purification may not be necessary. In some cases, the compound may be purified by crystallization. In some cases, impurities may be stirred out using a suitable solvent. In some cases, the compound may be purified by chromatography, particularly flash column chromatography, using, for example, a pre-packed silica gel cartridge, such as Biotage SNAP cartridge KP-Sil® or KP-NH®, in combination with a Biotage automated purification system (SP4® or Isolera Four®) and an eluent (such as a gradient of hexane / ethyl acetate or DCM / methanol).

[0381] In some cases, compounds can be purified by preparative HPLC using, for example, a Waters automated purification system equipped with a diode array detector and / or an online electrospray ionization mass spectrometer in combination with a suitable pre-packed reverse phase column and an eluent, for example, a gradient of water and acetonitrile that may contain additives such as trifluoroacetic acid, formic acid or aqueous ammonia.

[0382] In some cases, the above purification method can provide the compounds of the present invention having sufficiently basic or acidic functional groups in the form of salt, for example, in the case of sufficiently basic compounds of the present invention, for example, trifluoroacetate or formate salts, or in the case of sufficiently acidic compounds of the present invention, for example, ammonium salts. This type of salt can be converted to its free base or free acid form, respectively, by various methods known to those skilled in the art, and can also be used as a salt in subsequent biological assays. It should be understood that the specific form (e.g., salt, free base, etc.) of the compounds of the present invention isolated and described herein is not necessarily the only form in which the compounds can be applied to biological assays to quantify specific biological activities.

[0383] UPLC-MS standard procedure Analytical UPLC-MS was performed as follows. Masses (m / z) are reported from positive mode electrospray ionization unless negative mode is indicated (ESI-). In most cases, method 1 was used; otherwise indicated.

[0384] Analytical UPLC method: Method 1: Instrument: Waters Acquity UPLC MS SingleQuad; Column: Acquity UPLC BEH C18 1.7 μm, 50x2.1 mm; Eluent A: water + 0.1% by volume formic acid (99%), Eluent B: acetonitrile, Gradient: 0–1.6 min 1–99% B, 1.6–2.0 min 99% B; Flow rate: 0.8 ml / min; Temperature: 60 °C; DAD scan: 210–400 nm. Method 2: Instrument: Waters Acquity UPLC MS SingleQuad; Column: Acquity UPLC BEH C18 1.7 μm, 50x2.1 mm; Eluent A: water + 0.2% ammonia (32%) by volume, Eluent B: acetonitrile, Gradient: 0–1.6 min 1–99% B, 1.6–2.0 min 99% B; Flow rate: 0.8 ml / min; Temperature: 60 °C; DAD scan: 210–400 nm.

[0385] Analytical UPLC method: Method 3: Instrument: Waters Acquity UPLC MS SingleQuad; Column: Acquity UPLC BEH C18 1.7 50x2.1mm; Eluent A: water + 0.2% ammonia (32%) by volume, Eluent B: acetonitrile, Gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B; Flow rate: 0.8 ml / min; Temperature: 60°C; DAD scan: 210-400 nm Method 4: Instrument: Waters Acquity UPLC MS SingleQuad; Column: Acquity UPLC BEH C18 1.7 50x2.1mm; Eluent A: water + 0.1% by volume formic acid (99%), Eluent B: acetonitrile, Gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B; Flow rate: 0.8 ml / min; Temperature: 60 °C; DAD scan: 210-400 nm

[0386] Experimental section - intermediates Intermediate 1 tert-Butyl N-[(1S)-2-[methoxy(methyl)amino]-1-methyl-2-oxo-ethyl]carbamate [ka] To a solution of N-(tert-butoxycarbonyl)-L-alanine (250 g, 1.32 mol) in DCM (1.25 L) was added CDI (257 g, 1.59 mol, 1.20 equiv). The reaction mixture was stirred at 25-30 °C for 1 h. N-Methoxymethanamine hydrochloride (155 g, 1.59 mol) was added to the mixture. DIPEA (512 g, 3.96 mol, 690 mL) was then added and the mixture was stirred at 25-30 °C for 17 h. TLC (petroleum ether: EtOAc = 1:1) showed that the starting material (Rf = 0.15) was consumed and one new spot (Rf = 0.55) was formed. The reaction mixture was quenched by the addition of water (1.00 L) and extracted with CHCl (500 mL). The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the target compound (261 g, crude) as a white solid, which was sufficiently pure for the next reaction. 1 H NMR(400 MHz,CDCl3)δ5.35-5.17(m,1H),4.85-4.54(m,1H),3.77(s,3H),3.21(s,3H),1.44(s,9H),1.32(d,J=6.8 Hz,3H)

[0387] Intermediate 2 tert-Butyl N-[(1S)-2-[4-fluoro-3-(trifluoromethyl)phenyl]-1-methyl-2-oxo-ethyl]carbamate [ka] A solution of 31.2 g (129 mmol) of 4-bromo-1-fluoro-2-(trifluoromethyl)benzene in 200 mL of THF was added slowly to 3.10 g (129 mmol) of magnesium turnings vigorously stirred in 10 mL of THF. An exotherm appeared after the addition of several mL of the bromide solution, which was added at a rate to maintain warmth. Once the addition was complete, the mixture was stirred until cooled to room temperature. The formed Grignard reagent was then added via syringe to a solution of 15.0 g (64.5 mmol) of tert-butyl N-[(1S)-1-[methoxy(methyl)carbamoyl]ethyl]carbamate in 250 mL of THF cooled in an ice bath, and the mixture was stirred overnight and allowed to warm to room temperature. The dark solution was cooled in an ice bath and then quenched with saturated NH4Cl solution and transferred to a separatory funnel containing EtOAc. The EtOAc layer was removed, dried (MgSO4) and concentrated to give a brown oil. Addition of hexanes produced a brown solid which was filtered and rinsed with hexanes to recover 16.2 g (75%) of product. 1 H NMR(400 MHz,CDCl3)δ8.30(d,J=6.6 Hz,1H),8.27-8.18(m,1H),7.35(t,J=9.2 Hz,1H),5.41(d,J=7.2 Hz,1H),5.27(p,J=7.1 Hz,1H),1.47(s,9H),1.42(d,J=7.1 Hz,3H). 19 F NMR(376 MHz,CDCl3)δ-61.72(d,J=12.7 Hz),-105.66(q,J=12.5 Hz). 13C NMR(101 MHz,CDCl3)δ197.01,164.21-161.17(m),155.13,134.59(d,J=9.9 Hz),130.82(d,J=3.4 Hz),128.33,121.96(q,J=272.6 Hz),119.29(qd,J=33.8,13.2 Hz),117.62(d,J=21.3 Hz),80.10,50.93,28.27,19.06.Mass 336(M+1).

[0388] Intermediate 3 (5S)-6-[4-fluoro-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one [ka] To 3.15 g (9.39 mmol) of tert-butyl (S)-(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1-oxopropan-2-yl)carbamate in 10 mL of MeOH was added 927 mg (10.3 mmol) of methoxycarbohydrazide and 10 drops of 0.1 N HCl, which was heated at reflux for 4 h. After cooling and concentration, 2.08 g of the intermediate was isolated by chromatography with 10-70% EtOAc in a ratio of approximately 6:1 (54%). 1 H NMR of major isomers: 1 H NMR(400 MHz,CDCl3)δ7.60-7.45(m,3H),7.39(t,J=9.1 Hz,1H),5.20(s,1H),4.57(p,J=7.0 Hz,1H),3.81(s,3H),1.45(s,10H),1.35(d,J=6.9 Hz,3H). 19F NMR (376 MHz, CDCl3) δ -61.54 (d, J = 12.6 Hz), -110.76 (q, J = 12.5 Hz). To 335 mg (0.823 mmol) of this intermediate dissolved in 10 mL of CHCl2 and cooled in an ice bath was added 5 mL of TFA. The ice bath was removed and after 2 h the reaction was concentrated and dissolved in MeOH. Solid NaOEt was added to make the solution basic and the reaction was stirred overnight. The reaction was quenched with saturated NH4Cl solution, rinsed twice with EtOAc and the combined EtOAc layers were dried (MgSO4) and concentrated to an oil which was chromatographed with 0-100% EtOAc to give 93 mg of the product as a white solid (41%). 1 H NMR(400 MHz,CDCl3)δ8.13(s,1H),7.96(dd,J=6.7,2.1 Hz,1H),7.87(ddd,J=8.4,4.5,2.3 Hz,1H),7.28(t,J=9.2 Hz,1H),5.84(s,1H),4.72(qd,J=6.6,2.8 Hz,1H),1.45(d,J=6.8 Hz,3H). 19 F NMR(376 MHz,CDCl3)δ-61.61(d,J=12.6 Hz),-112.36(q,J=12.7 Hz). LC-MS (Method 1):R t =1.02 min;MS(ESIpos):m / z=276[M+H]+

[0389] Experimental section - Examples Example 1 (5S)-5-Methyl-6-{3-(trifluoromethyl)-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one [ka] To 86 mg of (S)-6-(4-fluoro-3-(trifluoromethyl)phenyl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (0.31 mmol, intermediate 3) dissolved in 1 mL of DMF was added 168 mg (1.24 mmol) of 3-(trifluoromethyl)-1H-pyrazole and 204 mg (0.62 mmol) of cesium carbonate, and the mixture was heated at 60° C. for 7 h. After cooling, water was added, the mixture was rinsed several times with EtOAc, and the combined EtOAc was dried (MgSO4) and concentrated to a solid, which was recrystallized from CHCl / hexanes and then from CHCl to give 23 mg (23%) of a white solid. 1H NMR(400 MHz,CDCl3)δ8.33(s,1H),8.22-8.13(m,1H),7.97(dd,J=8.3,1.6 Hz,1H),7.78(s,1H),7.66(d,J=8.4 Hz,1H),6.77(d,J=2.4 Hz,1H),5.96(s,1H),4.80(qd,J=6.6,3.2 Hz,1H),1.48(d,J=6.8 Hz,3H). 19 F NMR(376 MHz,CDCl3)δ-59.31,-62.25.Mass 392(M+1). Following the procedures described in the synthesis of Example 1 above, the following compounds can be prepared: (5S)-6-{4-[(2-methoxyethyl)amino]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(2-azaspiro[3.3]heptan-2-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-{[(2S)-3,3,3-trifluoro-2-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(morpholin-4-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-{3-(trifluoromethyl)-4-[4-(trifluoromethyl)-2H-1,2,3-triazol-2-yl]phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one rel-(5R)-6-{4-[(1R,5R)-3-azabicyclo[3.1.0]hexan-3-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-({[1-(hydroxymethyl)cyclobutyl]methyl}amino)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(3-fluoro-1H-pyrazol-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(4-ethyl-4-hydroxypiperidin-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(3S)-3-hydroxypiperidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(3R)-3-hydroxypiperidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(piperidin-1-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(3R)-3-hydroxy-3-methylpyrrolidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(3S)-3-hydroxy-3-methylpyrrolidin-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(4,4-difluoropiperidin-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one

[0390] Example 2 (5S)-5-Methyl-6-[4-{[(1H-pyrazol-5-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one [ka] To a stirred solution of (5S)-6-[4-fluoro-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (Intermediate Example 3, 150 mg, 545 μmol) in DMSO (1 mL) was added N,N-diisopropylethylamine (280 μl, 1.6 mmol) followed by 1-(1H-pyrazol-5-yl)methanamine (159 mg, 1.64 mmol) and the resulting mixture was stirred overnight at 120° C. The mixture was purified by mass-triggered preparative HPLC (Method 4) and lyophilized to give an off-white solid. LC-MS (Method 1):R t =0.80min;MS(ESIpos):m / z=353[M+H] + 1H-NMR(400 MHz,DMSO-d6)δ[ppm]:1.131(16.00),1.148(15.83),2.518(2.59),2.523(1.63),2.539(6.68),4.417(4.21),4.430(4.19) ,4.541(0.68),4.558(2.37),4.566(2.38),4.574(2.36),4.582(2.35),4.599(0.67),6.112(5.42),6.117(5.29),6.304(1. 44), 6.318(2.70), 6.332(1.43), 6.838(2.57), 6.860(2.69), 7.367(3.08), 7.373(4.22), 7.380(3.03), 7.613(0.82), 7.654(3.19), 7.659(3.34), 7.676(2.85), 7.681(3.03), 7.778(6.69), 7.784(6.21), 9.843(6.23), 9.849(6.14), 12.642(0.79).

[0391] Example 3 (5S)-6-[4-(3-hydroxy-3-methylazetidin-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one [ka] The compound was synthesized in the same manner as in Example 2 from intermediate 3 and 3-methylazetidin-3-ol trifluoroacetate (1 / 1). LC-MS (Method 1):R t =0.92min;MS(ESIpos):m / z=343[M+H] + 1H-NMR(400 MHz,DMSO-d6)δ[ppm]:1.145(9.26),1.163(9.18),1.439(16.00),2.074(2.78),2.518(3.30),2.523(2.08),2.673( 0.60),3.864(1.93),3.884(3.92),3.918(4.56),3.938(2.18),4.586(0.41),4.594(1.34),4.602(1.29),4.611(1. 29), 4.619(1.34), 4.627(0.41), 5.606(7.30), 6.587(2.85), 6.609(2.95), 7.392(1.60), 7.399(2.21), 7.405(1.60), 7.720(1.82), 7.725(1.98), 7.742(1.70), 7.747(1.87), 7.816(3.95), 7.822(3.62), 9.891(3.60), 9.896(3.56).

[0392] Example 4 (5S)-6-[4-(cyclopentylamino)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one [ka] The compound was synthesized in the same manner as in Example 2 from Intermediate 3 and cyclopentanamine. LC-MS (Method 1):R t =1.26min;MS(ESIpos):m / z=341[M+H] + 1H-NMR(400 MHz,DMSO-d6)δ[ppm]:1.151(15.41),1.168(16.00),1.171(9.66),1.181(1.45),1.187(2.35),1.189(2.98),1.477(0.61),1.49 1(1.54),1.508(2.30),1.523(2.47),1.539(3.02),1.550(3.36),1.563(2.30),1.573(2.74),1.581(1.91),1.588(2.22),1.591 (2.26), 1.613(1.22), 1.626(0.95), 1.631(0.89), 1.657(2.60), 1.666(2.34), 1.672(3.08), 1.680(1.97), 1.687(1.82), 1.711(0.43), 1.951(1.06), 1.969(2.30), 1.986(9.55), 1.998(2.67), 2.012(1.58), 2.518(2.74), 2.522(1.67), 2.539(5.54), 2.590(0. 50), 3.890(0.93), 3.906(1.76), 3.925(2.76), 3.937(0.98), 3.999(0.50), 4.016(1.58), 4.034(1.58), 4.052(0.50), 4.566(0.59), 4.574(0.65), 4.583(2.15), 4.592(2.10), 4.599(2.08), 4.608(2.11), 4.616(0.65), 4.624(0.56), 4.959(2.69), 4.976(2.63) ,6.891(4.02),6.913(4.19),7.381(2.52),7.388(3.49),7.394(2.50),7.590(0.46),7.724(2.35),7.729(2.86),7.751(2.97),7.767(6.49),7.772(4.80),7.957(0.50),8.049(0.57),8.063(0.56),9.865(5.58),9.870(5.51),10.197(0.46),10.202(0.48).

[0393] Example 5 (5S)-5-Methyl-6-[4-{[(2R)-3,3,3-trifluoro-2-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one [ka] The compound was synthesized in the same manner as in Example 2 from Intermediate 3 and (2R)-3-amino-1,1,1-trifluoropropan-2-ol-hydrogen chloride (1 / 1). LC-MS (Method 1):R t =1.00min;MS(ESIpos):m / z=385[M+H] + 1 H-NMR(400 MHz,DMSO-d6)δ[ppm]:1.150(16.00),1.167(15.98),1.181(0.91),2.074(5.53),2.33 1(0.69),2.518(4.22),2.522(2.62),2.539(0.45),2.673(0.73),3.352(1.52),3.372 (2.16), 3.392(1.58), 3.406(1.22), 3.531(1.25), 3.542(1.76), 3.556(1.47), 3.565(1.07), 3.577(1.25), 3.591(0.89), 3.926(1.39), 4.216(0.66), 4.233(1.24), 4.244(1 .40), 4.260(1.29), 4.579(0.66), 4.596(2.34), 4.604(2.31), 4.612(2.29), 4.621(2.29), 4.638(0.63), 5.699(1.58), 5.713(3.12), 5.727(1.57), 6.614(4.85), 6.630(4.8 3), 6.920(4.49), 6.943(4.67), 7.393(2.99), 7.400(4.12), 7.740(2.77), 7.745(3.15), 7.767(3.10), 7.793(7.08), 7.798(5.71), 7.957(0.41), 9.879(6.45), 9.885(6.33).

[0394] Example 6 (5S)-5-Methyl-6-[4-{[(pyrazin-2-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one [ka] Synthesized in the same manner as in Example 2 from Intermediate 3 and 1-(pyrazin-2-yl)methanamine. LC-MS (Method 1):R t =0.92min;MS(ESIpos):m / z=365[M+H] + 1 H-NMR(400 MHz,DMSO-d6)δ[ppm]:1.125(16.00),1.142(15.96),2.322(1.04),2.32 6(1.35),2.331(0.99),2.522(4.66),2.664(0.97),2.668(1.33),2.673 (0.97),4.537(0.69),4.554(2.41),4.562(2.45),4.570(2.45),4.579( 2.41),4.595(0.71),4.645(7.56),4.659(7.65),6.679(1.81),6.694(3. 71), 6.708(1.86), 6.737(4.93), 6.759(5.10), 7.381(4.44), 7.654(3.09), 7.659(3.27), 7.676(2.96), 7.680(3.12), 7.820(6.78), 7.825(6.65), 8.543(7.12), 8.550(8.35), 8.599(7.96), 8.602(10.01), 8.620(7.03), 8.623(6.30), 8.626(6.92), 8.630(4.91), 9.864(6.59), 9.869(6.67). The following compounds can be prepared according to the procedures described in the general synthesis described herein: According to general synthetic route 1 or route 2i: (5S)-6-[4'-fluoro-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(2-aminopyridin-4-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(5-chloropyridin-2-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(2-methylprop-1-en-1-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(1E)-3-methoxyprop-1-en-1-yl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(E)-2-ethoxyvinyl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(pyridin-4-yl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(cyclopent-1-en-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4'-chloro-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[3'-fluoro-4'-methyl-2-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(dimethylamino)methyl]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-(4'-fluoro-2'-methyl[biphenyl]-4-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4'-fluoro-2'-(trifluoromethyl)[biphenyl]-4-yl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(morpholin-4-ylmethyl)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one By general synthetic route 1 or route 2i followed by hydrogenation: (5S)-6-[4-isobutyl-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(3-methoxypropyl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one General synthesis via route 1 or route 3m / n / o: (5S)-6-{4-[(2R)-2-hydroxypropoxy]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(2-hydroxy-2-methylpropoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-{4-[(2S)-2-hydroxypropoxy]-3-(trifluoromethyl)phenyl}-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-propoxy-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(2-methoxyethoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(cyclobutylmethoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-{4-[(2S)-tetrahydrofuran-2-ylmethoxy]-3-(trifluoromethyl)phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-{4-[(2R)-tetrahydrofuran-2-ylmethoxy]-3-(trifluoromethyl)phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[3-(trifluoromethyl)-4-(3,3,3-trifluoropropoxy)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-butoxy-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(3,3-dimethylbutoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-(1H-pyrazol-3-ylmethoxy)-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one

[0395] Experimental section - Biological assays The Examples were tested one or more times in the selected biological assays. When tested more than once, the data are reported as either the mean or median, where The average value is also called the arithmetic mean value and is calculated by dividing the total number of tests performed. · The median is the middle number in a group of values ​​when sorted in ascending or descending order. If the number of values ​​in a set of data is odd, the median is the middle value. If the number of values ​​in a set of data is even, the median is the arithmetic average of the two middle values.

[0396] The Examples were synthesized one or more times. When synthesized more than once, the biological assay data represent the mean or median values ​​calculated utilizing data sets derived from testing one or more synthetic batches. The in vitro activity of the compounds of the present invention can be demonstrated in the following assays:

[0397] Assay 1 Cell proliferation assay The antiproliferative activity of the compounds of general formula (I) was investigated in vitro in human cancer cells. For this purpose, appropriate numbers of cells (Hela:800; SK-MEL-3:1000; IGR37:2000; GB-1:600; H4:600; PFSK:1000, DBTRG05MG:600, DKMG:1000, SW1783:1000, M059J:800, 42-MG-BA:600, GAMG:800, LN229:800, T98G:800, U118-MG:1000, U-251MG:600, YKG1:800, 92.1:800, Mel202:800) were cultured in appropriate growth medium (FCS 10% final (Biochrom; no. S 0415); Hela:DMEM / Ham's F12 (Biochrom; no. FG 4815 stable glutamine), FCS 10% final (Biochrom; number S 0415); SK-MEL-3: McCoy's 5A (Biochrom; number F 1015), FCS 10% final (Biochrom; number S 0415), L-alanyl-L-glutamine final: 2 mM (Biochrom; number K 0302)); IGR37 DMEM (Biochrom; number FG 0445, high glucose; + FCS 10% final (Biochrom; number S 0415); H4 DMEM Gibco number 31966-047 + FCS 10% final (Biochrom; number S 0415); PFSK RPMI-1640 medium + FCS 10% final (Biochrom; number 0415); DBTRG05MG RPMI 1640 (Biochrom; number FG 1215+FCS 10% final (Biochrom; number S 0415); DKMG RPMI-1640 medium+FCS 10% final (Biochrom; number S 0415); GB1 DMEM Gibco number 31966-047+FCS 10% final (Biochrom; number S 0415); SW1783 DMEM / Ham's F12 (Biochrom; number FG 4815+FCS 10% final (Biochrom; number S 0415); M059J DMEM / Ham's F12 (Biochrom; number FG 4815+FCS 10% final (Biochrom; number S 0415); 42-MG-BA RPMI 1640 (50%) (Biochrom; number FG 1215)+MEM Earle's (50%) (Biochrom; number FG 0325); GAMG DMEM high glucose + GlutaMAX (Gibco number 31966-021) + high quality calf serum (final: 10%) (Biochrom; number S 0615); LN229 DMEM (Biochrom; number FG 0445), high quality FCS (final 5%) (Biochrom; number S 0615) L-alanyl-L-glutamine (4 mM final with 2 mM surplus, Biochrom, number K 0302); T98G DMEM (Biochrom; number FG 0445, high glucose + FCS 10% final (Biochrom; number S 0415); U118-MG DMEM (Biochrom; number FG 0435 + FCS 10% final (Biochrom; number S 0415); U-251MG Cells were plated in 384-well plates containing RPMI-1640 medium + FCS 10% final (Biochrom; no. S 0415); YKG1 DMEM (Biochrom; no. FG 0435 + FCS 10% final (Biochrom; no. S 0415); 92.1 RPMI-1640 medium + FCS 10% final (Biochrom; no. S 0415); Mel202 RPMI-1640 medium + FCS 10% final (Biochrom; no. S 0415) and incubated overnight at 37 °C. To determine cell viability at the start of treatment, after 24 h, cells on one plate (0 h plate) were treated with 30 μl / cavity of CTG solution (Promega Cell Titer Glo (cat. no. G755B and G756B)), incubated for 10 min at room temperature and luminescence was measured using VICTOR V (Perkin The cell count was measured by a ELISA kit (Elmer). Cells on the test plate were treated with compounds of general formula (I) and incubated at 37°C for 72 hours. Compounds were added to the cells using a HP D300 digital dispenser, typically in ten 2.5-fold dilution series starting at a maximum final drug concentration of 100 nM, or 30 μM for COV318. As a control, cells were treated with vehicle (DMSO at a final concentration of 0.3%).To determine cell viability at the end of treatment, after 72 hours, cells were treated with 30 μl / cavity of CTG solution (Promega Cell Titer Glo (cat. no. G755B and G756B)), incubated for 10 minutes at room temperature and luminescence was measured by VICTOR V (Perkin Elmer). Values ​​from the 0 hour plate (=maximum inhibition) and the DMSO control (=minimal inhibition) were used to determine the % effect on cell proliferation and the resulting IC50 for each test substance. A four-parameter fit was used to calculate IC50 values.

[0398] [Table 2]

[0399] [Table 3]

[0400] Thus, one aspect of the present invention is the use of a compound of formula (I) for treating cervical cancer.

[0401] Another aspect of the invention is the use of the compounds of formula (I) for the treatment of skin cancer, particularly melanoma.

[0402] Thus, one aspect of the present invention is the use of the compounds of formula (I) for the treatment of brain cancer, in particular glioblastoma, astrocytoma, anaplastic astrocytoma, primitive neuroectodermal tumor.

[0403] Yet another aspect of the present invention is the use of the compounds of formula (I) for the treatment of skin cancer, particularly melanoma, cervical cancer and ovarian cancer.

[0404] Yet another aspect of the present invention is the use of the compounds of formula (I) for the treatment of skin cancer, particularly melanoma, brain cancer, cervical cancer and ovarian cancer.

[0405] Another aspect is an IC 50values ​​of less than 100 nM and effectively inhibit tumor cell proliferation (eg, in HeLa cells).

[0406] Another aspect is an IC 50 values ​​of less than 10 nM and effectively inhibit tumor cell proliferation (eg, in HeLa cells).

[0407] Assay 2 Methods of PDE3A Enzyme Inhibition A commercially available 3H-cAMP scintillation proximity assay (SPA, Perkin Elmer) system was used for enzyme inhibition testing. To determine the in vitro effect of example compounds on PDE3A reaction, 2 μl of each example compound solution in DMSO (serial dilution) was placed in a well of a microtiter plate (Isoplate-96 / 200W; Perkin Elmer). 50 μl of dilutions of PDE3A cell extract from Sf9 cells (SB Drug Discovery, UK) overexpressing human full-length PDE3A in buffer A (50 mM Tris / HCl pH 7.5, 8.3 mM MgCl2, 1.7 mM EDTA, 0.2% BSA) were added. The dilutions of PDE3A cell extract were selected so that the reaction kinetics was linear and less than 70% of the substrate was consumed (typical dilution 1:5000). The reaction was started by adding 50 μl (0.025 μCi) of 1:2000 in buffer A without BSA diluted substrate [8-3H]adenosine 3',5'-cyclic phosphate (1 μCi / μl; Perkin Elmer). After 60 min incubation at room temperature, the reaction was stopped by adding 25 μl of a suspension containing 18 mg / ml yttrium scintillation proximity beads (Perkin Elmer) in water. The microtiter plate was sealed and measured in a Microbeta scintillation counter (PerkinElmer Wallac). IC was calculated from the sigmoidal curve by plotting % PDE3A activity against log compound concentration. 50 value was determined.

[0408] Assay 3 PDE3B enzyme inhibition Commercially available 3H-cAMP scintillation proximity assay (SPA, Perkin Elmer) system was used for enzyme inhibition test. To determine the in vitro effect of example compounds on PDE3B reaction, 2 μl of each example compound solution in DMSO (serial dilution) was placed in a well of a microtiter plate (Isoplate-96 / 200W; Perkin Elmer). 50 μl of dilution of PDE3B cell extract from Sf9 cells (SB Drug Discovery, UK) overexpressing human full-length PDE3B in buffer A (50 mM Tris / HCl pH 7.5, 8.3 mM MgCl2, 1.7 mM EDTA, 0.2% BSA) was added. Dilution of PDE3B cell extract was selected so that reaction kinetics was linear and less than 70% of substrate was consumed (typical dilution 1:6000). The reaction was started by adding 50 μl (0.025 μCi) of 1:2000 in Buffer A without BSA-diluted substrate [8-3H] adenosine 3',5'-cyclic phosphate (1 μCi / μl; Perkin Elmer). After 60 min incubation at room temperature, the reaction was stopped by adding 25 μl of a suspension containing 18 mg / ml yttrium scintillation proximity beads (Perkin Elmer) in water. The microtiter plate was sealed and measured in a Microbeta scintillation counter (PerkinElmer Wallac). IC50 values ​​were determined from sigmoidal curves by plotting % PDE3B activity against log compound concentration. The inhibitory activities of Examples 1-6 are shown in Table 4.

[0409] One embodiment of the invention is, for example, an IC 50 values, but not for inhibition of the enzymes PDE3A or PDE3B. 50 The value is usually IC 50 The compound of formula (I) is more than 10 times higher than the value.

[0410] Another aspect of the invention is a method for detecting IgG1-related markers that are resistant to IgG1-related markers, e.g., IC10 of less than 100 nM in HeLa cells. 50values, but not for inhibition of the enzymes PDE3A or PDE3B. 50 The value is usually IC 50 The compound of formula (I) is more than 30 times higher than the value.

[0411] Another aspect of the invention is a method for detecting IgG1-related markers that are resistant to IgG1-related markers, e.g., IC10 of less than 10 nM in HeLa cells. 50 values, but not for inhibition of the enzymes PDE3A or PDE3B. 50 The value is usually IC 50 The compound of formula (I) is more than 30 times higher than the value.

[0412] [Table 4]

[0413] Assay 4 In vivo pharmacokinetics in mice, rats, dogs and monkeys For in vivo pharmacokinetic experiments, test compounds were administered intravenously to female CD-1 mice, male Wistar rats, beagle dogs, or cynomolgus monkeys at doses of 0.3–1 mg / kg formulated as a solution with a well-tolerated amount of a solubilizing agent such as PEG400.

[0414] Studies may be conducted as cassette administration of up to three compounds given simultaneously at low doses.

[0415] For pharmacokinetics after intravenous administration, test compounds were administered as an intravenous bolus in female mice and male rats, and as a short infusion (15 min) in dogs and monkeys. Blood samples were taken, for example, from the jugular vein (mice, rats) or saphenous vein (dogs, monkeys) at 2 min, 8 min, 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 6 h, 8 h and 24 h after administration. Blood was collected in lithium-he...

Claims

1. Compounds of formula (I): [Formula 1] (In the formula, R 1 is a hydrogen atom, a halogen atom, C 1 ~C 3 -Alkyl group or C 1 ~C 3 - a haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 3 is an ortho-substituted phenyl group, R 1 and R 2 Except that both of R and R may be hydrogen atoms. 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 teeth, Fluorine atom, hydroxyl group and C 1 ~C 3 - a 4- to 6-membered heterocycloalkyl group, substituted one or more times with groups independently selected from alkyl groups; [Case 2] base, [C3] base, [C4] base, Amino group, halogen atom and C 1 ~C 3 - a 5- to 10-membered heteroaryl group, substituted one or more times with groups independently selected from haloalkyl groups; NR 5 R 6 Groups, and [C5] basis and R 4 is a hydrogen atom or C 1 ~C 3 is an alkyl group, R 5is a hydrogen atom, R 6 teeth, 5-6 membered heteroaryl groups, C 1 ~C 3 -Alkoxy group, hydroxy group, C 1 ~C 3 -Haloalkyl groups and themselves C 1 ~C 3 -C optionally substituted with hydroxyalkyl groups 4 ~C 6 -C substituted one or more times with a group selected from cycloalkyl groups 1 ~C 3 -alkyl group, And C 5 ~C 6 -Cycloalkyl group (selected from or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

2. R 1 is hydrogen atom, halogen atom, C 1 ~C 3 -Alkyl group or C 1 ~C 3 - a haloalkyl group; R 2 is a hydrogen atom or a halogen atom; However, R 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 but, Fluorine atom, hydroxyl group and C 1 ~C 3 - a 4- to 6-membered heterocycloalkyl group, substituted one or more times with groups independently selected from alkyl groups; [C6] base, [C7] base, [C8] base, a 5- to 10-membered heteroaryl group substituted one or more times with a group independently selected from an amino group, a chlorine atom, a fluorine atom, a trifluoromethyl group and a difluoromethyl group; NR 5 R 6 Groups, and [C9] basis and R 4 is a hydrogen atom or C 1 ~C 3 - is an alkyl group; R 5 is a hydrogen atom, R 6 but, 5-6 membered heteroaryl groups, C 1 ~C 3 -Alkoxy group, hydroxy group, C 1 ~C 3 -Haloalkyl groups and themselves C 1 ~C 3 -C optionally substituted with hydroxyalkyl groups 4 ~C 6 -C substituted one or more times with a group selected from cycloalkyl groups 1 ~C 3 -alkyl group, And C 5 ~C 6 -Cycloalkyl group Selected from:

2. The compound of claim 1 or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or a mixture thereof.

3. R 1 is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group, or a trifluoromethyl group; R 2 is a hydrogen atom, a fluorine atom or a chlorine atom; However, R 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 3-hydroxy-piperidin-1-yl group, 4,4-difluoro-piperidin-1-yl group, 4-ethyl-4-hydroxy-piperidin-1-yl group, [C10] basis, [C11] basis, [C12] group, 3-hydroxy-3-methyl-pyrrolidin-1-yl group, 4-methyl-piperazin-1-yl group, 2-amino-pyridin-4-yl group, 3-chloro-pyridin-6-yl group, 3-fluoro-pyrazol-1-yl group, 3-trifluoromethyl-pyrazol-1-yl group, 1-difluoromethyl-pyrazol-4-yl group, 4-trifluoromethyl-1,2,3-triazol-2-yl group, -NH-CH 2 -(pyrazol-3-yl) group, -NH-CH 2 -(pyrazol-5-yl) group, -NH-CH 2 -pyrazin-2-yl group, -NH-(CH 2 ) 2 -O-CH 3 group, -NH-CH 2 -CH(OH)CF 3 basis, [C13] a cyclopentyl group; and an NH-cyclopentyl group; R 4 is a hydrogen atom or a methyl group; 2. The compound of claim 1 or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or a mixture thereof.

4. R 1 is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group or a trifluoromethyl group, R 2is a hydrogen atom, a fluorine atom or a chlorine atom, However, R 1 and R 2 cannot both be hydrogen atoms at the same time; R 3 but, a 5- to 6-membered heteroaryl group substituted by a trifluoromethyl group; Hydroxy group or C 1 ~C 3 - a 4- to 6-membered heterocycloalkyl group substituted with an alkyl group; C 1 ~C 3 C optionally substituted with one or two groups selected from alkyl and hydroxy groups 4 ~C 6 heterocycloalkyl groups, And NR 5 R 6 basis is selected from R 4 is a methyl group; R 5 is a hydrogen atom; R 6 but, Itself a heteroaryl group, C 1 ~C 3 - C substituted one or more times with a group independently selected from haloalkyl and hydroxy groups 1 ~C 3 -Alkyl group And C 5 ~C 6 -Cycloalkyl group That is, 2. The compound of claim 1 or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or a mixture thereof.

5. R 1 is a trifluoromethyl group, R 2 is a hydrogen atom, R 3 But -NH-CH 2 -CH(OH)CF 3 group, -NH-cyclopentyl group, -NH-CH 2 -(pyrazol-5-yl) group, -NH-CH 2 -pyrazin-2-yl, 3-hydroxy-3-methyl-azetidin-1-yl and 3-trifluoromethyl-pyrazol-1-yl groups; R 4 is a methyl group; 3. A compound according to claim 1 or 2, or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or a mixture thereof.

6. A compound according to any one of claims 1 to 5, selected from: (5S)-5-Methyl-6-{3-(trifluoromethyl)-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-{[(1H-pyrazol-5-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(3-hydroxy-3-methylazetidin-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-6-[4-(cyclopentylamino)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-{[(2R)-3,3,3-trifluoro-2-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one (5S)-5-Methyl-6-[4-{[(pyrazin-2-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2,4-triazin-3(2H)-one or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a salt of a stereoisomer, a salt of a tautomer, a salt of an N-oxide or mixtures thereof.

7. A process for preparing a compound of general formula (I) according to any one of claims 1 to 6, comprising the step of: [C14] (In the formula, R 1 , R 2 and R 3 is as defined for the compounds of general formula (I) according to claim 1, and R 3 where the functional groups in are optionally appropriately protected, and Pg represents a protecting group for an amine group. of, In step 1): H 2 NNHCOOC 3 and under acidic conditions, in alcoholic solutions, and In step 2): with trifluoroacetic acid (TFA) in dichloromethane (DCM) at 0° C. to 20° C.; and Step 3): Under basic conditions at room temperature React, Optionally deprotecting any still protected functional groups; Thereby, the compound of the general formula (I) [C15] (In the formula, R 1 , R 2 , R 3 and R 4 is as defined in any one of claims 1 to 6) The method includes the step of obtaining.

8. 8. The method of claim 7, wherein the basic condition in step 3) is in the presence of NaOEt / EtOH or NaOMe / MeOH at 20°C.

9. 8. The method of claim 7, further comprising optionally separating the enantiomers or diastereoisomers.

10. A pharmaceutical composition comprising a compound of general formula (I) as defined in any one of claims 1 to 6 and one or more pharma- ceutically acceptable excipients.

11. one or more first active ingredients which are compounds of general formula (I) according to any one of claims 1 to 6, and - one or more further active ingredients which are anticancer agents, 23. A pharmaceutical combination comprising:

12. Use of a compound of general formula (I) according to any one of claims 1 to 6 for preparing a pharmaceutical composition according to claim 9 or 10.

13. A pharmaceutical composition for treating or preventing a disease, comprising a compound of general formula (I) according to any one of claims 1 to 6.

14. 14. The pharmaceutical composition of claim 13, wherein the disease is a hyperproliferative disease.

15. The pharmaceutical composition of claim 14, wherein the hyperproliferative disease is a cancer disease.

16. 16. The pharmaceutical composition of claim 15, wherein the cancer disease is selected from brain cancer, cervical cancer, skin cancer and ovarian cancer.

17. Compounds of general formula (IV): [C16] (In the formula, R 1 , R 2 and R 3is as defined for compounds of general formula (I) according to any one of claims 1 to 6, and Pg means a protecting group for an amine group).

18. For the preparation of a compound of general formula (I) according to any one of claims 1 to 6, Intermediate compound of general formula (IV) [C17] (In the formula, R 1 , R 2 and R 3 is as defined for the compounds of general formula (I) according to any one of claims 1 to 6, and Pg means a protecting group for the amine group. Use of.

Citation Information

Patent Citations

  • Heterocyclic compounds

    EP0052442A1

  • Pharmaceutically active phenyl-thia-, oxa- or triazinones

    EP0080296A1

  • Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same

    EP0122494A2

  • Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same

    EP0122627A2

  • Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same

    EP0123254A1